{
  "directed": true,
  "graph": {
    "annotation_list": {},
    "annotation_pattern": {
      "Species": "^\\d+$"
    },
    "annotation_url": {
      "Anatomy": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/anatomy/anatomy-20170511.belanno",
      "Cell": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell/cell-20170511.belanno",
      "CellLine": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-line/cell-line-20170511.belanno",
      "CellStructure": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-structure/cell-structure-20170511.belanno",
      "Confidence": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/confidence/confidence-1.0.0.belanno",
      "Disease": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/disease/disease-20170511.belanno",
      "MeSHAnatomy": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-anatomy/mesh-anatomy-20170511.belanno",
      "MeSHDisease": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-diseases/mesh-diseases-20170511.belanno",
      "Subgraph": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/neurommsig/neurommsig-1.0.3.belanno",
      "TextLocation": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/text-location/text-location-1.0.1.belanno"
    },
    "document_metadata": {
      "authors": "Rana Aldisi",
      "contact": "charles.hoyt@scai.fraunhofer.de",
      "copyright": "Copyright © 2018 Fraunhofer Institute SCAI, All rights reserved.",
      "description": "This file encodes the article M1 muscarinic acetylcholine receptor in Alzheimer’s disease by Jiang et al, 2014",
      "licenses": "CC BY 4.0",
      "name": "M1 muscarinic acetylcholine receptor in Alzheimer’s disease",
      "version": "1.0.0"
    },
    "namespace_pattern": {
      "DBSNP": "rs[0-9]+",
      "TAXONOMY": "^\\d+$"
    },
    "namespace_url": {
      "CHEBI": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/chebi-names.belns",
      "CONSO": "https://raw.githubusercontent.com/pharmacome/conso/501ceccdc9a27d97edbdc48a89ebe8e1dd3626e9/export/conso-names.belns",
      "DRUGBANK": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/drugbank-names.belns",
      "ECCODE": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/ec-code.belns",
      "FPLX": "https://raw.githubusercontent.com/sorgerlab/famplex/d9ec0526c20795146a9a6aef17496efe1a36cac6/export/famplex.belns",
      "GO": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/go-names.belns",
      "HGNC": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/hgnc-names.belns",
      "HGNCGENEFAMILY": "https://raw.githubusercontent.com/pharmacome/terminology/3074b85b858455d8eeb76cfcdef685ced19bbe11/external/hgnc.genefamily-names.belns",
      "HP": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/hp/hp-20171108.belns",
      "INTERPRO": "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/interpro-names.belns",
      "MESH": "https://raw.githubusercontent.com/pharmacome/terminology/8ccfed235e418e4c8aa576f9a5ef0f838e794c7f/external/mesh-names.belns",
      "MGI": "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/mgi-names.belns",
      "NCBIGENE": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/entrez.belns",
      "PFAM": "https://raw.githubusercontent.com/pharmacome/terminology/8ccfed235e418e4c8aa576f9a5ef0f838e794c7f/external/pfam-names.belns",
      "RGD": "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/rgd-names.belns"
    },
    "namespaces_uncached": [],
    "path": "receptors/jiang2014.bel",
    "pybel_version": "0.13.2"
  },
  "links": [
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Alzheimer’s disease (AD) is a debilitating neurodegenerative disorder afflicting millions of people. It is diagnosed by the progressive loss of cognitive function and behavioral defi cits and is characterized by the presence of neurofibrillary tangles (NFTs), senile plaques, cholinergic neuron loss, and neuronal atrophy at autopsy",
      "key": "82e56170ee15b0a83e55e686e535e70095d653d9fb2921805588d59bab0d4a1d63082d7f28930641e7ad1cdac270288226e70baece24c9aecbbf39898c8fc75f",
      "line": 80,
      "relation": "isA",
      "source": 112,
      "target": 117
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Alzheimer’s disease (AD) is a debilitating neurodegenerative disorder afflicting millions of people. It is diagnosed by the progressive loss of cognitive function and behavioral defi cits and is characterized by the presence of neurofibrillary tangles (NFTs), senile plaques, cholinergic neuron loss, and neuronal atrophy at autopsy",
      "key": "d8f53cc2a1a69645d2beda747503bd26f1d50703475e7f0ebaf5e24414ea1aff8210048e2fef2c4ae8166442c75c168e3887411d06508a85d553393cc4275ff1",
      "line": 81,
      "relation": "decreases",
      "source": 112,
      "target": 63
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Alzheimer’s disease (AD) is a debilitating neurodegenerative disorder afflicting millions of people. It is diagnosed by the progressive loss of cognitive function and behavioral defi cits and is characterized by the presence of neurofibrillary tangles (NFTs), senile plaques, cholinergic neuron loss, and neuronal atrophy at autopsy",
      "key": "07708eda3159a9248cc3319fe62985999b2245a0597a242823559c98087863fd3c120e7baf649268a5609820b8be5c8d0359f759c571f0644cf9d2cdaecdfd36",
      "line": 82,
      "relation": "association",
      "source": 112,
      "target": 122
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Alzheimer’s disease (AD) is a debilitating neurodegenerative disorder afflicting millions of people. It is diagnosed by the progressive loss of cognitive function and behavioral defi cits and is characterized by the presence of neurofibrillary tangles (NFTs), senile plaques, cholinergic neuron loss, and neuronal atrophy at autopsy",
      "key": "42039d4402039eaf37b4572778ae8d86bd96bd941a961d9bbc9ac0079b759b5fcd8e5dd6dc3bc2fef9b1444b61c828d64efd7712ef3b7d8495a0878274f0b327",
      "line": 83,
      "relation": "association",
      "source": 112,
      "target": 118
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Alzheimer’s disease (AD) is a debilitating neurodegenerative disorder afflicting millions of people. It is diagnosed by the progressive loss of cognitive function and behavioral defi cits and is characterized by the presence of neurofibrillary tangles (NFTs), senile plaques, cholinergic neuron loss, and neuronal atrophy at autopsy",
      "key": "cc293caf41153d62a48c4fb10dec85401dfa806c3aecfc202bd597280746d0c8a04be17f1e9d759bc7b8b84ab2964936faed2327a7a8551185f97fcca0ffbf4d",
      "line": 84,
      "relation": "decreases",
      "source": 112,
      "target": 26
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "The third important hallmark of AD is cholinergic hypofunction. The neurotransmitter acetylcholine (ACh) exerts its physiological functions by activating either ionotropic nicotinic ACh receptors (nAChRs) or metabotropic muscarinic ACh receptors (mAChRs). It has been reported that in AD brains there are (1) reduced choline acetyltransferase levels accompanied by decreased ACh synthesis; (2) significant loss of cholinergic neurons; (3) reduction in the numbers of postsynaptic neurons accessible to ACh; (4) cholinergic neuronal and axonal abnormalities; and (5) reduction in nAChR levels",
      "key": "4a9a75ab0627f461e6e5cd0e9ec843e0f9d3a795f5264641d88f9c584fbd548a49391151f7e8b0f7794d161c7d33ec387bff7eaece3529ef68b535b2a623a0dc",
      "line": 128,
      "relation": "decreases",
      "source": 112,
      "target": 26
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Alzheimer’s disease (AD) is a debilitating neurodegenerative disorder afflicting millions of people. It is diagnosed by the progressive loss of cognitive function and behavioral defi cits and is characterized by the presence of neurofibrillary tangles (NFTs), senile plaques, cholinergic neuron loss, and neuronal atrophy at autopsy",
      "key": "b640a60cbd0f01f5c0d111b407668a6cc8c47438010aa29ca25428d4bf9d4580b39bdfd8d61d522af616235a40c440f24f173d9e0badc1c07b61ac2aaa51abcc",
      "line": 85,
      "relation": "increases",
      "source": 112,
      "target": 53
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "The third important hallmark of AD is cholinergic hypofunction. The neurotransmitter acetylcholine (ACh) exerts its physiological functions by activating either ionotropic nicotinic ACh receptors (nAChRs) or metabotropic muscarinic ACh receptors (mAChRs). It has been reported that in AD brains there are (1) reduced choline acetyltransferase levels accompanied by decreased ACh synthesis; (2) significant loss of cholinergic neurons; (3) reduction in the numbers of postsynaptic neurons accessible to ACh; (4) cholinergic neuronal and axonal abnormalities; and (5) reduction in nAChR levels",
      "key": "1f1ae3f07c38b7e1bcfe248a9a4b4ca06b1e7d76a7730075bd1e3d9f084ed136d45a35e18c26c26cdc4f0238d4e80b7e5f15f4ff0b24db456990afd533fe3006",
      "line": 123,
      "relation": "decreases",
      "source": 112,
      "target": 61
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "The third important hallmark of AD is cholinergic hypofunction. The neurotransmitter acetylcholine (ACh) exerts its physiological functions by activating either ionotropic nicotinic ACh receptors (nAChRs) or metabotropic muscarinic ACh receptors (mAChRs). It has been reported that in AD brains there are (1) reduced choline acetyltransferase levels accompanied by decreased ACh synthesis; (2) significant loss of cholinergic neurons; (3) reduction in the numbers of postsynaptic neurons accessible to ACh; (4) cholinergic neuronal and axonal abnormalities; and (5) reduction in nAChR levels",
      "key": "b6690a05b65463f51d30d00ee87dbe16cf346d3d81877daee78bafac512555f8f88228f168142493e9979a55db9844e8459f5eb2ddd9f8f29f99d7381e07303a",
      "line": 126,
      "relation": "decreases",
      "source": 112,
      "target": 87
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "The third important hallmark of AD is cholinergic hypofunction. The neurotransmitter acetylcholine (ACh) exerts its physiological functions by activating either ionotropic nicotinic ACh receptors (nAChRs) or metabotropic muscarinic ACh receptors (mAChRs). It has been reported that in AD brains there are (1) reduced choline acetyltransferase levels accompanied by decreased ACh synthesis; (2) significant loss of cholinergic neurons; (3) reduction in the numbers of postsynaptic neurons accessible to ACh; (4) cholinergic neuronal and axonal abnormalities; and (5) reduction in nAChR levels",
      "key": "00ead7fe3d990fa29fed56f656eb6b1f1006a326e392b7bc6bd7d61df8524836a50339730b7cb2c2662ff557bccf0acb775c245a403444e149913281090ad3a2",
      "line": 129,
      "relation": "decreases",
      "source": 112,
      "target": 101
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Recent evidence indicates that cholinergic hypofunction is closely linked to Abeta and tau pathologies[20]. As a major receptor group for ACh, mAChRs have also been implicated in the pathophysiology of AD.",
      "key": "3f4f4350cfeefa37b3660de9fb381785d42bf9b3cd3ee37d7048d1f6b0bee4eeff8843380f8bed9b4f1621af7f1a2cd6a9e3bbdd9827755f73d5197e84200e6e",
      "line": 139,
      "relation": "association",
      "source": 112,
      "target": 100
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Alzheimer’s disease (AD) is a debilitating neurodegenerative disorder afflicting millions of people. It is diagnosed by the progressive loss of cognitive function and behavioral defi cits and is characterized by the presence of neurofibrillary tangles (NFTs), senile plaques, cholinergic neuron loss, and neuronal atrophy at autopsy",
      "key": "638bc9bf0cee92bf635635a83a1a17a3080b51f98c709be321f2bc1057afb86d10a947f8b40c2f88ce7989eb5133de023460bcd975f191f4c0712a940b37ba4c",
      "line": 82,
      "relation": "association",
      "source": 122,
      "target": 112
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Recent evidence indicates that cholinergic hypofunction is closely linked to Abeta and tau pathologies[20]. As a major receptor group for ACh, mAChRs have also been implicated in the pathophysiology of AD.",
      "key": "36e2a48ce16695801c7e7950cf634b4067741193e1714ac33fc4f23fa84b1676052c706258f32a38c2d6661a947481ae15f93571bdff5866ef9de4f6af7fc9a2",
      "line": 137,
      "relation": "association",
      "source": 122,
      "target": 61
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Alzheimer’s disease (AD) is a debilitating neurodegenerative disorder afflicting millions of people. It is diagnosed by the progressive loss of cognitive function and behavioral defi cits and is characterized by the presence of neurofibrillary tangles (NFTs), senile plaques, cholinergic neuron loss, and neuronal atrophy at autopsy",
      "key": "93abd431722c5b10cadc0c82f6e431542af16a9b93aba7d13b1e2b0fedeec4c8e9de7945b99f55b3feca64d51621c4ee5b17041ede3ce21062a2b8e5bc50cded",
      "line": 83,
      "relation": "association",
      "source": 118,
      "target": 112
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Recent evidence indicates that cholinergic hypofunction is closely linked to Abeta and tau pathologies[20]. As a major receptor group for ACh, mAChRs have also been implicated in the pathophysiology of AD.",
      "key": "da00fe540f87aba0e378027bf8a16b8a606ce733167900b0503ace3d7b21080339008d10c517d1645e30c82c3dcdf78de59fc645bb26e68e320e87adbd1d9a4f",
      "line": 138,
      "relation": "association",
      "source": 118,
      "target": 61
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Senile plaques consist of deposits of small peptides called beta-amyloid (Abeta). Multiple lines of evidence suggest that the overproduction/ aggregation of neurotoxic Abeta in vulnerable brain regions is the primary cause of AD",
      "key": "e22413ab1a9c31bd089fec4e27866346c81140b4993a384a78aab9cabac15b64bf4b1a8f1c35d9016cdf19c662aca5a8c5bae38ea19ad2c895f6f937266e8121",
      "line": 94,
      "relation": "increases",
      "source": 13,
      "target": 122
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Senile plaques consist of deposits of small peptides called beta-amyloid (Abeta). Multiple lines of evidence suggest that the overproduction/ aggregation of neurotoxic Abeta in vulnerable brain regions is the primary cause of AD",
      "key": "a93c6f54f621d5a51d83f5fbe7be1a86ac3e80c12cda55c42407bfaf890498a2d058a3b9a73c732957283e80e854dc66ecd7a122d157b3f3f16520511563755d",
      "line": 95,
      "relation": "increases",
      "source": 13,
      "target": 112
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "NFTs are formed by accumulation of hyperphosphorylated tau protein[7, 8]. Tau is a microtubule-binding protein whose function is to stabilize microtubules and facilitate fast axonal transport. Once highly phosphorylated, tau dissociates from microtubules and is prone to aggregate, forming paired helical fi laments that aggregate into NFTs",
      "key": "9b22d0884d0d70f19f48f6a4362f3f1248638ccc4c82350968da11e306a98205ffa4aea10c39627ac3cf856da3fdb457798302687d69b9374323fe24cf185548",
      "line": 106,
      "relation": "increases",
      "source": 12,
      "target": 118
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "NFTs are formed by accumulation of hyperphosphorylated tau protein[7, 8]. Tau is a microtubule-binding protein whose function is to stabilize microtubules and facilitate fast axonal transport. Once highly phosphorylated, tau dissociates from microtubules and is prone to aggregate, forming paired helical fi laments that aggregate into NFTs",
      "key": "0fbc1f99a05cc73d26f1ba65e264691c9f28b235c7e50c72beaaafca77883b3fea4025c058602569a258385c7757d45ec09d79e65a9e673e674faf474479f797",
      "line": 107,
      "relation": "regulates",
      "source": 97,
      "target": 51
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "NFTs are formed by accumulation of hyperphosphorylated tau protein[7, 8]. Tau is a microtubule-binding protein whose function is to stabilize microtubules and facilitate fast axonal transport. Once highly phosphorylated, tau dissociates from microtubules and is prone to aggregate, forming paired helical fi laments that aggregate into NFTs",
      "key": "3ccaa9cedde0377982394c910238b95bb0f9f5f1c6dead62663c66f9534737261c5d5742b97d6b8a4ecf99198a118d5bdcda6e0725f0e050c4f756cc63772be3",
      "line": 108,
      "relation": "regulates",
      "source": 97,
      "target": 45
    },
    {
      "key": "c4e71f1866eab20795e7e1d4b54fe09effb8b376e41712f8a130fe5192e07d83b0749cc2e2297b62cbea4bb7b1033909ea6d6423fa06166cb07543cee4249d48",
      "relation": "hasVariant",
      "source": 97,
      "target": 98
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Recent evidence indicates that cholinergic hypofunction is closely linked to Abeta and tau pathologies[20]. As a major receptor group for ACh, mAChRs have also been implicated in the pathophysiology of AD.",
      "key": "de61cd1aeefb6672aa6893fab82fc0169beabccd5c6e4140f768a32e8912ea53b45144bb067a093a072612573d7ae11396569d136bddebee0ebcde57b89faea6",
      "line": 137,
      "relation": "association",
      "source": 61,
      "target": 122
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Recent evidence indicates that cholinergic hypofunction is closely linked to Abeta and tau pathologies[20]. As a major receptor group for ACh, mAChRs have also been implicated in the pathophysiology of AD.",
      "key": "e8bd18af05154ec448f81d36b5b5670aad2d9bd40a49f5315ad10dd1342c7ea3afc5a1e53fafdc9a327da60bb54d26c0a7b73993c4ba3fbb4f7b9eb7e5d67930",
      "line": 138,
      "relation": "association",
      "source": 61,
      "target": 118
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "The third important hallmark of AD is cholinergic hypofunction. The neurotransmitter acetylcholine (ACh) exerts its physiological functions by activating either ionotropic nicotinic ACh receptors (nAChRs) or metabotropic muscarinic ACh receptors (mAChRs). It has been reported that in AD brains there are (1) reduced choline acetyltransferase levels accompanied by decreased ACh synthesis; (2) significant loss of cholinergic neurons; (3) reduction in the numbers of postsynaptic neurons accessible to ACh; (4) cholinergic neuronal and axonal abnormalities; and (5) reduction in nAChR levels",
      "key": "5a30b65f8392ef3a41e8a14c99f3e40c67d885034efab09a2aa60426ad926e9865e7fc38bcf2480c97ba85118e9ef9bce817d8e3f13ae564bdf12c567f9e0b4e",
      "line": 124,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 3,
      "target": 101
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "The third important hallmark of AD is cholinergic hypofunction. The neurotransmitter acetylcholine (ACh) exerts its physiological functions by activating either ionotropic nicotinic ACh receptors (nAChRs) or metabotropic muscarinic ACh receptors (mAChRs). It has been reported that in AD brains there are (1) reduced choline acetyltransferase levels accompanied by decreased ACh synthesis; (2) significant loss of cholinergic neurons; (3) reduction in the numbers of postsynaptic neurons accessible to ACh; (4) cholinergic neuronal and axonal abnormalities; and (5) reduction in nAChR levels",
      "key": "0059f50f495fcc89363a9e848250399bce28653b5c018cf6b6d74aca9ab06cc1c63cd00773ddda5ec55194e2eb3c848021cc13f2da8a94f1afb8ef2ac7d07a32",
      "line": 125,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 3,
      "target": 100
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Recent evidence indicates that cholinergic hypofunction is closely linked to Abeta and tau pathologies[20]. As a major receptor group for ACh, mAChRs have also been implicated in the pathophysiology of AD.",
      "key": "54d06d990f491abb96b080d763763c26577000774f7022f8dc65e842b9df7d7cd90f1caae2f1a4ed1260f7151f7397a73c0d9a428c2c5eacb37eaa7cb81b855e",
      "line": 139,
      "relation": "association",
      "source": 100,
      "target": 112
    },
    {
      "key": "62dbefd014b2640be6054627159be5cd6d7f49059979324a714d72f58566624865f78a0121fbc73dfebf2fe3e0750081250d01fc838e8d918274ddcf18c89834",
      "relation": "hasMember",
      "source": 100,
      "target": 88
    },
    {
      "key": "2b4bc8fce844a314bfb31519b1b7e13f79d8ca898451c95f286596103f910ff0d55a6191dad87decb361d9dc6aea3732cb11f669553deaf3865ecf776bb4e987",
      "relation": "hasMember",
      "source": 100,
      "target": 89
    },
    {
      "key": "95817d2b8faba441748e658ebbe5322a1dcab234446a208819a41611ad3ab72b13ad154235ce432b6f6dbfc5433fd230bbcd648c1cae86525b57ffcee5c41c8a",
      "relation": "hasMember",
      "source": 100,
      "target": 90
    },
    {
      "key": "7dc597e9afbc30a0465f961c7c3659b902599cef838ee83fadc12632d5901b97e84e0ffa2d283e579012b0addebac5394654371b32801b6c5d25e344edcb3fb4",
      "relation": "hasMember",
      "source": 100,
      "target": 91
    },
    {
      "key": "8890538f3b9f954a65ac787c38690fd68e419e31e4a81e5a98651388808029641719b13df51a0901165045b715714d34bd36a6e8e55637dc5522388019a5b018",
      "relation": "hasMember",
      "source": 100,
      "target": 92
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Members of the mAChR family are widely expressed in various regions in the central nervous system (CNS) and in the peripheral system. They play crucial roles in diverse physiological processes such as memory, attention, nociception, motor control, sleep-wake cycles, and cardiovascular, renal, and gastrointestinal functions",
      "key": "bc372b9f502fa51dba90185b820ff2d14b2a0cd168d9f5ce334ea00b4798844dda39114c27e3533b3827087b7075e017e18cc62684bae85a66df88e9b8fc0c1e",
      "line": 180,
      "relation": "association",
      "source": 100,
      "target": 65
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Members of the mAChR family are widely expressed in various regions in the central nervous system (CNS) and in the peripheral system. They play crucial roles in diverse physiological processes such as memory, attention, nociception, motor control, sleep-wake cycles, and cardiovascular, renal, and gastrointestinal functions",
      "key": "2c4afc227285b770e4d110dbdb03cb355fbbda2efd69c882438540acc6731e964b249e98ebe2cf311617bb7e4dc546152e770330b2af2c0f90613fcb2ce27e1f",
      "line": 181,
      "relation": "association",
      "source": 100,
      "target": 126
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Members of the mAChR family are widely expressed in various regions in the central nervous system (CNS) and in the peripheral system. They play crucial roles in diverse physiological processes such as memory, attention, nociception, motor control, sleep-wake cycles, and cardiovascular, renal, and gastrointestinal functions",
      "key": "0f59e649aeddb51507544e6b18e920b8d01b72fa47c0513aa65274bc167c3be9f7ec76a89b4def70727d325fbe293c7fe4013ff844e782641fa8e3a4a4cc0abb",
      "line": 182,
      "relation": "association",
      "source": 100,
      "target": 130
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Members of the mAChR family are widely expressed in various regions in the central nervous system (CNS) and in the peripheral system. They play crucial roles in diverse physiological processes such as memory, attention, nociception, motor control, sleep-wake cycles, and cardiovascular, renal, and gastrointestinal functions",
      "key": "f4c9765d7ffa47d1cedb5d6085b83c39c9cba5a72bd71658455e839e92be4549c96d6afd11e8cbf42846fd2566bae526e000823450cb423633dce779e1dd5511",
      "line": 183,
      "relation": "association",
      "source": 100,
      "target": 48
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Members of the mAChR family are widely expressed in various regions in the central nervous system (CNS) and in the peripheral system. They play crucial roles in diverse physiological processes such as memory, attention, nociception, motor control, sleep-wake cycles, and cardiovascular, renal, and gastrointestinal functions",
      "key": "5ac21d82f51507986f7210c9851971c4523f900d9269ce2177d5cc6ecbb7c7f4da6347f35299184f5bf5142f20ffa905110e52ea563c3485bc38c3950c7c770b",
      "line": 184,
      "relation": "association",
      "source": 100,
      "target": 24
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Members of the mAChR family are widely expressed in various regions in the central nervous system (CNS) and in the peripheral system. They play crucial roles in diverse physiological processes such as memory, attention, nociception, motor control, sleep-wake cycles, and cardiovascular, renal, and gastrointestinal functions",
      "key": "8176eb5fb39db25870911adf6e0dc4fe5a5949fd1268b47dd4d4336dbb90b60a0c25eb5c20f0b21bf82a8b8876e305ab75e61aea7963e49e68e4275ec3011ad5",
      "line": 185,
      "relation": "association",
      "source": 100,
      "target": 35
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Members of the mAChR family are widely expressed in various regions in the central nervous system (CNS) and in the peripheral system. They play crucial roles in diverse physiological processes such as memory, attention, nociception, motor control, sleep-wake cycles, and cardiovascular, renal, and gastrointestinal functions",
      "key": "6bf9ecb080d8168b3fb263b09ae9976abc106921aeb41856b1e9dc2986aa01eba9a6f384e6410269002ef9c6dc3ccaa9549109a86d413cff8494dce2d8594e3b",
      "line": 186,
      "relation": "association",
      "source": 100,
      "target": 29
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "The third important hallmark of AD is cholinergic hypofunction. The neurotransmitter acetylcholine (ACh) exerts its physiological functions by activating either ionotropic nicotinic ACh receptors (nAChRs) or metabotropic muscarinic ACh receptors (mAChRs). It has been reported that in AD brains there are (1) reduced choline acetyltransferase levels accompanied by decreased ACh synthesis; (2) significant loss of cholinergic neurons; (3) reduction in the numbers of postsynaptic neurons accessible to ACh; (4) cholinergic neuronal and axonal abnormalities; and (5) reduction in nAChR levels",
      "key": "0167c5ebebd500e10e86867866c282cd4850a44148696c7fbe5306ccfba0fc7a534ac5ee7f08e965c949ecac488bbbe61a8087fc030557ed763ca6b9c0a30058",
      "line": 127,
      "relation": "decreases",
      "source": 87,
      "target": 3
    },
    {
      "key": "62dcb61002f0667ac7724333c9be471d131a515f5d76fa4796c9de0025076fcc6d0d8d44bdad27e4063b406711bc9b98e750c376db70495cd6e1c0e49c52da3f",
      "relation": "hasComponent",
      "source": 68,
      "target": 3
    },
    {
      "key": "e1035700f47e99ccb7a6f6bfb8cb1f5ec5adbe22a4de88269fc6928ebb7d1e8540ed550a04bb5970704ff97ddd0bef51875b0313e1fa488823b15166a1bd5db5",
      "relation": "hasComponent",
      "source": 68,
      "target": 81
    },
    {
      "key": "0077dc51614cccd27b069698be6ed1d33e5107537ead5ce5df2530b13cef5ca29b7fad61b5840b9cba667fced6f431a734b67f89f8642b9bc7a64bf47a5c1aaa",
      "relation": "hasComponent",
      "source": 68,
      "target": 100
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "mAChRs are seven-transmembrane G-proteincoupled receptors. Upon binding to the endogenous neurotransmitter ACh, mAChRs couple to G proteins to transduct signals",
      "key": "58d25d60733ddfa8b31666c89826def8f4b459953f27a1e98b55df440cf79e2aef88a55486197cf8c1176789051bb8f85cd2ac2a52c4f60494b87b679e2b1b08",
      "line": 147,
      "relation": "increases",
      "source": 68,
      "target": 61
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Among the mAChR family members, the M1 subtype makes up 50–60% of the total and is predominantly expressed in all major areas of the forebrain, including the hippocampus, cerebral cortex, corpus striatum, and thalamus[36-38]. M1 mAChR-knockout mice show a series of cognitive defi cits and impairments in long-term potentiation, indicating that the M1 subtype is physiologically linked to multiple functions such as synaptic plasticity, neuronal excitability, neuronal differentiation during early development, and learning and memory",
      "key": "3c4e4a347e87b32a2c167a7c9af18953ea810de1bc2223b6f5abde808f21891e84fbdfecb59061e48f6c08d4efaa44b29eb79854f333310e1a28b153be56a377",
      "line": 200,
      "relation": "association",
      "source": 88,
      "target": 33
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Among the mAChR family members, the M1 subtype makes up 50–60% of the total and is predominantly expressed in all major areas of the forebrain, including the hippocampus, cerebral cortex, corpus striatum, and thalamus[36-38]. M1 mAChR-knockout mice show a series of cognitive defi cits and impairments in long-term potentiation, indicating that the M1 subtype is physiologically linked to multiple functions such as synaptic plasticity, neuronal excitability, neuronal differentiation during early development, and learning and memory",
      "key": "66f4407f6cec731c3447a39042be9e79b5adac4603c7be1b2686d5dfb369a1ac57b07550edaa50ce4ccb4ff7614465b54cf74d37d56708bc6f39e05928477db1",
      "line": 201,
      "relation": "association",
      "source": 88,
      "target": 25
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Among the mAChR family members, the M1 subtype makes up 50–60% of the total and is predominantly expressed in all major areas of the forebrain, including the hippocampus, cerebral cortex, corpus striatum, and thalamus[36-38]. M1 mAChR-knockout mice show a series of cognitive defi cits and impairments in long-term potentiation, indicating that the M1 subtype is physiologically linked to multiple functions such as synaptic plasticity, neuronal excitability, neuronal differentiation during early development, and learning and memory",
      "key": "3f4d9ff99c5a8a14cf8ba2fc562881ff0013da43b654a6f9dc74b9866460e15783c1f1c3297f6e62bd87a0d3949d6c5ec8a26380957cd48bfb0ea6f3f2ca8803",
      "line": 202,
      "relation": "association",
      "source": 88,
      "target": 27
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Among the mAChR family members, the M1 subtype makes up 50–60% of the total and is predominantly expressed in all major areas of the forebrain, including the hippocampus, cerebral cortex, corpus striatum, and thalamus[36-38]. M1 mAChR-knockout mice show a series of cognitive defi cits and impairments in long-term potentiation, indicating that the M1 subtype is physiologically linked to multiple functions such as synaptic plasticity, neuronal excitability, neuronal differentiation during early development, and learning and memory",
      "key": "0a7e51c9afd978a75f11a705099686e4419c96c1821b88a5767266b787553203fc4d6b64080267e45e0b67f113f368a857e4591f8d9c13c7a1d807efe6918a36",
      "line": 203,
      "relation": "association",
      "source": 88,
      "target": 37
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Among the mAChR family members, the M1 subtype makes up 50–60% of the total and is predominantly expressed in all major areas of the forebrain, including the hippocampus, cerebral cortex, corpus striatum, and thalamus[36-38]. M1 mAChR-knockout mice show a series of cognitive defi cits and impairments in long-term potentiation, indicating that the M1 subtype is physiologically linked to multiple functions such as synaptic plasticity, neuronal excitability, neuronal differentiation during early development, and learning and memory",
      "key": "890b758ecdd0a1b41cacececb604920797029d7734e9cae117a08e159a3cbea1de4529f57479502654f6de525afb18ae80a53201272b4a1586c308ed86384ff6",
      "line": 212,
      "relation": "association",
      "source": 88,
      "target": 57
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Among the mAChR family members, the M1 subtype makes up 50–60% of the total and is predominantly expressed in all major areas of the forebrain, including the hippocampus, cerebral cortex, corpus striatum, and thalamus[36-38]. M1 mAChR-knockout mice show a series of cognitive defi cits and impairments in long-term potentiation, indicating that the M1 subtype is physiologically linked to multiple functions such as synaptic plasticity, neuronal excitability, neuronal differentiation during early development, and learning and memory",
      "key": "94a1784e971afcefe4c43f4ba49532c0a4ce9dcad72e9dd5707291f73a4a5fcb9234aaea047bfaf32b36624db9b079e303c04893bb30d681493e931d1a14ca77",
      "line": 213,
      "relation": "association",
      "source": 88,
      "target": 64
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Among the mAChR family members, the M1 subtype makes up 50–60% of the total and is predominantly expressed in all major areas of the forebrain, including the hippocampus, cerebral cortex, corpus striatum, and thalamus[36-38]. M1 mAChR-knockout mice show a series of cognitive defi cits and impairments in long-term potentiation, indicating that the M1 subtype is physiologically linked to multiple functions such as synaptic plasticity, neuronal excitability, neuronal differentiation during early development, and learning and memory",
      "key": "4df1724df9fab482fabb819208a97cda6109236b25fe4688fd86d687ee2ba03d37e99efb3e60e453bbe15b096655afed7918404994a90880b6129c512e9b36b8",
      "line": 214,
      "relation": "association",
      "source": 88,
      "target": 65
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Among the mAChR family members, the M1 subtype makes up 50–60% of the total and is predominantly expressed in all major areas of the forebrain, including the hippocampus, cerebral cortex, corpus striatum, and thalamus[36-38]. M1 mAChR-knockout mice show a series of cognitive defi cits and impairments in long-term potentiation, indicating that the M1 subtype is physiologically linked to multiple functions such as synaptic plasticity, neuronal excitability, neuronal differentiation during early development, and learning and memory",
      "key": "0b5eaf1967237173dd89975f4dc4df52a6687ee341ee723c15038c0fb55ac65af0ad2626304e1bb8169b3cd89c6913ec0fae2bbf2fbaac87f373526976d60af9",
      "line": 215,
      "relation": "association",
      "source": 88,
      "target": 55
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Among the mAChR family members, the M1 subtype makes up 50–60% of the total and is predominantly expressed in all major areas of the forebrain, including the hippocampus, cerebral cortex, corpus striatum, and thalamus[36-38]. M1 mAChR-knockout mice show a series of cognitive defi cits and impairments in long-term potentiation, indicating that the M1 subtype is physiologically linked to multiple functions such as synaptic plasticity, neuronal excitability, neuronal differentiation during early development, and learning and memory",
      "key": "b7a4e81335d89c47e641a83e424675b534b56071757132d9abb4650a9b0870038704ef2bbcc8f3458c778804e2bc8cf07943d69c3ffd51b01e03a1c4dbed6ed8",
      "line": 216,
      "relation": "association",
      "source": 88,
      "target": 54
    },
    {
      "annotations": {
        "Cell": {
          "glutamatergic neuron": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "At the cellular level, M1 mAChR is highly expressed in striatonigral, striatopallidal, and glutamatergic pyramidal neurons, especially in extrasynaptic regions. This localization of M1 mAChR is consistent with the cholinergic modulation of glutamatergic neurotransmission",
      "key": "5e96e48a43f6353f5d5a7da22ce3e6f600d99683a058eb1db87fb95d3e6b3f95281bebaf85b3c57984f2a2796efd51ac17a18cd33bbf93b40c3a4d994c385b85",
      "line": 228,
      "relation": "regulates",
      "source": 88,
      "target": 62
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Interestingly, stimulation of M1 mAChR by agonists has been found to enhance sAPPalpha generation and reduce Abeta production[61-70]. Protein kinase C (PKC) is well-known to be activated upon stimulation of M1 mAChR. PKC may promote the activity of alpha-secretase[71] and the traffi cking of APP from the Golgi/ trans-Golgi network to the cell surface",
      "key": "6b54613b1671303ceb21e71d8bd6dff538fe9b91fb3758f15dba65a9fab0e68fb48000f71af2b429ab6cc64d0a52742c6ed5b38500c3f7da0b8a2d049311001c",
      "line": 392,
      "relation": "increases",
      "source": 88,
      "subject": {
        "modifier": "Activity"
      },
      "target": 77
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Interestingly, stimulation of M1 mAChR by agonists has been found to enhance sAPPalpha generation and reduce Abeta production[61-70]. Protein kinase C (PKC) is well-known to be activated upon stimulation of M1 mAChR. PKC may promote the activity of alpha-secretase[71] and the traffi cking of APP from the Golgi/ trans-Golgi network to the cell surface",
      "key": "e945120c7c62860e90fb35a427d90822fa50242d4d5ec4bca005ce2776d731e4c65c85c649791edb0f7cb92bf6dd51d2f195589787170288b7c4e0491f1b7197",
      "line": 393,
      "relation": "decreases",
      "source": 88,
      "subject": {
        "modifier": "Activity"
      },
      "target": 2
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Interestingly, stimulation of M1 mAChR by agonists has been found to enhance sAPPalpha generation and reduce Abeta production[61-70]. Protein kinase C (PKC) is well-known to be activated upon stimulation of M1 mAChR. PKC may promote the activity of alpha-secretase[71] and the traffi cking of APP from the Golgi/ trans-Golgi network to the cell surface",
      "key": "5299c5f5955266aebc2a842dfb1e9ed34fe3379e4cb93007c416ed3864256937e6430b35e1581c54f59aa464f8fa6fecaffa002e1f82d552f69d771ae56653c7",
      "line": 394,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 88,
      "subject": {
        "modifier": "Activity"
      },
      "target": 82
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "When APP/PS1/tau triple transgenic (3×Tg) AD mice are treated with the selective M1 mAChR agonist AF267B, the endogenous level of BACE1 decreases via an unclear mechanism, accompanied by a decreased Abeta level[77]. However, another study found that stimulation of M1 mAChR upregulates BACE1 levels in SK-SH-SY5Y cells via the PKC and MAPK signaling cascades[78]. We recently found that M1 mAChR directly interacts with BACE1 and mediates its proteasomal degradation[79]. These results suggest that M1 mAChR modulates BACE1 in a mixed manner.",
      "key": "c5fc68db6a1f15e9143e6a01459ddc7bc4419524568b705d4ecb7999cdda6e330079b9c5869ab46727ebcd2cf2844251e5bf9ccbe0399ddf16abaa1f96b99bd4",
      "line": 451,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 88,
      "subject": {
        "modifier": "Activity"
      },
      "target": 82
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "In addition to inhibiting Abeta generation, activation of M1 mAChR counteracts Abeta-induced neurotoxicity through the Wnt signaling pathway, as Abeta impairs the Wnt pathway and M1 mAChR stimulation inactivates GSK-3beta via PKC activation, stabilizes beta-catenin, and induces the expression of Wnt-targeting genes engrailed and cyclin-D1 for neuron survival",
      "key": "60cabbb1ca01ef60cf0accde1df00c25d571dd46ce4178ad1cbbdb8646c9ed0ad204880332b99647714eb2e60fd4cf0bdee9915637193fb938de97df5dbfb59b",
      "line": 468,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 88,
      "subject": {
        "modifier": "Activity"
      },
      "target": 82
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Some studies suggest that M1 mAChR stimulation also leads to activation of ERK1/2, which can modulate alpha-secretase activity and APP processing[67, 73],",
      "key": "51818d302e118373be4e1e34a535b0484184b2dece045d9e5e640a424f5c12e9904368bd43f85d64f4e7dcae8ed6ac28e7ddd8dc59180c0c31692665465e1211",
      "line": 406,
      "relation": "increases",
      "source": 88,
      "subject": {
        "modifier": "Activity"
      },
      "target": 41
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "though there are contradictory findings showing that the alpha-secretase-mediated APP processing via M1 mAChR stimulation is not modulated by the ERK1/MEK cascade[71]. On the other hand, loss of M1 mAChR increases amyloidogenic APP processing in neurons and promotes brain Abeta plaque pathology in a mouse model of AD",
      "key": "ba563417b3b7f8247e2d18ae2d410debd8552550901e2e387bd26a62b5e31ca2e9a3b4240fb54ac3e4668565a7633e767ccf22106d5bc0993553418b3f923a8f",
      "line": 419,
      "relation": "causesNoChange",
      "source": 88,
      "subject": {
        "modifier": "Activity"
      },
      "target": 41
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "When APP/PS1/tau triple transgenic (3×Tg) AD mice are treated with the selective M1 mAChR agonist AF267B, the endogenous level of BACE1 decreases via an unclear mechanism, accompanied by a decreased Abeta level[77]. However, another study found that stimulation of M1 mAChR upregulates BACE1 levels in SK-SH-SY5Y cells via the PKC and MAPK signaling cascades[78]. We recently found that M1 mAChR directly interacts with BACE1 and mediates its proteasomal degradation[79]. These results suggest that M1 mAChR modulates BACE1 in a mixed manner.",
      "key": "3333291fa61bf1c9dcf4c228bef2b44c7de0d2a098a46442ec0fef89e09c0961e1091cf2a6b3eabd06c5693ed7626bf380125ea0f002d506a7ad7579ac84eb4d",
      "line": 450,
      "relation": "increases",
      "source": 88,
      "subject": {
        "modifier": "Activity"
      },
      "target": 86
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "When APP/PS1/tau triple transgenic (3×Tg) AD mice are treated with the selective M1 mAChR agonist AF267B, the endogenous level of BACE1 decreases via an unclear mechanism, accompanied by a decreased Abeta level[77]. However, another study found that stimulation of M1 mAChR upregulates BACE1 levels in SK-SH-SY5Y cells via the PKC and MAPK signaling cascades[78]. We recently found that M1 mAChR directly interacts with BACE1 and mediates its proteasomal degradation[79]. These results suggest that M1 mAChR modulates BACE1 in a mixed manner.",
      "key": "ba7c45aa435eb0d88ecc62e4124f21515991b05f3c84325f6f941cfca8187e0291a70f8f4d347f83e3789d8d14db7c26ac323cbe5b9e5effab305b886f229b11",
      "line": 456,
      "relation": "regulates",
      "source": 88,
      "target": 86
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "When APP/PS1/tau triple transgenic (3×Tg) AD mice are treated with the selective M1 mAChR agonist AF267B, the endogenous level of BACE1 decreases via an unclear mechanism, accompanied by a decreased Abeta level[77]. However, another study found that stimulation of M1 mAChR upregulates BACE1 levels in SK-SH-SY5Y cells via the PKC and MAPK signaling cascades[78]. We recently found that M1 mAChR directly interacts with BACE1 and mediates its proteasomal degradation[79]. These results suggest that M1 mAChR modulates BACE1 in a mixed manner.",
      "key": "dd2041947abfd77c1156ccaf0b49aa153bb87b93e9215ecfc905d15a8198c26b3de12dee1e0cbebc0e6a281e38418c49b685080b836a8520388137983ed17b7e",
      "line": 453,
      "relation": "increases",
      "source": 88,
      "subject": {
        "modifier": "Activity"
      },
      "target": 42
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "In addition to inhibiting Abeta generation, activation of M1 mAChR counteracts Abeta-induced neurotoxicity through the Wnt signaling pathway, as Abeta impairs the Wnt pathway and M1 mAChR stimulation inactivates GSK-3beta via PKC activation, stabilizes beta-catenin, and induces the expression of Wnt-targeting genes engrailed and cyclin-D1 for neuron survival",
      "key": "16b6a77ec39d9da41d3aab4ed4d3e279554d9036c1348f4f795456b3934215dfd7b93b2f26407c8d6d1ebbb021dc37dfdc6379a9e14579289f8fa4fa8f8c6068",
      "line": 467,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 88,
      "subject": {
        "modifier": "Activity"
      },
      "target": 96
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "In addition to inhibiting Abeta generation, activation of M1 mAChR counteracts Abeta-induced neurotoxicity through the Wnt signaling pathway, as Abeta impairs the Wnt pathway and M1 mAChR stimulation inactivates GSK-3beta via PKC activation, stabilizes beta-catenin, and induces the expression of Wnt-targeting genes engrailed and cyclin-D1 for neuron survival",
      "key": "c0761a3b88033dffdd4f65b698c56bd485b1e1499686f0c07eb31918f1e8e6c9b2f0cd2a2a1bf5bbbcec1a225d37f174a7ea822b76f73ecfa31298769b29b902",
      "line": 470,
      "relation": "decreases",
      "source": 88,
      "subject": {
        "modifier": "Activity"
      },
      "target": 111
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "In addition to inhibiting Abeta generation, activation of M1 mAChR counteracts Abeta-induced neurotoxicity through the Wnt signaling pathway, as Abeta impairs the Wnt pathway and M1 mAChR stimulation inactivates GSK-3beta via PKC activation, stabilizes beta-catenin, and induces the expression of Wnt-targeting genes engrailed and cyclin-D1 for neuron survival",
      "key": "b4ffc5f3e57a20e91158c55b3948b35d3197e7cfbf043d6d027a5e35b7aa6932482cb99f22f66fd6cb8d3e79b5eaec9fce05d946e5b2eb0521f271addde1d7e9",
      "line": 472,
      "relation": "increases",
      "source": 88,
      "subject": {
        "modifier": "Activity"
      },
      "target": 44
    },
    {
      "annotations": {
        "CellLine": {
          "PC12": true
        },
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Stimulation of M1 mAChR by two agonists, carbachol and AF102B, time- and dose-dependently decreases tau phosphorylation in PC12 cells[81]. Chronic treatment with AF267B also alleviates tau pathology in 3×Tg AD mice, possibly by activating PKC and inhibiting GSK-3beta",
      "key": "7f713547866f40aac29443685d27505edd21bd411d618b72019bbf065a243b8f111ec46e953a4d07a9a2124cc0d0d850426ec1c9fe044d3e8495f3c888ef97da",
      "line": 488,
      "relation": "decreases",
      "source": 88,
      "subject": {
        "modifier": "Activity"
      },
      "target": 98
    },
    {
      "annotations": {
        "CellLine": {
          "SH-SY5Y": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Activation of M1 mAChR also protects against apoptotic factors in human neuroblastoma SH-SY5Y cells, such as DNA damage, oxidative stress, caspase activation, and mitochondrial impairment[83]. In addition, apoptosis induced by serum deprivation is blocked by M1 mAChR activation in a phosphoinositide 3-kinase- and MAPK/ERKindependent manner",
      "key": "6e16244b3c6e74ccc21148e9a64fff99d5392cb59ef10738bf105ec2aebcca49308633857169cc703c562825f77112a0e35e50c4ad377ed08f95083d2d170f6d",
      "line": 511,
      "relation": "decreases",
      "source": 88,
      "subject": {
        "modifier": "Activity"
      },
      "target": 114
    },
    {
      "annotations": {
        "CellLine": {
          "SH-SY5Y": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Activation of M1 mAChR also protects against apoptotic factors in human neuroblastoma SH-SY5Y cells, such as DNA damage, oxidative stress, caspase activation, and mitochondrial impairment[83]. In addition, apoptosis induced by serum deprivation is blocked by M1 mAChR activation in a phosphoinositide 3-kinase- and MAPK/ERKindependent manner",
      "key": "91eb9a65a463d7a0ba7e0326383856f6291961487ed85453bce0bc82e4d8886544d57be6d2725c2de1de8cc5e1246bb924528555c2a4b5f5cbdb430d6541ff98",
      "line": 512,
      "relation": "decreases",
      "source": 88,
      "subject": {
        "modifier": "Activity"
      },
      "target": 120
    },
    {
      "annotations": {
        "CellLine": {
          "SH-SY5Y": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Activation of M1 mAChR also protects against apoptotic factors in human neuroblastoma SH-SY5Y cells, such as DNA damage, oxidative stress, caspase activation, and mitochondrial impairment[83]. In addition, apoptosis induced by serum deprivation is blocked by M1 mAChR activation in a phosphoinositide 3-kinase- and MAPK/ERKindependent manner",
      "key": "b006c7599836ee16f0361ef8abe4dcf83dd91c9158d6b0b519efab9d0c401dc9afd0dbee3e101a09fddbdfb73a0c7e6ed38b5a66002821ad93b5e906a31ff2c3",
      "line": 513,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 88,
      "subject": {
        "modifier": "Activity"
      },
      "target": 102
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Activation of M1 mAChR also protects against apoptotic factors in human neuroblastoma SH-SY5Y cells, such as DNA damage, oxidative stress, caspase activation, and mitochondrial impairment[83]. In addition, apoptosis induced by serum deprivation is blocked by M1 mAChR activation in a phosphoinositide 3-kinase- and MAPK/ERKindependent manner",
      "key": "214d66448ecd91610f47b9999cef6b7ada05e066fa39125d3507e6024f92255ae9e9811879b97f93a2734f92d62e42703d4bc1358590185709c9fb83c09abb66",
      "line": 517,
      "relation": "decreases",
      "source": 88,
      "subject": {
        "modifier": "Activity"
      },
      "target": 47
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Hippocampus": true,
          "Pyramidal Cells": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Nevertheless, a compound developed later, TBPB, selectively activates M1 mAChR in cell lines and shows no agonist activity in any other mAChR subtype. Interestingly, TBPB also potentiates the NMDA-evoked current in hippocampal pyramidal neurons, which is considered to be important for the effect of M1 mAChR on improving cognition. In addition, TBPB shifts the processing of APP in the non-amyloidogenic direction and thereafter decreases neurotoxic Abeta production vitro[120].",
      "key": "7d6d815318a11fa97c99c51a0357b8d56d1b8a456aa766bd645d40b85f0d0c3f022e74c887fa1b9714929b7e34461841a1e561a609bdb4b6d4e8edfb1709cca0",
      "line": 699,
      "relation": "increases",
      "source": 88,
      "subject": {
        "modifier": "Activity"
      },
      "target": 63
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "M2 mAChR is expressed throughout the brain, including the hippocampus and neocortex, and is abundant in non-cholinergic neurons that project to these areas. In the caudate-putamen, M2 mAChR acts as an inhibitory modulator on dopaminergic terminals[46-48].",
      "key": "ffc54c6ac326d88ab9574ca7354a330051d70700cd3c8760f9605f674b2e1d91f49a3047bb3157627ca7c451d9fad3a2ebc6e11ab3836fd7870ffd323507451b",
      "line": 239,
      "relation": "association",
      "source": 89,
      "target": 33
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "M2 mAChR is expressed throughout the brain, including the hippocampus and neocortex, and is abundant in non-cholinergic neurons that project to these areas. In the caudate-putamen, M2 mAChR acts as an inhibitory modulator on dopaminergic terminals[46-48].",
      "key": "4b309cbf2fa2c6d23e86d4e326e89d41047f5e68214aa85427351704277f6d244e8ef8dfc9ee0c7c7629ef10b5ded94811b0384b3cb10e2d7876601902d08950",
      "line": 240,
      "relation": "association",
      "source": 89,
      "target": 36
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Neostriatum": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "M2 mAChR is expressed throughout the brain, including the hippocampus and neocortex, and is abundant in non-cholinergic neurons that project to these areas. In the caudate-putamen, M2 mAChR acts as an inhibitory modulator on dopaminergic terminals[46-48].",
      "key": "b56df01d43d65bd90caed16d120f28e819e512148cd3231843334c25e0bf7e447e55f221f47654a3008381a474cc1c1e9563329aab592cbe2cb8e293f4d6c6bc",
      "line": 244,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 89,
      "target": 8
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "M3 mAChR is expressed at a relatively high level in the hypothalamus, but is also found in many other regions including the hippocampus[47]. Mice lacking M3 mAChR appear hypophagic and lean, suggesting a general function of M2 mAChR in regulating food intake[50].",
      "key": "8846d4e7c3f59858c7b30f046df7628aac8bd93e284b56285e92d9450cda222412bc798e6a1fcb393c415a2f9fede6e22eb5588b702b0b67a7edb3ba0952295c",
      "line": 267,
      "relation": "association",
      "source": 90,
      "target": 34
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "M3 mAChR is expressed at a relatively high level in the hypothalamus, but is also found in many other regions including the hippocampus[47]. Mice lacking M3 mAChR appear hypophagic and lean, suggesting a general function of M2 mAChR in regulating food intake[50].",
      "key": "7e14b0d7b751b4b57b8290565658584d81a35b2b692731b00f0da7e041fa834e3761efc9f3e96727d9b374f38465a7403c12ab2c25e2fda75e32de22dd787b63",
      "line": 268,
      "relation": "association",
      "source": 90,
      "target": 33
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "M4 mAChR is mainly expressed in the corpus striatum in the CNS and on various prejunctional nerve terminals in the periphery. M4 mAChR has been suggested to play a role in psychosis and to be a promising target for the treatment of schizophrenia[52]. Indeed, the mixed M1/M4 mAChR agonist xanomeline has antipsychotic effects, and M4 mAChR-knockout mice display increased sensitivity to the disruptive effects of phencyclidine, a drug of abuse",
      "key": "5d13c382559bc9da86729b0f88c08917c67070652a5a46f841cbcfed6f6c92d223b548467f223b74f6bba088c257c4a69a598277e9f3c2d45e8b3ab4553c57b5",
      "line": 300,
      "relation": "association",
      "source": 91,
      "target": 27
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "M4 mAChR is mainly expressed in the corpus striatum in the CNS and on various prejunctional nerve terminals in the periphery. M4 mAChR has been suggested to play a role in psychosis and to be a promising target for the treatment of schizophrenia[52]. Indeed, the mixed M1/M4 mAChR agonist xanomeline has antipsychotic effects, and M4 mAChR-knockout mice display increased sensitivity to the disruptive effects of phencyclidine, a drug of abuse",
      "key": "6962c3d44881c36a5e651906ee48af03674250c4520ce0c17819b49941016d86fea8fcbe4c73ec4ac3d0a8dbdfa57fef39ce2e3b1923d3216e03d6a716c8a41f",
      "line": 301,
      "relation": "association",
      "source": 91,
      "target": 123
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "M4 mAChR is also involved in the pathology of Parkinson’s disease, which is associated with the loss of dopaminergic neurons projecting to the striatum and an imbalance between cholinergic and dopaminergic systems. In the corpus striatum, M4 mAChR is closely co-localized with dopamine receptors on striatal-projecting neurons and the striatal M4 mAChR inhibits dopamine D1 receptor function. Mice lacking M4 mAChR show increased locomotor activity and enhanced dopamine D1 receptor-mediated effects[55]. Consequently, selective M4 mAChR antagonists, such as benzoxazines, have been developed for the treatment of Parkinson’s disease",
      "key": "94651e2ed2988ca443d0ea59decce087a9d843073208a5f0dff10f2c4e7912f2fbe6215e37f45f0234dd2744c162edaab6e6295f34432ba5ca0e7ad4aec7ec05",
      "line": 324,
      "relation": "association",
      "source": 91,
      "target": 121
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "MeSHAnatomy": {
          "Corpus Striatum": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "M4 mAChR is also involved in the pathology of Parkinson’s disease, which is associated with the loss of dopaminergic neurons projecting to the striatum and an imbalance between cholinergic and dopaminergic systems. In the corpus striatum, M4 mAChR is closely co-localized with dopamine receptors on striatal-projecting neurons and the striatal M4 mAChR inhibits dopamine D1 receptor function. Mice lacking M4 mAChR show increased locomotor activity and enhanced dopamine D1 receptor-mediated effects[55]. Consequently, selective M4 mAChR antagonists, such as benzoxazines, have been developed for the treatment of Parkinson’s disease",
      "key": "1876724e074b1cdc14649e417c3609b69e52dc45cc20bb072b3cc69e1ea594a0307c870c1db265a46b8b9ec55c48031217d4ebab55e84f2b665a2a86f7c3f131",
      "line": 329,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 91,
      "target": 93
    },
    {
      "annotations": {
        "Anatomy": {
          "substantia nigra pars compacta": true,
          "ventral tegmental area": true
        },
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "M5 mAChR is predominantly distributed in the pars compacta of the substantia nigra, a structure that provides dopaminergic innervation to the striatum, and in the ventral tegmental area, a structure providing dopaminergic innervation to the nucleus accumbens and other limbic areas[26, 57]. These areas are well known to play a critical role in the rewarding effects of several drugs of abuse. M5 mAChR-knockout mice are less sensitive to addictive drugs such as morphine and cocaine[58].",
      "key": "d2d359a4b09a1e0ed5a98376d2bc31442b5aad7fd6d9ad0cba88faf61eff7f6ae5a17e12136a5cf2856b437300691822807dbcddd832bfe518296561ee45f99f",
      "line": 356,
      "relation": "increases",
      "source": 92,
      "target": 58
    },
    {
      "annotations": {
        "Anatomy": {
          "substantia nigra pars compacta": true,
          "ventral tegmental area": true
        },
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "M5 mAChR is predominantly distributed in the pars compacta of the substantia nigra, a structure that provides dopaminergic innervation to the striatum, and in the ventral tegmental area, a structure providing dopaminergic innervation to the nucleus accumbens and other limbic areas[26, 57]. These areas are well known to play a critical role in the rewarding effects of several drugs of abuse. M5 mAChR-knockout mice are less sensitive to addictive drugs such as morphine and cocaine[58].",
      "key": "1648127ccb143994f82f234d05e2679a8c2c7e37ebfbc5aa1c9f7feb50088e5afb2b11de090ca811efb2405a55e2bcef093e25fbfbc88bdd4805d28e938a9d69",
      "line": 357,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 92,
      "target": 9
    },
    {
      "annotations": {
        "Anatomy": {
          "substantia nigra pars compacta": true,
          "ventral tegmental area": true
        },
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "M5 mAChR is predominantly distributed in the pars compacta of the substantia nigra, a structure that provides dopaminergic innervation to the striatum, and in the ventral tegmental area, a structure providing dopaminergic innervation to the nucleus accumbens and other limbic areas[26, 57]. These areas are well known to play a critical role in the rewarding effects of several drugs of abuse. M5 mAChR-knockout mice are less sensitive to addictive drugs such as morphine and cocaine[58].",
      "key": "d1a18316cfc429531fb2ad2b0a0fba00585b3c3b4d7331ff001f1fbbee25242b3f5c6b9d80c260c1ebc3d7588fed7c6abc12b36ede12b522af212d43ce7fc82f",
      "line": 358,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 92,
      "target": 7
    },
    {
      "key": "7cd4cf5c57d0cd2ca0aa1b5290a39ad935690cbaf9fc2bc5797e608c8cf4ca3d735f2868cf79164254ff156c25752c97e1534e31aa9d99a005ab0e61319f7d4f",
      "relation": "hasComponent",
      "source": 72,
      "target": 88
    },
    {
      "key": "a8e2d491f35afa123473c2500ca55ef0ea7d78c493766b964391a6427457fbab27d0808586796367eb71bf1b065bca27ac06dacca6f9778e7c24c7da8093d8fd",
      "relation": "hasComponent",
      "source": 72,
      "target": 94
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "So far, five mAChR subtypes (M1– M5) have been identified and are divided into two categories based on the manner of signal transduction: M1, M3, and M5 subtypes preferentially interact with the Gq/11 family of G proteins, activating phospholipase C and mobilizing intracellular calcium, while M2 and M4 subtypes couple to the Go/i family, inhibiting adenylate cyclases and reducing intracellular cAMP levels",
      "key": "635e4a36d65413335dae66f012c9fff37411146cb03d12360e45837fd9c788224d4c733fb811e61c210d3e52e84423cf640fdd0ef0996baeb81c41c94678c60c",
      "line": 160,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 72,
      "target": 83
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "So far, five mAChR subtypes (M1– M5) have been identified and are divided into two categories based on the manner of signal transduction: M1, M3, and M5 subtypes preferentially interact with the Gq/11 family of G proteins, activating phospholipase C and mobilizing intracellular calcium, while M2 and M4 subtypes couple to the Go/i family, inhibiting adenylate cyclases and reducing intracellular cAMP levels",
      "key": "0ee96538a7ac5bb52167cb690643447a363bbdbcca33cbd379fe8107684d5cef3bcdfd64a2468c5696bb5f8056a8ad3e1b6156c0a51d50e42e82398a5e17792e",
      "line": 161,
      "relation": "increases",
      "source": 72,
      "target": 46
    },
    {
      "key": "d1753eb82f84e33ccb1d5762146671298fd0030e5526e29c763b881bc9ba73b64cb65473fd1374afbe8c36a2a4710fa80c0ae5217d01a3afb3f627a3707714cb",
      "relation": "hasComponent",
      "source": 74,
      "target": 90
    },
    {
      "key": "82eb8dc1ae2d02aceb4644474d8eadeb74dde3210fd440d89f87976540f3fa5c29d66c9db16be248b2c3e6951a5cca6b40708e174cf0d7cc99736ed1c780239c",
      "relation": "hasComponent",
      "source": 74,
      "target": 94
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "So far, five mAChR subtypes (M1– M5) have been identified and are divided into two categories based on the manner of signal transduction: M1, M3, and M5 subtypes preferentially interact with the Gq/11 family of G proteins, activating phospholipase C and mobilizing intracellular calcium, while M2 and M4 subtypes couple to the Go/i family, inhibiting adenylate cyclases and reducing intracellular cAMP levels",
      "key": "f7c4125e0b48e8ea6236ed53a700de79dd7dbe2495aa496b3314e98358cc02d7e0386fa84db1ccc410c827bdc5664939f4a8b9a30f78fbac10a7c1a4241d1c54",
      "line": 162,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 74,
      "target": 83
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "So far, five mAChR subtypes (M1– M5) have been identified and are divided into two categories based on the manner of signal transduction: M1, M3, and M5 subtypes preferentially interact with the Gq/11 family of G proteins, activating phospholipase C and mobilizing intracellular calcium, while M2 and M4 subtypes couple to the Go/i family, inhibiting adenylate cyclases and reducing intracellular cAMP levels",
      "key": "c778cf583920ea50a7b1dbd0c932c73d9fc04e3ada10435dfd569b3386e04af021a55d8f9787da16223a7caa1a0696f3fb5d60dff0a38a6000a1459ed6788bbc",
      "line": 163,
      "relation": "increases",
      "source": 74,
      "target": 46
    },
    {
      "key": "afbf51e0ff9b2d5184725caeb486265e75d557ac1c2fc5bdd10df9cf0c9190fee339c84a5d05917a8ada19c9d5305e55aeab127d26aae393408d4f4e38b4a0e7",
      "relation": "hasComponent",
      "source": 76,
      "target": 92
    },
    {
      "key": "6939e33356f5dc9ce255ba7fb66a183d6a49a2af0bceb9aed5d7d4d849ee9b402c0132fa74ca3202c228108c4e30cb1dbee5a40a70660dab8b059f23860cc557",
      "relation": "hasComponent",
      "source": 76,
      "target": 94
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "So far, five mAChR subtypes (M1– M5) have been identified and are divided into two categories based on the manner of signal transduction: M1, M3, and M5 subtypes preferentially interact with the Gq/11 family of G proteins, activating phospholipase C and mobilizing intracellular calcium, while M2 and M4 subtypes couple to the Go/i family, inhibiting adenylate cyclases and reducing intracellular cAMP levels",
      "key": "ec55182c6cd6acf6593067ae277212ef51065dacf310e1e433a1ef890cf324c438dde463b6b9a6a4b3e3faf9ecc2a44c9698a71c70f01e1f6c714835063533d8",
      "line": 164,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 76,
      "target": 83
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "So far, five mAChR subtypes (M1– M5) have been identified and are divided into two categories based on the manner of signal transduction: M1, M3, and M5 subtypes preferentially interact with the Gq/11 family of G proteins, activating phospholipase C and mobilizing intracellular calcium, while M2 and M4 subtypes couple to the Go/i family, inhibiting adenylate cyclases and reducing intracellular cAMP levels",
      "key": "a28a91abfdc2899e3a964df587faad31106aec9a32de10d4a2e2c6c929d35cc0818cfe8e88888834b21fbfe3ce769617c0b9176d7f0dc35859a912e3869eda94",
      "line": 165,
      "relation": "increases",
      "source": 76,
      "target": 46
    },
    {
      "key": "efb4a4ed3e4d18380aa51c512af64b15870c71da8adc72ea05faa52db89cf3fde3ac8ddbb9be38667ee8692c92bc178de3b5e9e241dd234aecc11b8b81c04b5d",
      "relation": "hasComponent",
      "source": 73,
      "target": 89
    },
    {
      "key": "3255939218716d905dc6cab5e584eccef66df1817a6063a092a676072e8bb752709c952318c5f75ff1e4851d1f5b4bd30ce734bf0d736ec9cb06a31123f7dffe",
      "relation": "hasComponent",
      "source": 73,
      "target": 95
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "So far, five mAChR subtypes (M1– M5) have been identified and are divided into two categories based on the manner of signal transduction: M1, M3, and M5 subtypes preferentially interact with the Gq/11 family of G proteins, activating phospholipase C and mobilizing intracellular calcium, while M2 and M4 subtypes couple to the Go/i family, inhibiting adenylate cyclases and reducing intracellular cAMP levels",
      "key": "8fc6195e248805892a68be9b7791881c862c58e745662be60da84c08e49ad11d54229d169eca7814bfc13a950bceb4dd7438d0d2f581de7d332b8e2440094dc0",
      "line": 166,
      "relation": "decreases",
      "source": 73,
      "target": 99
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "So far, five mAChR subtypes (M1– M5) have been identified and are divided into two categories based on the manner of signal transduction: M1, M3, and M5 subtypes preferentially interact with the Gq/11 family of G proteins, activating phospholipase C and mobilizing intracellular calcium, while M2 and M4 subtypes couple to the Go/i family, inhibiting adenylate cyclases and reducing intracellular cAMP levels",
      "key": "8dfd0fbaf606bda6cc83ce19c41db039195ae30cd541c43b188152edc0bef081b742c22b5ef5a1c288f826c5cfe997456f6a530566bc05e994ec7690f0e28d7e",
      "line": 167,
      "relation": "decreases",
      "source": 73,
      "target": 0
    },
    {
      "key": "710c477d6c2d658459dd1c24b1f9197678467399eb0be361cc6643fb2e9ee7c7f149bc7590b6cf6f12ea787d3206169dcff6b4745e3b9bd181d8c1559a14ef83",
      "relation": "hasComponent",
      "source": 75,
      "target": 91
    },
    {
      "key": "160d2707ebe8b86ffcd97b3c66de99072965b3275e86be4806a6b0ea0556cdcd065601bab1c1ddb6efeca7934316c458ba14e631fb11ce355cf6933c9cf75cce",
      "relation": "hasComponent",
      "source": 75,
      "target": 95
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "So far, five mAChR subtypes (M1– M5) have been identified and are divided into two categories based on the manner of signal transduction: M1, M3, and M5 subtypes preferentially interact with the Gq/11 family of G proteins, activating phospholipase C and mobilizing intracellular calcium, while M2 and M4 subtypes couple to the Go/i family, inhibiting adenylate cyclases and reducing intracellular cAMP levels",
      "key": "e0618ea9e6aba270a25dfde34df226a3b8bc74d08047aa87be141881246c57994731871c18a2005eafe8148dcc2f3bab794c0889a452786d9090d3fe1e155c2a",
      "line": 168,
      "relation": "decreases",
      "source": 75,
      "target": 99
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "So far, five mAChR subtypes (M1– M5) have been identified and are divided into two categories based on the manner of signal transduction: M1, M3, and M5 subtypes preferentially interact with the Gq/11 family of G proteins, activating phospholipase C and mobilizing intracellular calcium, while M2 and M4 subtypes couple to the Go/i family, inhibiting adenylate cyclases and reducing intracellular cAMP levels",
      "key": "ba8588427ac252ca5d38a110ab03ba3c8e280b6e07c8e224981ce5afc0e1e9b8e2ab55b8a2258d7cd2bd90bef805d3fe02599c69ccac3e77ef98c5896c7977e6",
      "line": 169,
      "relation": "decreases",
      "source": 75,
      "target": 0
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Members of the mAChR family are widely expressed in various regions in the central nervous system (CNS) and in the peripheral system. They play crucial roles in diverse physiological processes such as memory, attention, nociception, motor control, sleep-wake cycles, and cardiovascular, renal, and gastrointestinal functions",
      "key": "699d581156587a67683de8d76b7ed626e04d061f0a701fa380ab5d902a5346b397f76caa95daedd44adff17c1f02c11e09be707339d730ad6f971b9d649b12d6",
      "line": 180,
      "relation": "association",
      "source": 65,
      "target": 100
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Among the mAChR family members, the M1 subtype makes up 50–60% of the total and is predominantly expressed in all major areas of the forebrain, including the hippocampus, cerebral cortex, corpus striatum, and thalamus[36-38]. M1 mAChR-knockout mice show a series of cognitive defi cits and impairments in long-term potentiation, indicating that the M1 subtype is physiologically linked to multiple functions such as synaptic plasticity, neuronal excitability, neuronal differentiation during early development, and learning and memory",
      "key": "69243c5b36eb95de9ca07e196c99b68ed054b8a3a54b468580b57687c576ec055d6605c7bd46ccd199c4a99a1f19f95174f3a03be88f5b2a47104f9bcf6f98e6",
      "line": 214,
      "relation": "association",
      "source": 65,
      "target": 88
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Members of the mAChR family are widely expressed in various regions in the central nervous system (CNS) and in the peripheral system. They play crucial roles in diverse physiological processes such as memory, attention, nociception, motor control, sleep-wake cycles, and cardiovascular, renal, and gastrointestinal functions",
      "key": "8905dc868c1c0d5d3b6bb151a300e0777651028e80f7437b7f5b8127a94ff8173b9c9686d63f6ea6b6651e7bbc04898b789cc8b51a17112b421247b133f37503",
      "line": 181,
      "relation": "association",
      "source": 126,
      "target": 100
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Members of the mAChR family are widely expressed in various regions in the central nervous system (CNS) and in the peripheral system. They play crucial roles in diverse physiological processes such as memory, attention, nociception, motor control, sleep-wake cycles, and cardiovascular, renal, and gastrointestinal functions",
      "key": "e915a67090da9226e53a0d42346a72f4717a54883c71bf8385f64d280b1d734c6cdf502842d4ce160accd636484c4e87a32ed2a09faef690f489e6ae6794e7e6",
      "line": 182,
      "relation": "association",
      "source": 130,
      "target": 100
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Members of the mAChR family are widely expressed in various regions in the central nervous system (CNS) and in the peripheral system. They play crucial roles in diverse physiological processes such as memory, attention, nociception, motor control, sleep-wake cycles, and cardiovascular, renal, and gastrointestinal functions",
      "key": "b7ebe98c93145be04a0d811d4def8573d26ad0971b1a42c49d0b1a7e6a2ce99287bf070df36adee03bd76edad4656e452d81bace722032d5ead77d74e9def2ea",
      "line": 183,
      "relation": "association",
      "source": 48,
      "target": 100
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Members of the mAChR family are widely expressed in various regions in the central nervous system (CNS) and in the peripheral system. They play crucial roles in diverse physiological processes such as memory, attention, nociception, motor control, sleep-wake cycles, and cardiovascular, renal, and gastrointestinal functions",
      "key": "3b5e4084f45a59579db8061e47623646e49899abc045c83cfc74e969f746c67056c63ac6706713376f6ff4c67abe97e6b23b378c841fe3a078afd4015bea1a3f",
      "line": 184,
      "relation": "association",
      "source": 24,
      "target": 100
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Members of the mAChR family are widely expressed in various regions in the central nervous system (CNS) and in the peripheral system. They play crucial roles in diverse physiological processes such as memory, attention, nociception, motor control, sleep-wake cycles, and cardiovascular, renal, and gastrointestinal functions",
      "key": "a9de22e2679a1a0ac68b2c1905278d2a9ea62dd8f0d98175d29c3a0e4864c0af088a9e0d7ae6bfb2ac10470ff81a6f0c4eaaa4f7ff52dffbe6364adf316c2c49",
      "line": 185,
      "relation": "association",
      "source": 35,
      "target": 100
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Members of the mAChR family are widely expressed in various regions in the central nervous system (CNS) and in the peripheral system. They play crucial roles in diverse physiological processes such as memory, attention, nociception, motor control, sleep-wake cycles, and cardiovascular, renal, and gastrointestinal functions",
      "key": "0cebca7aec24a2beef0987cf5ec94a8109497c93e12947ed8ba6df6579963e4f93fc074df59148846cd3a8259fa152a7d2356edf2b3abde008ad6fc5de605398",
      "line": 186,
      "relation": "association",
      "source": 29,
      "target": 100
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Among the mAChR family members, the M1 subtype makes up 50–60% of the total and is predominantly expressed in all major areas of the forebrain, including the hippocampus, cerebral cortex, corpus striatum, and thalamus[36-38]. M1 mAChR-knockout mice show a series of cognitive defi cits and impairments in long-term potentiation, indicating that the M1 subtype is physiologically linked to multiple functions such as synaptic plasticity, neuronal excitability, neuronal differentiation during early development, and learning and memory",
      "key": "3e2b1cc73b556576d0fd5ddd4abc6737c1eba49cd90c83319797fe040a394dfb1a20ae3c46b52f909c7c502c55c41654fc32cbcb810d1c1cfe7bcf76df725f45",
      "line": 200,
      "relation": "association",
      "source": 33,
      "target": 88
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "M2 mAChR is expressed throughout the brain, including the hippocampus and neocortex, and is abundant in non-cholinergic neurons that project to these areas. In the caudate-putamen, M2 mAChR acts as an inhibitory modulator on dopaminergic terminals[46-48].",
      "key": "4b95550d192946642f5f98f8d3a9a76356f24c1a429f42d224729b8346d2ab37ba1f61779188ddf9e8402c27ba9c2e9bab9543b5fef3701082ab8873d54924e7",
      "line": 239,
      "relation": "association",
      "source": 33,
      "target": 89
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "M3 mAChR is expressed at a relatively high level in the hypothalamus, but is also found in many other regions including the hippocampus[47]. Mice lacking M3 mAChR appear hypophagic and lean, suggesting a general function of M2 mAChR in regulating food intake[50].",
      "key": "97b9358fcacc94d79a41e5c44bac485f9afd372778a8c9f0941a683c40b56b39a07ab7d8ca7cdaeb6af087ee4008262807149707bb2c47ab392ac8a53162c4e4",
      "line": 268,
      "relation": "association",
      "source": 33,
      "target": 90
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Among the mAChR family members, the M1 subtype makes up 50–60% of the total and is predominantly expressed in all major areas of the forebrain, including the hippocampus, cerebral cortex, corpus striatum, and thalamus[36-38]. M1 mAChR-knockout mice show a series of cognitive defi cits and impairments in long-term potentiation, indicating that the M1 subtype is physiologically linked to multiple functions such as synaptic plasticity, neuronal excitability, neuronal differentiation during early development, and learning and memory",
      "key": "d14190a778d81fa0b7f1a9a79d472297dc957ef64e75b42d9831627e3c15ddc3ea263bee999d146e4a77fceaa35a8274d2c79b82a68e9731fda85f1d6c49ff9b",
      "line": 201,
      "relation": "association",
      "source": 25,
      "target": 88
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Among the mAChR family members, the M1 subtype makes up 50–60% of the total and is predominantly expressed in all major areas of the forebrain, including the hippocampus, cerebral cortex, corpus striatum, and thalamus[36-38]. M1 mAChR-knockout mice show a series of cognitive defi cits and impairments in long-term potentiation, indicating that the M1 subtype is physiologically linked to multiple functions such as synaptic plasticity, neuronal excitability, neuronal differentiation during early development, and learning and memory",
      "key": "cd9448bee8758ecefd6329c3ba1af0280fd411a22ee649e024c4de2b4ce80fa61e7f314c730d434abf4ea98dca8b8e64b3968c32a8f5c674419d30a786c9dbd6",
      "line": 202,
      "relation": "association",
      "source": 27,
      "target": 88
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "M4 mAChR is mainly expressed in the corpus striatum in the CNS and on various prejunctional nerve terminals in the periphery. M4 mAChR has been suggested to play a role in psychosis and to be a promising target for the treatment of schizophrenia[52]. Indeed, the mixed M1/M4 mAChR agonist xanomeline has antipsychotic effects, and M4 mAChR-knockout mice display increased sensitivity to the disruptive effects of phencyclidine, a drug of abuse",
      "key": "63aab9bb7347fe6307f9ffe8dcd5095e03c9292961819f7051e6e9477ab96ecfcab78fa60557305f3060eb0137f62a0b35d0c35973a177fbe0a3e1683e0bada3",
      "line": 300,
      "relation": "association",
      "source": 27,
      "target": 91
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Among the mAChR family members, the M1 subtype makes up 50–60% of the total and is predominantly expressed in all major areas of the forebrain, including the hippocampus, cerebral cortex, corpus striatum, and thalamus[36-38]. M1 mAChR-knockout mice show a series of cognitive defi cits and impairments in long-term potentiation, indicating that the M1 subtype is physiologically linked to multiple functions such as synaptic plasticity, neuronal excitability, neuronal differentiation during early development, and learning and memory",
      "key": "372a61a902f30a89119d257f6d79ba217d14b3ad583fee2b16f1cc9d6fde0332e1e13312a66613065d9d9a0cde8fd85bdffe164cb969f99d9149482786775276",
      "line": 203,
      "relation": "association",
      "source": 37,
      "target": 88
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Among the mAChR family members, the M1 subtype makes up 50–60% of the total and is predominantly expressed in all major areas of the forebrain, including the hippocampus, cerebral cortex, corpus striatum, and thalamus[36-38]. M1 mAChR-knockout mice show a series of cognitive defi cits and impairments in long-term potentiation, indicating that the M1 subtype is physiologically linked to multiple functions such as synaptic plasticity, neuronal excitability, neuronal differentiation during early development, and learning and memory",
      "key": "8405559e1482182cc12b7cbf1fc95b99b97687e49824edb1b53b1a3afb575836737a067ada743973946b0a61fac913e4ea639c379f4d1441d8e5069c1fe4dc4e",
      "line": 207,
      "relation": "increases",
      "source": 104,
      "target": 63
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Among the mAChR family members, the M1 subtype makes up 50–60% of the total and is predominantly expressed in all major areas of the forebrain, including the hippocampus, cerebral cortex, corpus striatum, and thalamus[36-38]. M1 mAChR-knockout mice show a series of cognitive defi cits and impairments in long-term potentiation, indicating that the M1 subtype is physiologically linked to multiple functions such as synaptic plasticity, neuronal excitability, neuronal differentiation during early development, and learning and memory",
      "key": "878e27103a80e67bc4428d30c3b7bac671c0a431e5668b1e6d52c30474e5d8b8a7bca23024c0272ad44c37c45ab42ba8929e900502320e35ce0c040fd5370df8",
      "line": 208,
      "relation": "increases",
      "source": 104,
      "target": 50
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "though there are contradictory findings showing that the alpha-secretase-mediated APP processing via M1 mAChR stimulation is not modulated by the ERK1/MEK cascade[71]. On the other hand, loss of M1 mAChR increases amyloidogenic APP processing in neurons and promotes brain Abeta plaque pathology in a mouse model of AD",
      "key": "540620d4af8cec492446cdff3a3753e90d1a869675620c588cf62b4418da9d8089b9fef2ca1ef289e6e55b41ea4f34589219db9d2473a468f459f22e9c4598fd",
      "line": 424,
      "relation": "decreases",
      "source": 104,
      "subject": {
        "modifier": "Activity"
      },
      "target": 40
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "though there are contradictory findings showing that the alpha-secretase-mediated APP processing via M1 mAChR stimulation is not modulated by the ERK1/MEK cascade[71]. On the other hand, loss of M1 mAChR increases amyloidogenic APP processing in neurons and promotes brain Abeta plaque pathology in a mouse model of AD",
      "key": "106392d234a32ffb132d96e2ae38381dd048de453bf43c1ae234f73bc5d3a85a57ecdf65b94bdd531ebbf15750d0530a3e6738fba34de1fbe685a71e8a9966ff",
      "line": 425,
      "relation": "decreases",
      "source": 104,
      "subject": {
        "modifier": "Activity"
      },
      "target": 122
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Among the mAChR family members, the M1 subtype makes up 50–60% of the total and is predominantly expressed in all major areas of the forebrain, including the hippocampus, cerebral cortex, corpus striatum, and thalamus[36-38]. M1 mAChR-knockout mice show a series of cognitive defi cits and impairments in long-term potentiation, indicating that the M1 subtype is physiologically linked to multiple functions such as synaptic plasticity, neuronal excitability, neuronal differentiation during early development, and learning and memory",
      "key": "d6ea088f79b6853316ba962ddbcd4a1a5d9a3cbb78bf051cd669c4f31841ebfc63e2387b9b52ed011f6cc16c2f26011cee243f26ac1d5aedc0ac055d149b1aca",
      "line": 212,
      "relation": "association",
      "source": 57,
      "target": 88
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Among the mAChR family members, the M1 subtype makes up 50–60% of the total and is predominantly expressed in all major areas of the forebrain, including the hippocampus, cerebral cortex, corpus striatum, and thalamus[36-38]. M1 mAChR-knockout mice show a series of cognitive defi cits and impairments in long-term potentiation, indicating that the M1 subtype is physiologically linked to multiple functions such as synaptic plasticity, neuronal excitability, neuronal differentiation during early development, and learning and memory",
      "key": "6aec0df9cb7e3ab26bc86af1b21f215750953542e677f00646f260f98872f2f3b672e66296ef0b674acff051b5aaf57d1c0542350622cba61a8c3ebae165d3ff",
      "line": 213,
      "relation": "association",
      "source": 64,
      "target": 88
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Among the mAChR family members, the M1 subtype makes up 50–60% of the total and is predominantly expressed in all major areas of the forebrain, including the hippocampus, cerebral cortex, corpus striatum, and thalamus[36-38]. M1 mAChR-knockout mice show a series of cognitive defi cits and impairments in long-term potentiation, indicating that the M1 subtype is physiologically linked to multiple functions such as synaptic plasticity, neuronal excitability, neuronal differentiation during early development, and learning and memory",
      "key": "9ae5b42b228574c71116ba54186864748ed0e98fced19f20a2b2f7a05ccdb3a6a8d311b3595983a004f29e6c06a0e25289daa021d5441161874ecc882b9afaf8",
      "line": 215,
      "relation": "association",
      "source": 55,
      "target": 88
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Among the mAChR family members, the M1 subtype makes up 50–60% of the total and is predominantly expressed in all major areas of the forebrain, including the hippocampus, cerebral cortex, corpus striatum, and thalamus[36-38]. M1 mAChR-knockout mice show a series of cognitive defi cits and impairments in long-term potentiation, indicating that the M1 subtype is physiologically linked to multiple functions such as synaptic plasticity, neuronal excitability, neuronal differentiation during early development, and learning and memory",
      "key": "480894d4b530163962a467511b6df238cb5904825b14008326c9da2b793ca10a8a55cbdab20345d23db012d927b32b29f46838769ed15378a0c86b296978fc2b",
      "line": 216,
      "relation": "association",
      "source": 54,
      "target": 88
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "M2 mAChR is expressed throughout the brain, including the hippocampus and neocortex, and is abundant in non-cholinergic neurons that project to these areas. In the caudate-putamen, M2 mAChR acts as an inhibitory modulator on dopaminergic terminals[46-48].",
      "key": "fcc54881a8db0380607803d9cd469f524040c2013fde3313a8a30e65342a4767214043b9aa8c1426702429d7f9239cdbce05922bb274488e552408f4ed303c0b",
      "line": 240,
      "relation": "association",
      "source": 36,
      "target": 89
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Mice deficient in M2 mAChR also show a striking reduction in muscarinic-dependent antinociceptive responses[49], suggesting a general antinociceptive effect.",
      "key": "9c2f0ecf66787ee3b7270b9b78cabae138dd40cd64c40da1a843dfe564a43519b2f2113a67c3c8d0dd38ce8674089ee94263f6dec49c24b9ccd088b79eec750b",
      "line": 255,
      "relation": "decreases",
      "source": 105,
      "target": 119
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "M3 mAChR is expressed at a relatively high level in the hypothalamus, but is also found in many other regions including the hippocampus[47]. Mice lacking M3 mAChR appear hypophagic and lean, suggesting a general function of M2 mAChR in regulating food intake[50].",
      "key": "c1fd45e6e83378980a85c70d695b4b88fe625bbb68781c86447e76f9aadc5f9deb019c7bfe52a88479160799326e50e8fd3c282e47d4d90923e69be03d79afe6",
      "line": 267,
      "relation": "association",
      "source": 34,
      "target": 90
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "M3 mAChR is expressed at a relatively high level in the hypothalamus, but is also found in many other regions including the hippocampus[47]. Mice lacking M3 mAChR appear hypophagic and lean, suggesting a general function of M2 mAChR in regulating food intake[50].",
      "key": "f17cdb781ae4b4c839c2dc79e6f35895148c7bede003ac89586be6759dd69535f15c09126f837d4188fbbdb31a1bdf032874d28fe7dafe43495a239db1c146d4",
      "line": 270,
      "relation": "regulates",
      "source": 106,
      "target": 59
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Consistently, mice with conditional knockout of M3 mAChR in the brain exhibit a dwarf phenotype. They also exhibit hypoplasia of the anterior pituitary gland and significantly decreased hormones including pituitary prolactin and growth hormone[51]. These fi ndings indicate that M3 mAChR plays a critical role in promoting body growth.",
      "key": "3c9f75745ed801c5b5375f5f463886f03bffc9d46507faa75a0d4630baed04bc309d53a4bfeac93c31cc9603d8e357ae0e53fe89d006f3db13b9d31079b150da",
      "line": 283,
      "relation": "increases",
      "source": 106,
      "target": 56
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Consistently, mice with conditional knockout of M3 mAChR in the brain exhibit a dwarf phenotype. They also exhibit hypoplasia of the anterior pituitary gland and significantly decreased hormones including pituitary prolactin and growth hormone[51]. These fi ndings indicate that M3 mAChR plays a critical role in promoting body growth.",
      "key": "1509ad36f263ea1cd5933bd00711e2e068420b916f327b024b2451328d3858f6b9a898777c4c5090d9b190d6c8568014616b2db00f4d67b1f24f09b892b27b5f",
      "line": 284,
      "relation": "increases",
      "source": 106,
      "target": 110
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Consistently, mice with conditional knockout of M3 mAChR in the brain exhibit a dwarf phenotype. They also exhibit hypoplasia of the anterior pituitary gland and significantly decreased hormones including pituitary prolactin and growth hormone[51]. These fi ndings indicate that M3 mAChR plays a critical role in promoting body growth.",
      "key": "a8ba876513f50b3e069b054cdcefa24c4050b55dfbb26ba7d20432631541881ec05e5f8349856fdc875f82ddb274926e90c41f6bb8d26edc677ce98ec43b01f6",
      "line": 285,
      "relation": "increases",
      "source": 106,
      "target": 109
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Consistently, mice with conditional knockout of M3 mAChR in the brain exhibit a dwarf phenotype. They also exhibit hypoplasia of the anterior pituitary gland and significantly decreased hormones including pituitary prolactin and growth hormone[51]. These fi ndings indicate that M3 mAChR plays a critical role in promoting body growth.",
      "key": "3f56572486cb1c9a67b60ef01a4aa80162ec558f703f2031ed8058e50cbc40ac9c671f82e5f27c1bcba2e4aa35645c411191da43856a634dc682c5a713a87609",
      "line": 286,
      "relation": "increases",
      "source": 106,
      "target": 52
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "M4 mAChR is mainly expressed in the corpus striatum in the CNS and on various prejunctional nerve terminals in the periphery. M4 mAChR has been suggested to play a role in psychosis and to be a promising target for the treatment of schizophrenia[52]. Indeed, the mixed M1/M4 mAChR agonist xanomeline has antipsychotic effects, and M4 mAChR-knockout mice display increased sensitivity to the disruptive effects of phencyclidine, a drug of abuse",
      "key": "deb46fe6f3c8a22146541f85a13eb30a28c7a72f67f00ce35d8952236ac6b942901b9ab15c12092c8c3f22ce1c1cbb11d55f46ab0f44e63f60d015f4ba50f5b0",
      "line": 301,
      "relation": "association",
      "source": 123,
      "target": 91
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "M4 mAChR is mainly expressed in the corpus striatum in the CNS and on various prejunctional nerve terminals in the periphery. M4 mAChR has been suggested to play a role in psychosis and to be a promising target for the treatment of schizophrenia[52]. Indeed, the mixed M1/M4 mAChR agonist xanomeline has antipsychotic effects, and M4 mAChR-knockout mice display increased sensitivity to the disruptive effects of phencyclidine, a drug of abuse",
      "key": "c960d24a12075c85103ce19aaedba2bfecc10b9752331ea7b095ebfdffaecac367e6600a75280bf758a869575144b7220da2b3b492cda96f906870d4a1b120d6",
      "line": 302,
      "relation": "decreases",
      "source": 11,
      "target": 123
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "One example is xanomeline, an mAChR agonist with selectivity for the M1 and M4 subtypes. Xanomeline improves working memory in rodents and improves cognition and reduces psychotic episodes in AD patients, but it failed during phase-II clinical trial because of serious side-effects, probably due to simultaneous activation of M1 and M4 mAChRs (M4 > M1)",
      "key": "7d4f193f697bc625b16526583dabff2bfe2db71f687ee7f80cc6603ecb18d524aab2aeb8fff1e67cb4525c5b23692d23955caa361bbfe0ceef7b8571837fdd02",
      "line": 569,
      "relation": "decreases",
      "source": 11,
      "target": 123
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "One example is xanomeline, an mAChR agonist with selectivity for the M1 and M4 subtypes. Xanomeline improves working memory in rodents and improves cognition and reduces psychotic episodes in AD patients, but it failed during phase-II clinical trial because of serious side-effects, probably due to simultaneous activation of M1 and M4 mAChRs (M4 > M1)",
      "key": "3c40736930ab144b5e7241d711b770d16c402f77d54ca347832b73371827701c6ff3d7293b517d3cc9e7956228852b4926032595b4409d5d648a510057c7d547",
      "line": 562,
      "relation": "increases",
      "source": 11,
      "target": 65
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "One example is xanomeline, an mAChR agonist with selectivity for the M1 and M4 subtypes. Xanomeline improves working memory in rodents and improves cognition and reduces psychotic episodes in AD patients, but it failed during phase-II clinical trial because of serious side-effects, probably due to simultaneous activation of M1 and M4 mAChRs (M4 > M1)",
      "key": "5f2a3fdd7315c211ca79aa862f2e719632abee986df01e9fba6fe538f9e68d8f0c9cf0766a8b3cdfba7542460d9b98b3b0b82da2030f0ea04bf6829af01f358b",
      "line": 563,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 11,
      "target": 88
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "One example is xanomeline, an mAChR agonist with selectivity for the M1 and M4 subtypes. Xanomeline improves working memory in rodents and improves cognition and reduces psychotic episodes in AD patients, but it failed during phase-II clinical trial because of serious side-effects, probably due to simultaneous activation of M1 and M4 mAChRs (M4 > M1)",
      "key": "fe803ae6aecd90daa979c076a9673cd41d6bdc341c8a80306e48d3aee61942c123e68952ab22a64cd0fae9952c8b933c518932797f43873ea08e0fb3f754c32b",
      "line": 564,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 11,
      "target": 91
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "One example is xanomeline, an mAChR agonist with selectivity for the M1 and M4 subtypes. Xanomeline improves working memory in rodents and improves cognition and reduces psychotic episodes in AD patients, but it failed during phase-II clinical trial because of serious side-effects, probably due to simultaneous activation of M1 and M4 mAChRs (M4 > M1)",
      "key": "11ab9de42a38ab7af2d646da02dbb2217df0e135af8360a714e306615558fe6d0f41273dc8a4fd3e8c8b96e3cfef2c333ff489620f36751e17ee9673e539c45d",
      "line": 568,
      "relation": "increases",
      "source": 11,
      "target": 63
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "M4 mAChR is mainly expressed in the corpus striatum in the CNS and on various prejunctional nerve terminals in the periphery. M4 mAChR has been suggested to play a role in psychosis and to be a promising target for the treatment of schizophrenia[52]. Indeed, the mixed M1/M4 mAChR agonist xanomeline has antipsychotic effects, and M4 mAChR-knockout mice display increased sensitivity to the disruptive effects of phencyclidine, a drug of abuse",
      "key": "c37e6d0ff8084e9ea08884102bee12abad9b76b70359f269ae675922d15d37d531da6f21cabd3cf9b31430599bf4f20e71682eb171259a67bd8ae11c53cc8120",
      "line": 306,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 107,
      "target": 10
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "M4 mAChR is also involved in the pathology of Parkinson’s disease, which is associated with the loss of dopaminergic neurons projecting to the striatum and an imbalance between cholinergic and dopaminergic systems. In the corpus striatum, M4 mAChR is closely co-localized with dopamine receptors on striatal-projecting neurons and the striatal M4 mAChR inhibits dopamine D1 receptor function. Mice lacking M4 mAChR show increased locomotor activity and enhanced dopamine D1 receptor-mediated effects[55]. Consequently, selective M4 mAChR antagonists, such as benzoxazines, have been developed for the treatment of Parkinson’s disease",
      "key": "0b03e94e3117e9203de623072d23bb8540ebd72ef45d89222fac58ea6bb45b0418b434dce24f002e0ab216fdf23fa22271034cd46bc476981ae4421eaa6a8bd1",
      "line": 335,
      "relation": "decreases",
      "source": 107,
      "target": 49
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "M4 mAChR is also involved in the pathology of Parkinson’s disease, which is associated with the loss of dopaminergic neurons projecting to the striatum and an imbalance between cholinergic and dopaminergic systems. In the corpus striatum, M4 mAChR is closely co-localized with dopamine receptors on striatal-projecting neurons and the striatal M4 mAChR inhibits dopamine D1 receptor function. Mice lacking M4 mAChR show increased locomotor activity and enhanced dopamine D1 receptor-mediated effects[55]. Consequently, selective M4 mAChR antagonists, such as benzoxazines, have been developed for the treatment of Parkinson’s disease",
      "key": "6bc4d6a60e0d9ab7f8dfee2ec69ddfe19028b13a908785daed593ca9487baf21ee726636641e2a62b7745568e45f4cef392a144225ee7b4914efb2ec50434d68",
      "line": 336,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 107,
      "target": 108
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "M4 mAChR is also involved in the pathology of Parkinson’s disease, which is associated with the loss of dopaminergic neurons projecting to the striatum and an imbalance between cholinergic and dopaminergic systems. In the corpus striatum, M4 mAChR is closely co-localized with dopamine receptors on striatal-projecting neurons and the striatal M4 mAChR inhibits dopamine D1 receptor function. Mice lacking M4 mAChR show increased locomotor activity and enhanced dopamine D1 receptor-mediated effects[55]. Consequently, selective M4 mAChR antagonists, such as benzoxazines, have been developed for the treatment of Parkinson’s disease",
      "key": "f0e1bf51baf01123326a9332738a491bffcf19bc6aef0aaabb277acb991cc14cc57ae13ff2b95432c96c15140b130dbfb824c6153e77a11ff6e9aed52b489832",
      "line": 324,
      "relation": "association",
      "source": 121,
      "target": 91
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "M4 mAChR is also involved in the pathology of Parkinson’s disease, which is associated with the loss of dopaminergic neurons projecting to the striatum and an imbalance between cholinergic and dopaminergic systems. In the corpus striatum, M4 mAChR is closely co-localized with dopamine receptors on striatal-projecting neurons and the striatal M4 mAChR inhibits dopamine D1 receptor function. Mice lacking M4 mAChR show increased locomotor activity and enhanced dopamine D1 receptor-mediated effects[55]. Consequently, selective M4 mAChR antagonists, such as benzoxazines, have been developed for the treatment of Parkinson’s disease",
      "key": "249cf349bd02378940ab11454b21462400ec06737b79197b7d25a54ffe18297ad609faec1239620a1e74ca7d38093251da3923fc7538c1ed3f8e1b242c1cc04d",
      "line": 325,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 121,
      "target": 28
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "M4 mAChR is also involved in the pathology of Parkinson’s disease, which is associated with the loss of dopaminergic neurons projecting to the striatum and an imbalance between cholinergic and dopaminergic systems. In the corpus striatum, M4 mAChR is closely co-localized with dopamine receptors on striatal-projecting neurons and the striatal M4 mAChR inhibits dopamine D1 receptor function. Mice lacking M4 mAChR show increased locomotor activity and enhanced dopamine D1 receptor-mediated effects[55]. Consequently, selective M4 mAChR antagonists, such as benzoxazines, have been developed for the treatment of Parkinson’s disease",
      "key": "03d7341210d6335032c41bd0889603f38dd771ba095f13c2d6c5b4d655c472e6b7556fa1a38d39af9f72016fa0dbdaa13555697443d8405ba921dbbcb0b989ee",
      "line": 339,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 4,
      "target": 91
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "M4 mAChR is also involved in the pathology of Parkinson’s disease, which is associated with the loss of dopaminergic neurons projecting to the striatum and an imbalance between cholinergic and dopaminergic systems. In the corpus striatum, M4 mAChR is closely co-localized with dopamine receptors on striatal-projecting neurons and the striatal M4 mAChR inhibits dopamine D1 receptor function. Mice lacking M4 mAChR show increased locomotor activity and enhanced dopamine D1 receptor-mediated effects[55]. Consequently, selective M4 mAChR antagonists, such as benzoxazines, have been developed for the treatment of Parkinson’s disease",
      "key": "c44fb7418c3a391b1bc4c41493530887af1e5306016405da85ee19edc3dc0878079610c38ecdf33293cc0f90b9a6d5e0b1370d98957cc1f61017965a266cd3a7",
      "line": 341,
      "relation": "decreases",
      "source": 4,
      "target": 121
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Abeta, an important player in AD, is derived from beta-amyloid precursor protein (APP) through sequential cleavages by beta- and gamma-secretases: APP is cleaved by beta-secretase (BACE1) to generate the large secreted derivative sAPPbeta and the membrane-bound APP C-terminal fragment-beta; the latter can be further cleaved by gamma-secretase to generate Abeta and APP intracellular domain. Alternatively, APP can be cleaved by alpha-secretase within the Abeta domain, which precludes Abeta production and instead generates secreted sAPPalpha that has been shown to be neuroprotective",
      "key": "48049cf1b43a2e4e678d0804630ba19ca3fbee3186e5dcf5832e88d93c91518c8dce2c5d24196c89851092fa17f97a1cccabb60e120e9d45842b9581fc3385fd",
      "line": 373,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 86,
      "target": 85
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Abeta, an important player in AD, is derived from beta-amyloid precursor protein (APP) through sequential cleavages by beta- and gamma-secretases: APP is cleaved by beta-secretase (BACE1) to generate the large secreted derivative sAPPbeta and the membrane-bound APP C-terminal fragment-beta; the latter can be further cleaved by gamma-secretase to generate Abeta and APP intracellular domain. Alternatively, APP can be cleaved by alpha-secretase within the Abeta domain, which precludes Abeta production and instead generates secreted sAPPalpha that has been shown to be neuroprotective",
      "key": "45a89a501dc33da621ff6a343f35c2887a6f7466f81ce45d526358137d03f74e32e3682696fbd8ef29c59cfc548349c15c69b79fe633f3383aa35eb7953b15b4",
      "line": 374,
      "relation": "increases",
      "source": 86,
      "target": 78
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Abeta, an important player in AD, is derived from beta-amyloid precursor protein (APP) through sequential cleavages by beta- and gamma-secretases: APP is cleaved by beta-secretase (BACE1) to generate the large secreted derivative sAPPbeta and the membrane-bound APP C-terminal fragment-beta; the latter can be further cleaved by gamma-secretase to generate Abeta and APP intracellular domain. Alternatively, APP can be cleaved by alpha-secretase within the Abeta domain, which precludes Abeta production and instead generates secreted sAPPalpha that has been shown to be neuroprotective",
      "key": "8c8722faaff038653c3a708988eee04e6b5521e11bd83503e3ab861a6c6c6fb79227d9781adb5d9e0a853ddc795df75962158f33557431c420f530b11381eac3",
      "line": 376,
      "relation": "increases",
      "source": 86,
      "target": 80
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Abeta, an important player in AD, is derived from beta-amyloid precursor protein (APP) through sequential cleavages by beta- and gamma-secretases: APP is cleaved by beta-secretase (BACE1) to generate the large secreted derivative sAPPbeta and the membrane-bound APP C-terminal fragment-beta; the latter can be further cleaved by gamma-secretase to generate Abeta and APP intracellular domain. Alternatively, APP can be cleaved by alpha-secretase within the Abeta domain, which precludes Abeta production and instead generates secreted sAPPalpha that has been shown to be neuroprotective",
      "key": "9ccc2c99ecee73e706c5d600359d6079c523aa8def8c66e1fc2fdf62cf69a677d866f0b72d76b307bc83b25546fe611ba6178d7e41f986c68e356ece77472c2e",
      "line": 377,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 67,
      "target": 80
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Abeta, an important player in AD, is derived from beta-amyloid precursor protein (APP) through sequential cleavages by beta- and gamma-secretases: APP is cleaved by beta-secretase (BACE1) to generate the large secreted derivative sAPPbeta and the membrane-bound APP C-terminal fragment-beta; the latter can be further cleaved by gamma-secretase to generate Abeta and APP intracellular domain. Alternatively, APP can be cleaved by alpha-secretase within the Abeta domain, which precludes Abeta production and instead generates secreted sAPPalpha that has been shown to be neuroprotective",
      "key": "40f151ac2e9a0326c3986bc568164bb356539a26aecef4ef6099bc2f88757b5071d0cea0e2b414f6427f7408de4942bfa12cb421b3e6b5f6bba8dcf37c282db3",
      "line": 378,
      "relation": "increases",
      "source": 67,
      "target": 2
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Abeta, an important player in AD, is derived from beta-amyloid precursor protein (APP) through sequential cleavages by beta- and gamma-secretases: APP is cleaved by beta-secretase (BACE1) to generate the large secreted derivative sAPPbeta and the membrane-bound APP C-terminal fragment-beta; the latter can be further cleaved by gamma-secretase to generate Abeta and APP intracellular domain. Alternatively, APP can be cleaved by alpha-secretase within the Abeta domain, which precludes Abeta production and instead generates secreted sAPPalpha that has been shown to be neuroprotective",
      "key": "a5a5639a68a42a638c807d0c88bda470a74426395dd91a69bd8a46530bfc312b9d1a9b277719ebf2a1bc1c312315417babf2d95bf742d711fea378d198500de6",
      "line": 379,
      "relation": "increases",
      "source": 67,
      "target": 79
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "In fact, Abeta has been shown to induce the uncoupling of M1 mAChR from G-protein, antagonizing the function of M1 mAChR under the pathological conditions of AD[96, 97]. Such an uncoupling may result in decreased signal transduction, reduced levels of sAPPalpha, and increased production of Abeta, triggering a vicious cycle.",
      "key": "6a2fb3642e2a45223c84ba36ace0d61ebb137868689f56862b85e7480518719b92fe5b60eab3021002cb29f4a034987f679e9aeadf010d78c1bb434390edc0a3",
      "line": 545,
      "relation": "decreases",
      "source": 2,
      "target": 70
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "In fact, Abeta has been shown to induce the uncoupling of M1 mAChR from G-protein, antagonizing the function of M1 mAChR under the pathological conditions of AD[96, 97]. Such an uncoupling may result in decreased signal transduction, reduced levels of sAPPalpha, and increased production of Abeta, triggering a vicious cycle.",
      "key": "9ba8543b59cc10257aa7890320c35b17e27b8b7c2e7748b6203afd13a67975427b874ec277771011faab898b667ba957720e366f9401bde57b59f992f6e891cd",
      "line": 546,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 2,
      "target": 88
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Hippocampus": true,
          "Pyramidal Cells": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Nevertheless, a compound developed later, TBPB, selectively activates M1 mAChR in cell lines and shows no agonist activity in any other mAChR subtype. Interestingly, TBPB also potentiates the NMDA-evoked current in hippocampal pyramidal neurons, which is considered to be important for the effect of M1 mAChR on improving cognition. In addition, TBPB shifts the processing of APP in the non-amyloidogenic direction and thereafter decreases neurotoxic Abeta production vitro[120].",
      "key": "08fb8fda601a70bacaa2afb7c075d359764d6e133b29589b34f3588dbfdf22a6924a71dfa4d73be52ec9d54d5725f558886b4269d1fbb30020449cef674bf217",
      "line": 701,
      "relation": "increases",
      "source": 2,
      "target": 111
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Abeta, an important player in AD, is derived from beta-amyloid precursor protein (APP) through sequential cleavages by beta- and gamma-secretases: APP is cleaved by beta-secretase (BACE1) to generate the large secreted derivative sAPPbeta and the membrane-bound APP C-terminal fragment-beta; the latter can be further cleaved by gamma-secretase to generate Abeta and APP intracellular domain. Alternatively, APP can be cleaved by alpha-secretase within the Abeta domain, which precludes Abeta production and instead generates secreted sAPPalpha that has been shown to be neuroprotective",
      "key": "1e346fa6a75d0d3ebc79769b9eedf2828b622c9641cc5e529fb0f92a1c862a378d4f6196667f2ba87e285b87afe52a438b890055f47dc11bfbc03dd86e890abc",
      "line": 380,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 84,
      "target": 85
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Abeta, an important player in AD, is derived from beta-amyloid precursor protein (APP) through sequential cleavages by beta- and gamma-secretases: APP is cleaved by beta-secretase (BACE1) to generate the large secreted derivative sAPPbeta and the membrane-bound APP C-terminal fragment-beta; the latter can be further cleaved by gamma-secretase to generate Abeta and APP intracellular domain. Alternatively, APP can be cleaved by alpha-secretase within the Abeta domain, which precludes Abeta production and instead generates secreted sAPPalpha that has been shown to be neuroprotective",
      "key": "91b77d86bf9834dc251a7721607059fc8e6c0fc88d78931569d8101247db2f3c758b13f233ce05317df11dd29fbca803f6224dfdb4341d2aecba01a402697496",
      "line": 381,
      "relation": "increases",
      "source": 84,
      "target": 77
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Abeta, an important player in AD, is derived from beta-amyloid precursor protein (APP) through sequential cleavages by beta- and gamma-secretases: APP is cleaved by beta-secretase (BACE1) to generate the large secreted derivative sAPPbeta and the membrane-bound APP C-terminal fragment-beta; the latter can be further cleaved by gamma-secretase to generate Abeta and APP intracellular domain. Alternatively, APP can be cleaved by alpha-secretase within the Abeta domain, which precludes Abeta production and instead generates secreted sAPPalpha that has been shown to be neuroprotective",
      "key": "a2104d8d764b977b6f33ee656fef16c9fc9537d9e64c2c9992d73533b9ab00eeb8f38660287451c4eb2360c6f8b419fa03a042a01caf186c302d465c631bbe3c",
      "line": 382,
      "relation": "increases",
      "source": 77,
      "target": 66
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Interestingly, stimulation of M1 mAChR by agonists has been found to enhance sAPPalpha generation and reduce Abeta production[61-70]. Protein kinase C (PKC) is well-known to be activated upon stimulation of M1 mAChR. PKC may promote the activity of alpha-secretase[71] and the traffi cking of APP from the Golgi/ trans-Golgi network to the cell surface",
      "key": "6e5dd78b1f0ba6e126ded52b94140a46e26128f53d9feb540ba963901cbd9870523ba8f2acb31e759ba2a6199c62cbff213e8f00de2d3db3d014d1a45dccc44b",
      "line": 395,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 82,
      "subject": {
        "modifier": "Activity"
      },
      "target": 84
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Interestingly, stimulation of M1 mAChR by agonists has been found to enhance sAPPalpha generation and reduce Abeta production[61-70]. Protein kinase C (PKC) is well-known to be activated upon stimulation of M1 mAChR. PKC may promote the activity of alpha-secretase[71] and the traffi cking of APP from the Golgi/ trans-Golgi network to the cell surface",
      "key": "88b41971cd174791c7f2af96aa9edcfd86df311f806fbf140003422bf583e85d9e38516313833a2466daef6b97191e7cb12f04250cb170e06732f4d90c35c7b3",
      "line": 396,
      "object": {
        "effect": {
          "fromLoc": {
            "name": "Golgi apparatus",
            "namespace": "GO"
          },
          "toLoc": {
            "name": "cell surface",
            "namespace": "GO"
          }
        },
        "modifier": "Translocation"
      },
      "relation": "increases",
      "source": 82,
      "subject": {
        "modifier": "Activity"
      },
      "target": 85
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "When APP/PS1/tau triple transgenic (3×Tg) AD mice are treated with the selective M1 mAChR agonist AF267B, the endogenous level of BACE1 decreases via an unclear mechanism, accompanied by a decreased Abeta level[77]. However, another study found that stimulation of M1 mAChR upregulates BACE1 levels in SK-SH-SY5Y cells via the PKC and MAPK signaling cascades[78]. We recently found that M1 mAChR directly interacts with BACE1 and mediates its proteasomal degradation[79]. These results suggest that M1 mAChR modulates BACE1 in a mixed manner.",
      "key": "6be4036894065758c993283b09590fe125ade88de352eea7da472282fb97550ec0a35b5cc71ac2b73ea930b2566cfec7cfed87e6b17c10c0243f1ce6592d6d14",
      "line": 452,
      "relation": "increases",
      "source": 82,
      "subject": {
        "modifier": "Activity"
      },
      "target": 86
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "In addition to inhibiting Abeta generation, activation of M1 mAChR counteracts Abeta-induced neurotoxicity through the Wnt signaling pathway, as Abeta impairs the Wnt pathway and M1 mAChR stimulation inactivates GSK-3beta via PKC activation, stabilizes beta-catenin, and induces the expression of Wnt-targeting genes engrailed and cyclin-D1 for neuron survival",
      "key": "ecb446fb44c143548fb6a3bd6adfbbea90a4f56200bd1d763778d7a6cbc03930715054afc6be06cad792326b92330bf32ef6933df66898a2e1fd49ed22cc23b1",
      "line": 469,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 82,
      "subject": {
        "modifier": "Activity"
      },
      "target": 96
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Some studies suggest that M1 mAChR stimulation also leads to activation of ERK1/2, which can modulate alpha-secretase activity and APP processing[67, 73],",
      "key": "f53fb4dc75461419f1a82393f77c8eee40e5c9e649a30b80249fa78b6fcd04f02ebffab035296b132f4f96ac3aac6ff199db2c55f566e2f85416e747e6eb933a",
      "line": 407,
      "object": {
        "modifier": "Activity"
      },
      "relation": "regulates",
      "source": 41,
      "target": 84
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Some studies suggest that M1 mAChR stimulation also leads to activation of ERK1/2, which can modulate alpha-secretase activity and APP processing[67, 73],",
      "key": "37ca924589b7e9bafa9dc706780bbab41a522cec181c9d1f1e16be6889d9066cf9ab0a03a1d6d692e0b2836a627fb4a59b03cc2c302fa02a5bf4bef5fcd3facc",
      "line": 408,
      "relation": "regulates",
      "source": 41,
      "target": 40
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "When APP/PS1/tau triple transgenic (3×Tg) AD mice are treated with the selective M1 mAChR agonist AF267B, the endogenous level of BACE1 decreases via an unclear mechanism, accompanied by a decreased Abeta level[77]. However, another study found that stimulation of M1 mAChR upregulates BACE1 levels in SK-SH-SY5Y cells via the PKC and MAPK signaling cascades[78]. We recently found that M1 mAChR directly interacts with BACE1 and mediates its proteasomal degradation[79]. These results suggest that M1 mAChR modulates BACE1 in a mixed manner.",
      "key": "16e818e942d86005ac93d4dce3d1b2055d78fe56d605ebb6d9ed7ff2e259afb4194c7415d47349d2d4813a300947e3b5c999cbca24393db44b351c81a31d3432",
      "line": 445,
      "relation": "decreases",
      "source": 17,
      "target": 103
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "When APP/PS1/tau triple transgenic (3×Tg) AD mice are treated with the selective M1 mAChR agonist AF267B, the endogenous level of BACE1 decreases via an unclear mechanism, accompanied by a decreased Abeta level[77]. However, another study found that stimulation of M1 mAChR upregulates BACE1 levels in SK-SH-SY5Y cells via the PKC and MAPK signaling cascades[78]. We recently found that M1 mAChR directly interacts with BACE1 and mediates its proteasomal degradation[79]. These results suggest that M1 mAChR modulates BACE1 in a mixed manner.",
      "key": "dc4812eaaf8fae3f867e9dd523e2b1e8f4773a8c9c9694254ca1c8c12eaef965047717bfe28c75ae4aaaa6c0444b5f75a1d65f82576683138d46b17767d0ad21",
      "line": 446,
      "relation": "decreases",
      "source": 17,
      "target": 2
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Stimulation of M1 mAChR by two agonists, carbachol and AF102B, time- and dose-dependently decreases tau phosphorylation in PC12 cells[81]. Chronic treatment with AF267B also alleviates tau pathology in 3×Tg AD mice, possibly by activating PKC and inhibiting GSK-3beta",
      "key": "764c7b2f429d072a5f7b5ddb5485bb7858ca925efb733f45840d158c1f206934399d6560405f63621c5db3da8e987cce3d38145167aaebf526a393d641cee78c",
      "line": 494,
      "relation": "decreases",
      "source": 17,
      "target": 133
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Stimulation of M1 mAChR by two agonists, carbachol and AF102B, time- and dose-dependently decreases tau phosphorylation in PC12 cells[81]. Chronic treatment with AF267B also alleviates tau pathology in 3×Tg AD mice, possibly by activating PKC and inhibiting GSK-3beta",
      "key": "43f039fb3d34a2c82e0491b2757622600abfbd47311e13bb1b1ae5bb49a69b03ee2e4ed36a336f086d661c637aeea1cc7875f65f19c4ecdff2c0d2faf81f97bd",
      "line": 495,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 17,
      "target": 82
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Stimulation of M1 mAChR by two agonists, carbachol and AF102B, time- and dose-dependently decreases tau phosphorylation in PC12 cells[81]. Chronic treatment with AF267B also alleviates tau pathology in 3×Tg AD mice, possibly by activating PKC and inhibiting GSK-3beta",
      "key": "6702e5e07a24006c79f685de9c3edb8b4dc4654f83a88f9a5b0a2ca09c43e3edbedec48d2e379c65db20c91de9ae462f86cd392e416b0675fffe035d5f924f0f",
      "line": 496,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 17,
      "target": 96
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Chronic treatment with AF267B reduces Abeta plaques and tau hyperphosphorylation and rescues learning and memory impairments in 3×Tg AD mice",
      "key": "7c4d1db5aad5ef199769cf1a51ef8d4901a13c8757c2c188407de133330cce0294aa506717734d13fba27f99cf5070676cab086696475d40f6e835ada264b798",
      "line": 582,
      "relation": "decreases",
      "source": 17,
      "target": 122
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Chronic treatment with AF267B reduces Abeta plaques and tau hyperphosphorylation and rescues learning and memory impairments in 3×Tg AD mice",
      "key": "177ac309c0b2e64c466936d4b8ca5099ee7f4aa28d54cf0ac2a64936881cc0e56b493a1201799b17a4b80b3a54f65d7445006177c686953e88030f58b013ae95",
      "line": 583,
      "relation": "decreases",
      "source": 17,
      "target": 98
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Chronic treatment with AF267B reduces Abeta plaques and tau hyperphosphorylation and rescues learning and memory impairments in 3×Tg AD mice",
      "key": "cc48d17851d5dde8960a872e12da47145e4856f4a6a85a834362ec60e05d502c56169c907a05c4d17e00a9c78d13e8680139426596607d3ac1aba0657583b7dd",
      "line": 584,
      "relation": "increases",
      "source": 17,
      "target": 65
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Chronic treatment with AF267B reduces Abeta plaques and tau hyperphosphorylation and rescues learning and memory impairments in 3×Tg AD mice",
      "key": "f8076daed8a4b827452927a82efe248caf56fcb91c3c44d476203275d523a6c1179d51f1b6132b6a145cf1806cd99d18c596268ba127b16f282bbe67b229d96f",
      "line": 585,
      "relation": "increases",
      "source": 17,
      "target": 64
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "MeSHAnatomy": {
          "Cerebrospinal Fluid": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Administration of AF267B and AF102B (Cevimeline, EVOXACTM), an M1 mAChRselective agonist once prescribed for the treatment of Sjogren’s syndrome, decreases Abeta42 levels in the cerebral spinal fluid (CSF) of rabbits without affecting APP",
      "key": "c1d10119e9d6836ced75e90f23c765b3fe232ed893299cf784aa7311dd13c23b63ca074ad20ff075a8871c260a121f97c9b0ad220e7e44db7484bcb7908d1361",
      "line": 600,
      "relation": "decreases",
      "source": 17,
      "target": 1
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "MeSHAnatomy": {
          "Cerebrospinal Fluid": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Administration of AF267B and AF102B (Cevimeline, EVOXACTM), an M1 mAChRselective agonist once prescribed for the treatment of Sjogren’s syndrome, decreases Abeta42 levels in the cerebral spinal fluid (CSF) of rabbits without affecting APP",
      "key": "f2144ebc523f63a901bf305a772f5fd66d79a4698bd7fa345df110699631006a43207d27372b76898828372a9c79f3b9e1d276cab2b94eb317f658fe5f75dee5",
      "line": 602,
      "relation": "decreases",
      "source": 17,
      "target": 124
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "MeSHAnatomy": {
          "Cerebrospinal Fluid": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Administration of AF267B and AF102B (Cevimeline, EVOXACTM), an M1 mAChRselective agonist once prescribed for the treatment of Sjogren’s syndrome, decreases Abeta42 levels in the cerebral spinal fluid (CSF) of rabbits without affecting APP",
      "key": "b7ca4f056b9c13c240be358fd519e1d16e2fcf73d3ff44fed30428115b975f6f02a84414f6dacedcd6169442eced89da06a586fb8282cad977c2e70e789af881",
      "line": 604,
      "relation": "causesNoChange",
      "source": 17,
      "target": 85
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "When APP/PS1/tau triple transgenic (3×Tg) AD mice are treated with the selective M1 mAChR agonist AF267B, the endogenous level of BACE1 decreases via an unclear mechanism, accompanied by a decreased Abeta level[77]. However, another study found that stimulation of M1 mAChR upregulates BACE1 levels in SK-SH-SY5Y cells via the PKC and MAPK signaling cascades[78]. We recently found that M1 mAChR directly interacts with BACE1 and mediates its proteasomal degradation[79]. These results suggest that M1 mAChR modulates BACE1 in a mixed manner.",
      "key": "d7f3fc657ef6390e63dca57076ae82b941a039c5c2eb16d29b2919fc042ee8d10de1148fde912180653b6ccc2abafbad3ed0cfc6eca0c27b4ca64b8873cac67e",
      "line": 454,
      "relation": "increases",
      "source": 42,
      "target": 86
    },
    {
      "key": "1cb10ca93e5379d46c1d6d089635e7bb6d0726ab7762e70309809416cff336b799d89713f5179ae4f36e84b733f5303e54d8645df93c7e4a9aa9073ee84cb9e1",
      "relation": "hasComponent",
      "source": 71,
      "target": 86
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "When APP/PS1/tau triple transgenic (3×Tg) AD mice are treated with the selective M1 mAChR agonist AF267B, the endogenous level of BACE1 decreases via an unclear mechanism, accompanied by a decreased Abeta level[77]. However, another study found that stimulation of M1 mAChR upregulates BACE1 levels in SK-SH-SY5Y cells via the PKC and MAPK signaling cascades[78]. We recently found that M1 mAChR directly interacts with BACE1 and mediates its proteasomal degradation[79]. These results suggest that M1 mAChR modulates BACE1 in a mixed manner.",
      "key": "7152fdd30dbdd9dc76b732c8c273737cae872ce47db09fb369aaed74a333e02eaf9b24b26582c2c33a018d8969c842dcaec9c7454924c64e93f4d6b8a17821b0",
      "line": 455,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 71,
      "target": 86
    },
    {
      "key": "35c014eb9446064935cf8e29605fab9db9629cbdce010e6d038e1b510a63cde47da58d024a7e93efbbc115c6e2ded7df6be69c1d22fce79a186af724029e86c8",
      "relation": "hasComponent",
      "source": 71,
      "target": 88
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "In addition to inhibiting Abeta generation, activation of M1 mAChR counteracts Abeta-induced neurotoxicity through the Wnt signaling pathway, as Abeta impairs the Wnt pathway and M1 mAChR stimulation inactivates GSK-3beta via PKC activation, stabilizes beta-catenin, and induces the expression of Wnt-targeting genes engrailed and cyclin-D1 for neuron survival",
      "key": "6e1d2e9a3ffd1641b400031dd4245a78bede518f8e417e7d5b2d680d1e188a6ab3e8da4f43b1ec5b1ebb694ef2f1ad18f8cf69b85063bbfccd9a34acf77d5c35",
      "line": 473,
      "relation": "decreases",
      "source": 44,
      "target": 111
    },
    {
      "annotations": {
        "CellLine": {
          "PC12": true
        },
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Stimulation of M1 mAChR by two agonists, carbachol and AF102B, time- and dose-dependently decreases tau phosphorylation in PC12 cells[81]. Chronic treatment with AF267B also alleviates tau pathology in 3×Tg AD mice, possibly by activating PKC and inhibiting GSK-3beta",
      "key": "51377536335ad40c9c2996e0455d5534e74d32cf5bd19b17e7578d3016b54edf02ad2dbfa7229defa5ce4c44d7304e519063069c02da07e84927de4e95dfdacd",
      "line": 485,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 5,
      "target": 88
    },
    {
      "annotations": {
        "CellLine": {
          "PC12": true
        },
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Stimulation of M1 mAChR by two agonists, carbachol and AF102B, time- and dose-dependently decreases tau phosphorylation in PC12 cells[81]. Chronic treatment with AF267B also alleviates tau pathology in 3×Tg AD mice, possibly by activating PKC and inhibiting GSK-3beta",
      "key": "7247a2ced422d412e89317efd318496c6f7492a7162f055c447bb7b47a03dc322a97ba5b51f7ee45aad841d629c743cf2e3bb112a4bc4d85f0e904af10a64fcb",
      "line": 487,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 39,
      "target": 88
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "In mice with scopolamine-induced deficits, PQCA, a selective M1 mAChR positive allosteric modulator[87], improves not only recognition memory, spatial working memory, and executive function, but also blood-flow in the frontal cortex, though the mechanism is not yet clear.",
      "key": "e64cd3fd1fe01a0e3507950c54fe0d86d4e9b563b11ed30e1d69cd39b25114eedc496324043fa05779abb2e4159b09d1d30f314b56669e66370ab61bb453df62",
      "line": 529,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 18,
      "target": 104
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "In mice with scopolamine-induced deficits, PQCA, a selective M1 mAChR positive allosteric modulator[87], improves not only recognition memory, spatial working memory, and executive function, but also blood-flow in the frontal cortex, though the mechanism is not yet clear.",
      "key": "e7d3f084436aba772c94a933083e608e7b6ff2631663571e8cbe5f3b7b40e51a44864204b57f4409b97fc37d88cf59600918cfa23c8c5fab3c180d36e3bbf2fb",
      "line": 530,
      "relation": "increases",
      "source": 18,
      "target": 65
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "In mice with scopolamine-induced deficits, PQCA, a selective M1 mAChR positive allosteric modulator[87], improves not only recognition memory, spatial working memory, and executive function, but also blood-flow in the frontal cortex, though the mechanism is not yet clear.",
      "key": "62738ab73f30a247024b38f6b9f66ad2fd670ad14d3ae20eaa859a817d49ddc3a0caae6c8c66e308c5b331cb9746230a1d8d04f4674deb5270a633b0160ef6f8",
      "line": 531,
      "relation": "increases",
      "source": 18,
      "target": 115
    },
    {
      "key": "4b4a003faf5ef4da042a0b56a5cba8d00a8bcafb67763f74ec33d6b329a7c8f01f552aac78d209dd0610dd9037a8da8e92f785ae94d7828bb202c6bc609f24d7",
      "relation": "hasComponent",
      "source": 70,
      "target": 81
    },
    {
      "key": "4efc7af8d62c5b757151ef9eade02a395e989b4492c8a814e2410e7a8c5d6c1c26918a9f2ed3521631179c98e9d816cb2391a1b645828f6e378c840442a4c4d4",
      "relation": "hasComponent",
      "source": 70,
      "target": 88
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "In fact, Abeta has been shown to induce the uncoupling of M1 mAChR from G-protein, antagonizing the function of M1 mAChR under the pathological conditions of AD[96, 97]. Such an uncoupling may result in decreased signal transduction, reduced levels of sAPPalpha, and increased production of Abeta, triggering a vicious cycle.",
      "key": "38b177a3d881a2e6baa77e777a1198bfeefa37f5ea2d8a7b43543ea7d37b60049b94f6cfd4ab17bb4f4c40cfed5fc46e55d0b5e0eab164540a2105928546f844",
      "line": 547,
      "relation": "increases",
      "source": 70,
      "target": 77
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "In fact, Abeta has been shown to induce the uncoupling of M1 mAChR from G-protein, antagonizing the function of M1 mAChR under the pathological conditions of AD[96, 97]. Such an uncoupling may result in decreased signal transduction, reduced levels of sAPPalpha, and increased production of Abeta, triggering a vicious cycle.",
      "key": "c83875307409a402578cac7f21f49bab4c86d12da821445877afc5062631eceba8954b97ad9947582226651445bddcf053dc9ef7db07d120be1820428b3c1b4a",
      "line": 548,
      "relation": "decreases",
      "source": 70,
      "target": 2
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "In fact, Abeta has been shown to induce the uncoupling of M1 mAChR from G-protein, antagonizing the function of M1 mAChR under the pathological conditions of AD[96, 97]. Such an uncoupling may result in decreased signal transduction, reduced levels of sAPPalpha, and increased production of Abeta, triggering a vicious cycle.",
      "key": "9a248299c87bbb3def517c2a2177c975b8477d0e32bf0bf4d81a2c0df435813bcfb4ce0b09aa3efa545ef9baab297e2eaf1d12e5cc0645f39006c68afad0bb8d",
      "line": 549,
      "relation": "increases",
      "source": 70,
      "target": 60
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "MeSHAnatomy": {
          "Cerebrospinal Fluid": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Administration of AF267B and AF102B (Cevimeline, EVOXACTM), an M1 mAChRselective agonist once prescribed for the treatment of Sjogren’s syndrome, decreases Abeta42 levels in the cerebral spinal fluid (CSF) of rabbits without affecting APP",
      "key": "bd0b939a2a969c9b79c2a7a40c3e6480a13500492b2b91c621b0a28b562c2c509cdaeb340b197fb579e53655d9ecfa48afe2efaefa17d830f7a2175c3cbef22b",
      "line": 599,
      "relation": "decreases",
      "source": 6,
      "target": 1
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "MeSHAnatomy": {
          "Cerebrospinal Fluid": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Administration of AF267B and AF102B (Cevimeline, EVOXACTM), an M1 mAChRselective agonist once prescribed for the treatment of Sjogren’s syndrome, decreases Abeta42 levels in the cerebral spinal fluid (CSF) of rabbits without affecting APP",
      "key": "0b776a8816161e5c16babde032861fcde092c5fa308954f30c1b3a173dfcaa2194004aba2210c83df31b767008c9547bc2e2b7b90a4e6411b9e236fb22aa7107",
      "line": 601,
      "relation": "decreases",
      "source": 6,
      "target": 124
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "MeSHAnatomy": {
          "Cerebrospinal Fluid": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Administration of AF267B and AF102B (Cevimeline, EVOXACTM), an M1 mAChRselective agonist once prescribed for the treatment of Sjogren’s syndrome, decreases Abeta42 levels in the cerebral spinal fluid (CSF) of rabbits without affecting APP",
      "key": "cae937479a97d28ea7154b5fd6addafd096e2f97a630cb93626ac23b66cdae497abe399e5a036d449d6aaafd2d2397e47b1a85c6a5bef346687658f79361cee4",
      "line": 603,
      "relation": "causesNoChange",
      "source": 6,
      "target": 85
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Cerebrospinal Fluid": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Moreover, AF102B administration decreased the total CSF Abeta levels by 22% in 14 of 19 AD patients without affecting sAPPalpha levels. However, AF102B has serious side effects including gastrointestinal symptoms, diaphoresis, confusion, diarrhea, and asthenia",
      "key": "a4f3e39fd7d128724ffd47cc713447dcc2052bdfbb1ebc8b802df4e8f50347b822a39de3f2734171ed2d0365a67d1babd80a2050ff963d447d3cab6aef16725b",
      "line": 618,
      "relation": "decreases",
      "source": 6,
      "target": 2
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Cerebrospinal Fluid": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Moreover, AF102B administration decreased the total CSF Abeta levels by 22% in 14 of 19 AD patients without affecting sAPPalpha levels. However, AF102B has serious side effects including gastrointestinal symptoms, diaphoresis, confusion, diarrhea, and asthenia",
      "key": "e6e464c60802a7c9763739ca4e93327873d280215b5d76ef3d2310c0c77fb9c188cbf7c760d0d04acef25592adcd898c57bfde5f5c0de15de599da45e637b92f",
      "line": 619,
      "relation": "causesNoChange",
      "source": 6,
      "target": 77
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Cerebrospinal Fluid": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Moreover, AF102B administration decreased the total CSF Abeta levels by 22% in 14 of 19 AD patients without affecting sAPPalpha levels. However, AF102B has serious side effects including gastrointestinal symptoms, diaphoresis, confusion, diarrhea, and asthenia",
      "key": "25e7ae49c68f4a2ce722730316a550dbc8a86d2f3ea3473850993eb5e4d4cd79725c08f323ad389c9dc220d21b9575197fa90c87a778a4b78cd995de5602cc0d",
      "line": 620,
      "relation": "increases",
      "source": 6,
      "target": 127
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Cerebrospinal Fluid": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Moreover, AF102B administration decreased the total CSF Abeta levels by 22% in 14 of 19 AD patients without affecting sAPPalpha levels. However, AF102B has serious side effects including gastrointestinal symptoms, diaphoresis, confusion, diarrhea, and asthenia",
      "key": "f10da9a1809a53b5845d511416ebed9658822661d491375f6ff438f74f0f699aae6589e0e64c6846110f93a229e7267c894ea8a196b3f1166fd6deca9d82436f",
      "line": 621,
      "relation": "increases",
      "source": 6,
      "target": 128
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Cerebrospinal Fluid": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Moreover, AF102B administration decreased the total CSF Abeta levels by 22% in 14 of 19 AD patients without affecting sAPPalpha levels. However, AF102B has serious side effects including gastrointestinal symptoms, diaphoresis, confusion, diarrhea, and asthenia",
      "key": "0fb4ce814cc2e7470168c78997c68ab757626fea8d1b530b9d4bba1598e766a6f860208163acb4bac141c6a97e693a078d9a38372aca3bf6ea16129b4e2bad7e",
      "line": 622,
      "relation": "increases",
      "source": 6,
      "target": 125
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Cerebrospinal Fluid": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Moreover, AF102B administration decreased the total CSF Abeta levels by 22% in 14 of 19 AD patients without affecting sAPPalpha levels. However, AF102B has serious side effects including gastrointestinal symptoms, diaphoresis, confusion, diarrhea, and asthenia",
      "key": "2e9ec672d524d9a0451c49ffeb1e4b6309df1564c8a95413c23f78e81b005eaeee3907c1e6c19129d7af25c0d28eeda12e73e76d3e228b59a18924746d180c0d",
      "line": 623,
      "relation": "increases",
      "source": 6,
      "target": 116
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Another M1 mAChR-selective agonist, talsaclidine, enhances nonamyloidogenic processing of APP, resulting in increased sAPPalpha release from both a transfected human astrocytoma cell line and rat brain slices in a dose-dependent manner, as well as significantly decreasing CSF Abeta in AD patients[111]. However, talsaclidine at high doses had several side-effects such as sweating and salivation",
      "key": "4ab9c2a324c97adffc327a38d887a20f73bac7a898ea8294c7de3744739a987bf45064befecacc4f9429bde431b745c517754f7644137db0dcb6d88864901b1a",
      "line": 640,
      "relation": "increases",
      "source": 32,
      "target": 77
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "MeSHAnatomy": {
          "Cerebrospinal Fluid": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Another M1 mAChR-selective agonist, talsaclidine, enhances nonamyloidogenic processing of APP, resulting in increased sAPPalpha release from both a transfected human astrocytoma cell line and rat brain slices in a dose-dependent manner, as well as significantly decreasing CSF Abeta in AD patients[111]. However, talsaclidine at high doses had several side-effects such as sweating and salivation",
      "key": "28ae2dff5b0d5c61243235008f301a28ba6ce629354638c6d3ad45c4d1261ff0343b9b92054055e2b29f7be973dda79b439ea061c2707a805210a52a33f047f7",
      "line": 643,
      "relation": "decreases",
      "source": 32,
      "target": 2
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Another M1 mAChR-selective agonist, talsaclidine, enhances nonamyloidogenic processing of APP, resulting in increased sAPPalpha release from both a transfected human astrocytoma cell line and rat brain slices in a dose-dependent manner, as well as significantly decreasing CSF Abeta in AD patients[111]. However, talsaclidine at high doses had several side-effects such as sweating and salivation",
      "key": "300b853c7a9df2bc5fffc8c19e16b9f75d8657e060025b7ad52a0241f0dbe20b34a7a73e9b730ba0ed961b6db5d27602ebc48b342bac19e5ac73db6a49d33951",
      "line": 646,
      "relation": "increases",
      "source": 32,
      "target": 132
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Another M1 mAChR-selective agonist, talsaclidine, enhances nonamyloidogenic processing of APP, resulting in increased sAPPalpha release from both a transfected human astrocytoma cell line and rat brain slices in a dose-dependent manner, as well as significantly decreasing CSF Abeta in AD patients[111]. However, talsaclidine at high doses had several side-effects such as sweating and salivation",
      "key": "4b2311c4bf34865dd4403b6f838b67bee90c5546838cc51eef278d6b7797faa0b464c3bf8e7c8a1724719f4881942d3eab721db9a96aad5d08cbad2149d29388",
      "line": 647,
      "relation": "increases",
      "source": 32,
      "target": 131
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Similarly, the M1 agonist WAY-132983 at a low dose improves cognitive status in animal models but at a high dose causes side-effects such as salivation and hypothermia[102, 112].",
      "key": "d5ea89a0f5e090b2b3c9818ef7e13ae2a10a6c544010f1d2cb1e20d454333866677920264fb0eab2b9588ae9743f0441da96fe5f8a3b806dacf494554e6c0195",
      "line": 656,
      "relation": "increases",
      "source": 31,
      "target": 63
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Similarly, the M1 agonist WAY-132983 at a low dose improves cognitive status in animal models but at a high dose causes side-effects such as salivation and hypothermia[102, 112].",
      "key": "ae8c783446a5ac75ce26b5ed8a53ab5ed0f580828a303f1bccea58cf362d464b653f48784b3c8ac3c04a0d4459543e518b21708c130f061dd24f256e35eebe5f",
      "line": 657,
      "relation": "increases",
      "source": 31,
      "target": 131
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Similarly, the M1 agonist WAY-132983 at a low dose improves cognitive status in animal models but at a high dose causes side-effects such as salivation and hypothermia[102, 112].",
      "key": "b1b2bb521e307ff6e9467c1a2dc5bb997711322ca840403385bb9749c12891f0c8de7936ee0773d3113dc1515fb1eeb19f6eba5d35e2e2fd52b11aebc1659c03",
      "line": 658,
      "relation": "increases",
      "source": 31,
      "target": 129
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "After brucine, several other M1-PAMs have been discovered, including VU0029767, VU0090157, and benzyl quinolone carboxylic acid (BQCA)[115-117]. These compounds do not activate M1 mAChR directly but greatly increase the affi nity of ACh for the M1 subtype. In addition, BQCA is effective in restoring discrimination reversal learning in a mouse model of AD and regulating nonamyloidogenic APP processing[117].",
      "key": "94c9ad683463dbfb476793c60c851bb34692576337c1b74c17d44b86345732273620c8eb57878a74a5824c313ac7f4aa6c19050fb5e0ddfad55aa8df13328c91",
      "line": 670,
      "relation": "increases",
      "source": 14,
      "target": 69
    },
    {
      "key": "fb153ff3208c091cdd9b32e8eb9833c8945e8d1ced7c66c2de41ec9fe3416738f5c7d5ca59ac30c528fa9f80eb192c3b3ae8e2fc4125c332b5412ee281a29124",
      "relation": "hasComponent",
      "source": 69,
      "target": 3
    },
    {
      "key": "9068e42bb4e687fa6b99ae79905ff16f73d7b53587e49645c701414291adf203dc414541769c99cc58e888934d3efe003313681e3bdea0853e1075f0067a0de3",
      "relation": "hasComponent",
      "source": 69,
      "target": 88
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "After brucine, several other M1-PAMs have been discovered, including VU0029767, VU0090157, and benzyl quinolone carboxylic acid (BQCA)[115-117]. These compounds do not activate M1 mAChR directly but greatly increase the affi nity of ACh for the M1 subtype. In addition, BQCA is effective in restoring discrimination reversal learning in a mouse model of AD and regulating nonamyloidogenic APP processing[117].",
      "key": "2b1490ff3792a32cc66299e33450317a8649c9e3c7e9658a330c67a970a10004b73928cf7407239b95a30903f447f1d3b2ab345ac42a35e712061691c390250a",
      "line": 671,
      "relation": "increases",
      "source": 15,
      "target": 69
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "After brucine, several other M1-PAMs have been discovered, including VU0029767, VU0090157, and benzyl quinolone carboxylic acid (BQCA)[115-117]. These compounds do not activate M1 mAChR directly but greatly increase the affi nity of ACh for the M1 subtype. In addition, BQCA is effective in restoring discrimination reversal learning in a mouse model of AD and regulating nonamyloidogenic APP processing[117].",
      "key": "bd9dc1e4055c6be8081e920269675fc48424e0ee9cfd3910a0722c1b7f408142ca75052495ebce7ce01fd887fc3b826f272fea4f3cd0c3bf96d27f9cdefedd9a",
      "line": 672,
      "relation": "increases",
      "source": 21,
      "target": 69
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "After brucine, several other M1-PAMs have been discovered, including VU0029767, VU0090157, and benzyl quinolone carboxylic acid (BQCA)[115-117]. These compounds do not activate M1 mAChR directly but greatly increase the affi nity of ACh for the M1 subtype. In addition, BQCA is effective in restoring discrimination reversal learning in a mouse model of AD and regulating nonamyloidogenic APP processing[117].",
      "key": "f4860d92b20cc533b09876fb2ef86163c8690f06c3fe1a2c09df85aca82497ddf8bcb13ba09b4ccff312be102262b4335c97cf9f1e291bb03303f794bb88ba89",
      "line": 677,
      "relation": "increases",
      "source": 21,
      "target": 64
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "After brucine, several other M1-PAMs have been discovered, including VU0029767, VU0090157, and benzyl quinolone carboxylic acid (BQCA)[115-117]. These compounds do not activate M1 mAChR directly but greatly increase the affi nity of ACh for the M1 subtype. In addition, BQCA is effective in restoring discrimination reversal learning in a mouse model of AD and regulating nonamyloidogenic APP processing[117].",
      "key": "01b0ac8a07b2eda7d0e4fc039284bef0b8e472a574975512a891c4b54aba8f7c1568bd6d6f0c605974e351dd720a2fce8b466a7c16fff50e6df84db77fb110d0",
      "line": 678,
      "relation": "regulates",
      "source": 21,
      "target": 40
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Nevertheless, a compound developed later, TBPB, selectively activates M1 mAChR in cell lines and shows no agonist activity in any other mAChR subtype. Interestingly, TBPB also potentiates the NMDA-evoked current in hippocampal pyramidal neurons, which is considered to be important for the effect of M1 mAChR on improving cognition. In addition, TBPB shifts the processing of APP in the non-amyloidogenic direction and thereafter decreases neurotoxic Abeta production vitro[120].",
      "key": "b273a8ee629e86720ccceb9e07e240ccff81b8549f27289d464ea9c0af5f65a825a15e7592c655882ab638c8c303346bba548817ac0bf3fab39512310fc12977",
      "line": 694,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 19,
      "target": 88
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Hippocampus": true,
          "Pyramidal Cells": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Nevertheless, a compound developed later, TBPB, selectively activates M1 mAChR in cell lines and shows no agonist activity in any other mAChR subtype. Interestingly, TBPB also potentiates the NMDA-evoked current in hippocampal pyramidal neurons, which is considered to be important for the effect of M1 mAChR on improving cognition. In addition, TBPB shifts the processing of APP in the non-amyloidogenic direction and thereafter decreases neurotoxic Abeta production vitro[120].",
      "key": "c69e73aa6e4ca108302427500d5094f9f8a2cd82f21700f9595083ceec3dec39a0554041ae6e2a74890d067831e01dd8bd6cdca0b368bdd92ed769383cc7c8d8",
      "line": 698,
      "relation": "increases",
      "source": 19,
      "target": 43
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Hippocampus": true,
          "Pyramidal Cells": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Nevertheless, a compound developed later, TBPB, selectively activates M1 mAChR in cell lines and shows no agonist activity in any other mAChR subtype. Interestingly, TBPB also potentiates the NMDA-evoked current in hippocampal pyramidal neurons, which is considered to be important for the effect of M1 mAChR on improving cognition. In addition, TBPB shifts the processing of APP in the non-amyloidogenic direction and thereafter decreases neurotoxic Abeta production vitro[120].",
      "key": "dad7b3fe14502cf4928411b73395c05be41723f22bc5acb4c28c144e21b84350f51b7eb87161d5937642031e718ca928890983310783e22fd9229a4aef6cbe9a",
      "line": 700,
      "relation": "decreases",
      "source": 19,
      "target": 2
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Compound 77-LH-28-1 shows relatively higher selectivity for the M1 than for the M2, M4, and M5 subtypes, but retains weak agonist activity for M3 mAChR at high doses. Electrophysiological studies indicate that 77-LH-28-1 increases the activity of hippocampal CA1 pyramidal cells both in vitro and in vivo. Interestingly, unlike other normal orthosteric agonists, 77-LH-28-1 appears to selectively activate M1 mAChR in a distinct signaling pathway",
      "key": "fdde97a168b052ab72fff64d6813729782310e9c1c28920d71b33361e924d0aa55ca99371c24f274d21702a39b42dfa10654d4e1878b8260efef5197e3e57003",
      "line": 717,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 20,
      "target": 88
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "CA1 Region, Hippocampal": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Compound 77-LH-28-1 shows relatively higher selectivity for the M1 than for the M2, M4, and M5 subtypes, but retains weak agonist activity for M3 mAChR at high doses. Electrophysiological studies indicate that 77-LH-28-1 increases the activity of hippocampal CA1 pyramidal cells both in vitro and in vivo. Interestingly, unlike other normal orthosteric agonists, 77-LH-28-1 appears to selectively activate M1 mAChR in a distinct signaling pathway",
      "key": "ca61d1ee8642723faaf1c5d6d8312879fa52971276c7f7235fa1df88231d241643b86f52cded3fc33b704d33e132ccca7a964071b55b776603e4fa6b4eea43ed",
      "line": 721,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 20,
      "target": 30
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "The M1 mAChR agonist AC-260584 was recently reported to be orally bioavailable with favorable antipsychotic and cognition-enhancing effects[118, 122].",
      "key": "933fbec7fc6748b72aad750cc01b72758466e1ea54ad75612f9167834d92d968ed063e26111b023b9479d3abddc43d94da62d58aa8c0f0ae28d9f53f044e0025",
      "line": 730,
      "relation": "increases",
      "source": 22,
      "target": 63
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "The M1 mAChR agonist AC-260584 was recently reported to be orally bioavailable with favorable antipsychotic and cognition-enhancing effects[118, 122].",
      "key": "af1a618c42dcb20a123e72619388b5531c4d873301acdd7cb8c525250daa882c077052d2495a0282f2da1d7fee7600d7400da04c7fd8b19ef589c284246b21f0",
      "line": 731,
      "relation": "association",
      "source": 22,
      "target": 23
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "The M1 mAChR agonist AC-260584 was recently reported to be orally bioavailable with favorable antipsychotic and cognition-enhancing effects[118, 122].",
      "key": "dc58ac612d9cd028fbbf04407e8a34d4d0059683b562becf778b57016c68b22ad79f2862fa9a7542ae24000a015e86b732bbe51079126bae12fb65317bf5f534",
      "line": 731,
      "relation": "association",
      "source": 23,
      "target": 22
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "During the past few years, the M1 mAChR allosteric agonists VU0184670 and VU0357017 have been screened out, and have more exciting properties. Both compounds have high solubility in aqueous solutions as well as good CNS penetration, without any agonist or antagonist activity for the M2 and M5 subtypes",
      "key": "21cf7384c688b0600cf7593e39a5d3c145cedc0ef28d7e8cd875c9c91c26cb8bde7e67efe8d2df7ea711257064016622cb0dbd376a5d0adeedd3299c96b1505b",
      "line": 741,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 16,
      "target": 88
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "During the past few years, the M1 mAChR allosteric agonists VU0184670 and VU0357017 have been screened out, and have more exciting properties. Both compounds have high solubility in aqueous solutions as well as good CNS penetration, without any agonist or antagonist activity for the M2 and M5 subtypes",
      "key": "6f00c31da92806cb7b87698d32dca6c01f048790ce4f2c0e6c55ec08e9698dc8c5e82fd201607de2e1c137f4e4ea83c5b4ccfd624a9e1c702b64ca1122850539",
      "line": 743,
      "object": {
        "modifier": "Activity"
      },
      "relation": "causesNoChange",
      "source": 16,
      "target": 89
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "During the past few years, the M1 mAChR allosteric agonists VU0184670 and VU0357017 have been screened out, and have more exciting properties. Both compounds have high solubility in aqueous solutions as well as good CNS penetration, without any agonist or antagonist activity for the M2 and M5 subtypes",
      "key": "a87e387d2197b83b955ddbeed772b8b8c490af9f3edbbaa5972831937dab9a34af3e3ad51613fadb0c2eb5e426f9348431a0a0c439d7f79bed90d8d34fda4fbc",
      "line": 745,
      "object": {
        "modifier": "Activity"
      },
      "relation": "causesNoChange",
      "source": 16,
      "target": 92
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Hippocampus": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Moreover, VU0184670 potentiates neuronal NMDAR-mediated currents in hippocampal brain slices and VU0357017 reverses the cognitive deficits induced by an mAChR antagonist in a contextual fear conditioning paradigm, exhibiting improvement of hippocampus-dependent learning[110, 123].",
      "key": "4cf676d5184a0d18a881dc8daa34f7b73e09a5da64793d4f923ed430d98f5812be562eca981fc281520e61ca1b3191461d8ddf2b8fdb8dda197e162a0473878b",
      "line": 760,
      "relation": "increases",
      "source": 16,
      "target": 43
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "During the past few years, the M1 mAChR allosteric agonists VU0184670 and VU0357017 have been screened out, and have more exciting properties. Both compounds have high solubility in aqueous solutions as well as good CNS penetration, without any agonist or antagonist activity for the M2 and M5 subtypes",
      "key": "ca00bd61224018143fe6ccf0ffa3b197ba3a52a4f72aca19d2b25af5bbe56e19cbd5228adc2c3efa40fe22a29e08ef7fd87629c6a2d29a14f59165a106f518c1",
      "line": 742,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 38,
      "target": 88
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "During the past few years, the M1 mAChR allosteric agonists VU0184670 and VU0357017 have been screened out, and have more exciting properties. Both compounds have high solubility in aqueous solutions as well as good CNS penetration, without any agonist or antagonist activity for the M2 and M5 subtypes",
      "key": "908fe66dc43fe94669ce5fadfac636ccbcf23d7e4fe63ab8be2b04ca67edf56870f09204d1d6b13663803df9cdfbb339d1cb7504045878a47a3d72c21b1ff011",
      "line": 744,
      "object": {
        "modifier": "Activity"
      },
      "relation": "causesNoChange",
      "source": 38,
      "target": 89
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "During the past few years, the M1 mAChR allosteric agonists VU0184670 and VU0357017 have been screened out, and have more exciting properties. Both compounds have high solubility in aqueous solutions as well as good CNS penetration, without any agonist or antagonist activity for the M2 and M5 subtypes",
      "key": "efb19672e6ca2d71d9ca0a650a612916f266244c57bc1a6f8919d72428a6dd1a862c78caa6178e1feecb18c02007d5466cc52d781d63b13765864b2bc7758a1c",
      "line": 746,
      "object": {
        "modifier": "Activity"
      },
      "relation": "causesNoChange",
      "source": 38,
      "target": 92
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Hippocampus": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Moreover, VU0184670 potentiates neuronal NMDAR-mediated currents in hippocampal brain slices and VU0357017 reverses the cognitive deficits induced by an mAChR antagonist in a contextual fear conditioning paradigm, exhibiting improvement of hippocampus-dependent learning[110, 123].",
      "key": "b11296b3d02bbdcc9c185c2f019f0b254d2c10a85f2601ab1847362f5165ada88752650d21a30df20e6526b7c749ec3a1768e56d6ec867cce755cc3fd3b97921",
      "line": 761,
      "relation": "decreases",
      "source": 38,
      "target": 113
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Hippocampus": true
        }
      },
      "citation": {
        "authors": [
          "Bu G",
          "Jiang S",
          "Li Y",
          "Xu H",
          "Zhang C",
          "Zhang YW",
          "Zhao Y"
        ],
        "date": "2014-04-01",
        "first": "Jiang S",
        "last": "Zhang YW",
        "name": "Neuroscience bulletin",
        "pages": "295-307",
        "reference": "24590577",
        "title": "M1 muscarinic acetylcholine receptor in Alzheimer's disease.",
        "type": "PubMed",
        "volume": "30"
      },
      "evidence": "Moreover, VU0184670 potentiates neuronal NMDAR-mediated currents in hippocampal brain slices and VU0357017 reverses the cognitive deficits induced by an mAChR antagonist in a contextual fear conditioning paradigm, exhibiting improvement of hippocampus-dependent learning[110, 123].",
      "key": "585fedafac42f62ebfcc0d3ea394fa7bbde34adbfa23f68b99ae7fa3707a85e63b80307fb76fb205bb8c73ce06baa252994a2d43013fffbdd7c2c9b849eba4d3",
      "line": 762,
      "relation": "increases",
      "source": 38,
      "target": 64
    }
  ],
  "multigraph": true,
  "nodes": [
    {
      "bel": "a(CHEBI:\"3',5'-cyclic AMP\")",
      "function": "Abundance",
      "id": "e634e1d295920557f5cf0c1b3fd2bf18d082b00fb983d6632b989552d1ba51e14a88952b3abfc55d7ab65f035c7e90d951497cfa11719f0492edab0ddb91813a",
      "name": "3',5'-cyclic AMP",
      "namespace": "CHEBI"
    },
    {
      "bel": "a(CHEBI:\"amyloid-beta polypeptide 42\")",
      "function": "Abundance",
      "id": "c2da54109c90719396dfdfb558be74582b8522863849a50f3f5029b7d60f4d53df3cfa1a97b787e760a2f74ea1f74012eb49273beeded42a2873d788953b4a13",
      "name": "amyloid-beta polypeptide 42",
      "namespace": "CHEBI"
    },
    {
      "bel": "a(CHEBI:\"amyloid-beta\")",
      "function": "Abundance",
      "id": "a9487b29439483c6840095610dd3e496e3ca9cccc3a8d71e0385a39b570f3c0a26965ac06d83265e1c08deaae7998272d4f4c21ec0534f8be3fd8e4e57dbb3a2",
      "name": "amyloid-beta",
      "namespace": "CHEBI"
    },
    {
      "bel": "a(CHEBI:acetylcholine)",
      "function": "Abundance",
      "id": "bae5841bb74f1e9eb73cd433cda657927031217c24e17f21bb2975128d1d9be4dc899448ede71d9aa18224145a1681b90b33287454eabf938f405bc1b8894b62",
      "name": "acetylcholine",
      "namespace": "CHEBI"
    },
    {
      "bel": "a(CHEBI:benzoxazine)",
      "function": "Abundance",
      "id": "b41a6b1bff0541e3f64f341322242762f9f66bdb583aa6c987e4f428b50a5aa1dc92da232cb93fb22da49be56b9446781a0db18261fb3f4b17ed8d5340741cd3",
      "name": "benzoxazine",
      "namespace": "CHEBI"
    },
    {
      "bel": "a(CHEBI:carbachol)",
      "function": "Abundance",
      "id": "2c2f0e95e78210705815e4a9292120a1ded18de64eb0587a37926a71140e1a4d354c563a6de4a594ebfd3b43b0be778ab4d27cc270b1162cbb87e1e89aedf8d6",
      "name": "carbachol",
      "namespace": "CHEBI"
    },
    {
      "bel": "a(CHEBI:cevimeline)",
      "function": "Abundance",
      "id": "193a6239668f96659732e72e8897021f918afc4afcbccbb177e15d49541b51c308c1e6b522457a738749b0ef91ccd4f05d39e3885db1dba9672999296e368151",
      "name": "cevimeline",
      "namespace": "CHEBI"
    },
    {
      "bel": "a(CHEBI:cocaine)",
      "function": "Abundance",
      "id": "84dfe7798e7707f940f793d3e655496de7df2b51519e25a000e9206dab0caa4ab75dd25cf45655b9bbcbb3134f437cf2af40b8334db87e705d69fecdb63c3ccf",
      "name": "cocaine",
      "namespace": "CHEBI"
    },
    {
      "bel": "a(CHEBI:dopamine)",
      "function": "Abundance",
      "id": "70f7314679db5bae3c2260b6feff9a6ef3407fb6a585f92a58c59fd066a2ec279c0091a72edba3465c4f2aa033afff7fded0b16c4a84f4bbcecd092a934ea66e",
      "name": "dopamine",
      "namespace": "CHEBI"
    },
    {
      "bel": "a(CHEBI:morphine)",
      "function": "Abundance",
      "id": "ec0afc2d92ade98a60df72c635c817bb2e7bb56f0bc9a7b4390bd821a2259f6681a31fa9f929cf1f70b44e0cacd88986703ab2c8b7fe66b78378572ebaf36f4b",
      "name": "morphine",
      "namespace": "CHEBI"
    },
    {
      "bel": "a(CHEBI:phencyclidine)",
      "function": "Abundance",
      "id": "83b1704e60989264657e65aa571ab1317b15924ca33fa270dd88d2a44a789d590ffd39ba90837d9b85559933a21fdfa5d774647a428083af04086c5b9b99ddc3",
      "name": "phencyclidine",
      "namespace": "CHEBI"
    },
    {
      "bel": "a(CHEBI:xanomeline)",
      "function": "Abundance",
      "id": "2fc0c8095fa7470cf35b39ec64fdafb13d4aacaa5cf5fccb346bad55c7db083afc2172727fe8e5e1b11eedbf583482aa264cc408edc9e39f1d6e3a6ce1771a02",
      "name": "xanomeline",
      "namespace": "CHEBI"
    },
    {
      "bel": "a(CONSO:\"Tau aggregates\")",
      "function": "Abundance",
      "id": "102bd40eb29c18f3cd2b3c48aa1a96afad05e01e0f8090172738d382dcfa933ac25a510484a34dd66c94587194ad5f9d99148b59a7741edc83871b3edf50ed4e",
      "name": "Tau aggregates",
      "namespace": "CONSO"
    },
    {
      "bel": "a(CONSO:\"amyloid-beta aggregates\")",
      "function": "Abundance",
      "id": "fcc150a975d4e4470c5e429ea32220fdb47e51ef258188552e58fa57f7095a6257914f165d06469ed45b6a1bccc8149eacc0ad9fdf9248a2ac69db715285c72a",
      "name": "amyloid-beta aggregates",
      "namespace": "CONSO"
    },
    {
      "bel": "a(CONSO:VU0029767)",
      "function": "Abundance",
      "id": "ca48ee78db5e74989e0300e6d3d807154c138eae1291db30a9109cd9814bc7d5a303b9bcb20d0a5761acee07d561dcd6a41c9c73914cd3f1fab00059e0133b4a",
      "name": "VU0029767",
      "namespace": "CONSO"
    },
    {
      "bel": "a(CONSO:VU0090157)",
      "function": "Abundance",
      "id": "4e6b442f6c25727360d9a9623035af4304b9f9f49ac615095e7921e7e468dff6e24753aee9f9aa7b00be1b1a3abc1cb642109bb3ba5cd577a1e315adae249b51",
      "name": "VU0090157",
      "namespace": "CONSO"
    },
    {
      "bel": "a(CONSO:VU0184670)",
      "function": "Abundance",
      "id": "c15722dc670e3953d1f1e809b597bd24446613393d92e3218e0bef4f11fb14bb9144eb7779508d000ae37cecf573ced0e5a8ae93f5037eeff91da7605613d2d4",
      "name": "VU0184670",
      "namespace": "CONSO"
    },
    {
      "bel": "a(MESH:\"(S)-2-ethyl-8-methyl-1-thia-4,8-diazaspiro(4.5)decan-3-one\")",
      "function": "Abundance",
      "id": "38e1843a906b6279ca2a95c5dc6dc834704e57c748aa0b4f88f0c8100d80f1a6e9fdb1cb9085ba0caebac6ca3fd53d022433d91ed309b03dd9287f7f56f57aae",
      "name": "(S)-2-ethyl-8-methyl-1-thia-4,8-diazaspiro(4.5)decan-3-one",
      "namespace": "MESH"
    },
    {
      "bel": "a(MESH:\"1-((4-cyano-4-(pyridine-2-yl)piperidin-1-yl)methyl)-4-oxo-4H-quinolizine-3-carboxylic acid\")",
      "function": "Abundance",
      "id": "ab0c3af35d7f2693b1e07d9bed1b92697960aab06016365e88f55caba791c39d6ecf5e49ffc5645db06f7bd332d671209caef2e0b0ff9ee54055b0b208fa2d9e",
      "name": "1-((4-cyano-4-(pyridine-2-yl)piperidin-1-yl)methyl)-4-oxo-4H-quinolizine-3-carboxylic acid",
      "namespace": "MESH"
    },
    {
      "bel": "a(MESH:\"1-(1'-(2-methylbenzyl)-1,4'-bipiperidin-4-yl)-1H-benzo(d)imidazol-2-(3H)-one\")",
      "function": "Abundance",
      "id": "bb6bc6941a6b064cd867bc71f1b6f00fd6c710c549fc4289df8cad43c0336195f72fd5d0c96cc64e5f5fc70ece0a4863889b1365d785e94084e43dece76550a0",
      "name": "1-(1'-(2-methylbenzyl)-1,4'-bipiperidin-4-yl)-1H-benzo(d)imidazol-2-(3H)-one",
      "namespace": "MESH"
    },
    {
      "bel": "a(MESH:\"1-(3-(4-butyl-1-piperidinyl)propyl)-3,4-dihydro-2(1H)-quinolinone\")",
      "function": "Abundance",
      "id": "656617b3484cb4692bc99b750f41639fcafbbfe4286420d50f2199d7912e305aa1ba9a90dbe24b9ea966cce9cf5a3a1b907cd7c9fc2b76ed857ecf26c86a2367",
      "name": "1-(3-(4-butyl-1-piperidinyl)propyl)-3,4-dihydro-2(1H)-quinolinone",
      "namespace": "MESH"
    },
    {
      "bel": "a(MESH:\"1-(4-methoxybenzyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid\")",
      "function": "Abundance",
      "id": "7a8a9305fe3a5d5318b66eec8d6927f2c93c966c1c09af5650d426d5a65aaf808a41ff08e92f2905339a5db41490a09950fd7e07e44d007f7ef1569db8bcca28",
      "name": "1-(4-methoxybenzyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid",
      "namespace": "MESH"
    },
    {
      "bel": "a(MESH:\"4-(3-(4-butylpiperidin-1-yl)propyl)-7-fluoro-4H-benzo(1,4)oxazin-3-one\")",
      "function": "Abundance",
      "id": "e28566a2642096802d1fbbb58c63728d8c64f72835e5b40eb74e0ae2cc0de69f0e4c859ba934ed9c538faac7c380fe3cbf9747afbd5b852b8895f40d74422f72",
      "name": "4-(3-(4-butylpiperidin-1-yl)propyl)-7-fluoro-4H-benzo(1,4)oxazin-3-one",
      "namespace": "MESH"
    },
    {
      "bel": "a(MESH:\"Antipsychotic Agents\")",
      "function": "Abundance",
      "id": "157aa5f90d751d2504a76c89f10a71d28e5db0436a648c93c73d97011e20c996911eced4fcb5101321fb71c9b4144ce3517db952c988a3e3ff868c5a89102151",
      "name": "Antipsychotic Agents",
      "namespace": "MESH"
    },
    {
      "bel": "a(MESH:\"Cardiovascular System\")",
      "function": "Abundance",
      "id": "dc476bcb3aab217e25127fe06449ca8eef77c13ddb8771a6e1cc0c68c04a447f7b3e1caf7f5698785e5c61d08852d928fbbd2c6373f72f9f5528fb10f92944ae",
      "name": "Cardiovascular System",
      "namespace": "MESH"
    },
    {
      "bel": "a(MESH:\"Cerebral Cortex\")",
      "function": "Abundance",
      "id": "d570f84dde08e8887b0ba3cb15f79f0f4378d9c7417d64d2a363380e917313da6df600a00c005cef2a697249feaeb07da95f500476083923a8f77b9caedb6e35",
      "name": "Cerebral Cortex",
      "namespace": "MESH"
    },
    {
      "bel": "a(MESH:\"Cholinergic Neurons\")",
      "function": "Abundance",
      "id": "475e93ca136a9e7794a0aa5f656e5e5514ae3be3984ee430b1c69e597fa87e955ab73e3aa428c790e154477727ce382f73ecadc9ea6ee58ce4366c0b4ed73765",
      "name": "Cholinergic Neurons",
      "namespace": "MESH"
    },
    {
      "bel": "a(MESH:\"Corpus Striatum\")",
      "function": "Abundance",
      "id": "a247be869b9cb7ebed239b8bf5a38164896959a93569c5d8c3c7f34b351ee822a0f8176f09b51343dc7d84df7cfd3236071444ac447832e10bb565f55c791b5e",
      "name": "Corpus Striatum",
      "namespace": "MESH"
    },
    {
      "bel": "a(MESH:\"Dopaminergic Neurons\")",
      "function": "Abundance",
      "id": "33bf5a667c04792d6dbea2f308ab342792bd66ea8986863564b45b8ad252462f5ea440b2c9f2f12b90b991b1a11c0291fe2dc4b4afcad8e9442d3950ed576f6b",
      "name": "Dopaminergic Neurons",
      "namespace": "MESH"
    },
    {
      "bel": "a(MESH:\"Gastrointestinal Tract\")",
      "function": "Abundance",
      "id": "30ff2f20b1a4cdbe594a0acaf78deba2a52d30d9b8ac78c484832500abf9269671ba6998d96c7085398ed2955c3a0df2a49a44aa728f6c0bd6c171e3b09320ce",
      "name": "Gastrointestinal Tract",
      "namespace": "MESH"
    },
    {
      "bel": "a(MESH:\"Pyramidal Cells\")",
      "function": "Abundance",
      "id": "f03a7196338f7afb16d6411482ebf327d5cb3960a2d6597f9c53178af65732d9e5299caa1f3bc7b2532425bbb66fce8b7ed037eb2cf1c13d2a213931aea7b4aa",
      "name": "Pyramidal Cells",
      "namespace": "MESH"
    },
    {
      "bel": "a(MESH:\"WAY 132983\")",
      "function": "Abundance",
      "id": "730d5c30609d214ba9d7587f77dd44cf63c96c13428d51b872a17e2e3436387248c1dc8c25cb37e5f49e62693baa665b2fe0f5c51954dc784804afbc7c80cbb4",
      "name": "WAY 132983",
      "namespace": "MESH"
    },
    {
      "bel": "a(MESH:\"talsaclidine fumarate\")",
      "function": "Abundance",
      "id": "1bc7e9c35eb2ce5dc26e1789676adecaa46efb0735a6f19952f497baef43f199ffbaf6020498eed8832d9a16da6cd556beaf29ba687a49588f3973f0bee39e46",
      "name": "talsaclidine fumarate",
      "namespace": "MESH"
    },
    {
      "bel": "a(MESH:Hippocampus)",
      "function": "Abundance",
      "id": "caff813aaa3f73ff030fa368884d30438c42f1f22aa2b372a08646bda846d5a6ee94d85bb4de2153aaa55ba41bd82a361353793ade6e39bccfe43c75f5a95750",
      "name": "Hippocampus",
      "namespace": "MESH"
    },
    {
      "bel": "a(MESH:Hypothalamus)",
      "function": "Abundance",
      "id": "82abed8bcd5424ae8c8dcaa2cc79c63a132deb4d3c2898ecd806d47c6aa16919df259e5ee0fe33781f25fc51d23f4d3b203e5b85a94005e202cff20e5db86161",
      "name": "Hypothalamus",
      "namespace": "MESH"
    },
    {
      "bel": "a(MESH:Kidney)",
      "function": "Abundance",
      "id": "286a8f27cf5cb78939c22e58724480f25e6c424a0a81e4d086df38294c011f1a7212e8f82b0727c603b25d994b9b3852454b55bec3e48da792750b295e9a53b4",
      "name": "Kidney",
      "namespace": "MESH"
    },
    {
      "bel": "a(MESH:Neocortex)",
      "function": "Abundance",
      "id": "61181eb06c0d951f88e6481ee83dbd78fcc1daa349f16b98195ea0e074f543dd06be3d8f2f244362af223c7b475e6c125a03ae27d63edc655e6fd85001a9a8ee",
      "name": "Neocortex",
      "namespace": "MESH"
    },
    {
      "bel": "a(MESH:Thalamus)",
      "function": "Abundance",
      "id": "580bdff953741a6c94557dce2fe56d0065385625d3370ca1de472be3fbb316458f6868a312e6af0c5e45900a38ce3d7f793b612ed8155c312454a98c10e8a07f",
      "name": "Thalamus",
      "namespace": "MESH"
    },
    {
      "bel": "a(MESH:VU0357017)",
      "function": "Abundance",
      "id": "e484967f34ab300b97c9cd47a24b04c97464179c0b5d7fc096705723f9dbf6fd1f4b069b378e71477b02ad347a4af9429d044c5cfe8629b1157eb105180d09a3",
      "name": "VU0357017",
      "namespace": "MESH"
    },
    {
      "bel": "a(MESH:cevimeline)",
      "function": "Abundance",
      "id": "2f9d90874f41dbde472e6363d3cf24f7e1839e96325e83405bc047b4349b03e4fbdf8fd454b226435ca2378408b98c99e438a987d34cfb0f809c11e390188623",
      "name": "cevimeline",
      "namespace": "MESH"
    },
    {
      "bel": "bp(CONSO:\"APP processing\")",
      "function": "BiologicalProcess",
      "id": "62711cb0430d958ea1df74758e562e82ffbb815b3b9f5207a6675c49650e270d61dc34f2d7bdcce4859af35ff242b211f605dbcae46aa03b788fb8adc7114f7f",
      "name": "APP processing",
      "namespace": "CONSO"
    },
    {
      "bel": "bp(GO:\"ERK1 and ERK2 cascade\")",
      "function": "BiologicalProcess",
      "id": "b26b7d573b6c3ea532b8cf0fd8515acf653d19cb31f0ffefb016871bb5657c4da7b1c72c64df231d7c528ddae3f97ae015efa5bbdeca2b05364c1a452ced499a",
      "name": "ERK1 and ERK2 cascade",
      "namespace": "GO"
    },
    {
      "bel": "bp(GO:\"MAPK cascade\")",
      "function": "BiologicalProcess",
      "id": "ddc3208b4eeac05eb11865f5337227efcb688eef13c2d975b99df6e0def760b39095f64a9bf6771114c0da52d6566278d05ed99fdb3dfabc43e14dd8db596cec",
      "name": "MAPK cascade",
      "namespace": "GO"
    },
    {
      "bel": "bp(GO:\"NMDA selective glutamate receptor signaling pathway\")",
      "function": "BiologicalProcess",
      "id": "360a31f8b7aff3977439118fed11f7b6e5ece6a7acb5b593df5b64a7afb5c8bac1ab93bc2da5248d135d992a14a748ea72ebfa233ef73eb8e8256265d9c3b167",
      "name": "NMDA selective glutamate receptor signaling pathway",
      "namespace": "GO"
    },
    {
      "bel": "bp(GO:\"Wnt signaling pathway\")",
      "function": "BiologicalProcess",
      "id": "bb7db3c69b4ba4b1b094d58c8bc59fac8c0b58b50dafdb59d4a6ed1e5b8cd8689f56bcfb6c0d6c9c12035693d75345e4fb5c95ab311a8673bd4fed15585c67c8",
      "name": "Wnt signaling pathway",
      "namespace": "GO"
    },
    {
      "bel": "bp(GO:\"axonal transport\")",
      "function": "BiologicalProcess",
      "id": "05b46e2a47c4835f765deb7eb33b970b7abbb53b690b7881e2beda6bc739337253a12aaafa51ebf63ed9f7ad7f09bcd7f5ce4fda7373ed3f4f0eadedaf2c14d0",
      "name": "axonal transport",
      "namespace": "GO"
    },
    {
      "bel": "bp(GO:\"calcium ion transport\")",
      "function": "BiologicalProcess",
      "id": "7c1debe8c5aa50112a2768a7f845bfa93e1a6d2b911259a74f85603b0bd6b85e9b5f7092e547476c7cd51d82f313134048069f3cc2600eabc1ec0b33e88642b8",
      "name": "calcium ion transport",
      "namespace": "GO"
    },
    {
      "bel": "bp(GO:\"cell death\")",
      "function": "BiologicalProcess",
      "id": "b2ecb9d87645a0a7d5efbe2c9eeeaa14a705a36b6cdf787e071ba334fdd12b4caaf12b88508b99a8974005549b3c8123c9481c5d969630df072082b07e4dc586",
      "name": "cell death",
      "namespace": "GO"
    },
    {
      "bel": "bp(GO:\"circadian sleep/wake cycle\")",
      "function": "BiologicalProcess",
      "id": "6b7726173384f8eb927b7a773d744b2cdfb332c69f6d4ada3109cb6f66b163ed2ee53fe97142ff0cebaf797aa81de111046b936c028e1c0191455e9d03ab9781",
      "name": "circadian sleep/wake cycle",
      "namespace": "GO"
    },
    {
      "bel": "bp(GO:\"locomotor rhythm\")",
      "function": "BiologicalProcess",
      "id": "636a9f065232f27c187cac7717f60185050abb46354091319738dd78414f5c85d8a44cf20a5d7fa10c05e195672e30e113fd6b8d24371a9a09103178d6c0b6ee",
      "name": "locomotor rhythm",
      "namespace": "GO"
    },
    {
      "bel": "bp(GO:\"long-term synaptic potentiation\")",
      "function": "BiologicalProcess",
      "id": "90aca567c87981f32f4001b6386423cf473ef52decf04004bd136ab80fd9088c2698b76c8baf740f8e282b107790d3c88130dc99225bab73b22516859dc4203a",
      "name": "long-term synaptic potentiation",
      "namespace": "GO"
    },
    {
      "bel": "bp(GO:\"microtubule anchoring\")",
      "function": "BiologicalProcess",
      "id": "da84e5cf472496001611d6d7e2051592692376e58a6ed7574dd6c96b08a6027ce0fcff13f03ff1e20fded9226fb53686629d10631796e9106447195c13e6e7e7",
      "name": "microtubule anchoring",
      "namespace": "GO"
    },
    {
      "bel": "bp(GO:\"multicellular organism growth\")",
      "function": "BiologicalProcess",
      "id": "380a8504cf8a093af19a42e0f0a2995c857c80b8d58166c34734fabc495bf306927cda40aa73280c4539fd8d0b888d3c1ed8c4fff1b0916a09f992f55e772836",
      "name": "multicellular organism growth",
      "namespace": "GO"
    },
    {
      "bel": "bp(GO:\"neuron death\")",
      "function": "BiologicalProcess",
      "id": "ad7c90f2bc746a5118759fd1c8857478c02207d574a26faaac9d6e4d6fa4661d8d87446139db0024a4011aae26027d3cabdfba663aec0ac0a8242868efb81dcd",
      "name": "neuron death",
      "namespace": "GO"
    },
    {
      "bel": "bp(GO:\"neuron differentiation\")",
      "function": "BiologicalProcess",
      "id": "364018ff10b13aaa6d5c043c9ec30cf4471bd288a36a9e4ffb40bdd49e025a79c4190f7bd128cdd9bc24c4cf452053b8c675f3a5d8794baafde8fdfba90e129f",
      "name": "neuron differentiation",
      "namespace": "GO"
    },
    {
      "bel": "bp(GO:\"neuronal signal transduction\")",
      "function": "BiologicalProcess",
      "id": "ce8414fe0b7ad6712a400045db974257cb896b05f643160de6e6743d389ae433f08a4ed0725541a827e1dfb9f4f3613da37ae3329846ec0ca2a19c459dd08ca5",
      "name": "neuronal signal transduction",
      "namespace": "GO"
    },
    {
      "bel": "bp(GO:\"pituitary gland development\")",
      "function": "BiologicalProcess",
      "id": "159fb733e9a0f0a06199363019fc60d9c99941c02cf331a7434ed679bc3d93d1e8b5c42ffe42ef1083c44d7daf1bc42614ebd7fffea14897a7a06074780ee867",
      "name": "pituitary gland development",
      "namespace": "GO"
    },
    {
      "bel": "bp(GO:\"regulation of synaptic plasticity\")",
      "function": "BiologicalProcess",
      "id": "903846a9cf9209815f6dcfe040df50ed6f55896865a72567e9c38cd2dcf71773d60453fcfefaf38dc2933bb0c524d73f2b9c10afe99231cbd86c56860a8197da",
      "name": "regulation of synaptic plasticity",
      "namespace": "GO"
    },
    {
      "bel": "bp(GO:\"response to drug\")",
      "function": "BiologicalProcess",
      "id": "45c1395ee1c8810ad99354078a304911f025d80b2a5a78dd05e452e6f615c530022341aa9d40430c6927668235598365f0fa2097634c1f3836768ade4159a99c",
      "name": "response to drug",
      "namespace": "GO"
    },
    {
      "bel": "bp(GO:\"response to food\")",
      "function": "BiologicalProcess",
      "id": "31fb0b0546052cc5b655ae86daf5976418edbbd14604edc4a6ee2a283dcd3b3c3c529f363b34c0d97f5e8813d0d4b338991fae5d524414d351c7f55e4aae6cf6",
      "name": "response to food",
      "namespace": "GO"
    },
    {
      "bel": "bp(GO:\"signal transduction\")",
      "function": "BiologicalProcess",
      "id": "d3608eaee3f25f464803835ebd517e72f6846b665d75d61b45c66a6b129b218063af2c786170c0ce992cee3a5dbad92aa0cc0ab20038b430436f70147d366e4f",
      "name": "signal transduction",
      "namespace": "GO"
    },
    {
      "bel": "bp(GO:\"synaptic transmission, cholinergic\")",
      "function": "BiologicalProcess",
      "id": "4238cec14ccdcd7b90d308eb0687f5775f5b1ed79362c1d84004721894a52040968a92b357a6bf971a144e903a9b441d8be9ba5ee78e5e039c5f83c167933575",
      "name": "synaptic transmission, cholinergic",
      "namespace": "GO"
    },
    {
      "bel": "bp(GO:\"synaptic transmission, glutamatergic\")",
      "function": "BiologicalProcess",
      "id": "68a9f5219c953044883133bf5f935c2f9a074b8e719aa33dc0766bba8dd98b92cefd134205b93bd6f586b594e1438d307a554c9771bccd03dc6acf03e09bb82c",
      "name": "synaptic transmission, glutamatergic",
      "namespace": "GO"
    },
    {
      "bel": "bp(GO:cognition)",
      "function": "BiologicalProcess",
      "id": "8d73f2caa1c473289d5f37cbdd4ad391a120cdbdf2356b373070c2a7b2bc0c785eaa620782fa2dd947c666100f0a169e81f35864f359cadf3e1550962fcc4127",
      "name": "cognition",
      "namespace": "GO"
    },
    {
      "bel": "bp(GO:learning)",
      "function": "BiologicalProcess",
      "id": "24fec79fe31de63921d3028dd6ce5e335372d8d221877724830f05136d6c879daa7585768231b87272f0ebb8a7f6038f1aabb8785a626cca0c95b33018cc1633",
      "name": "learning",
      "namespace": "GO"
    },
    {
      "bel": "bp(GO:memory)",
      "function": "BiologicalProcess",
      "id": "87795d00588bdf77d28229ad379d58f00922f6339902a803d0672cc15e669269f8fe50785b2851e1e82046f4e1e49920534ec68c0b6911bea5a1b838dbc999cd",
      "name": "memory",
      "namespace": "GO"
    },
    {
      "bel": "bp(MESH:Neuroprotection)",
      "function": "BiologicalProcess",
      "id": "4faae7cda7ea712ac9d9c27de14c6457cd84758cc7195c23f72e23fa92f07677fd6328b40deb0811b5e6fdda4375bc95095893a935493c67ad814bd89755e3b1",
      "name": "Neuroprotection",
      "namespace": "MESH"
    },
    {
      "bel": "complex(FPLX:\"Gamma_secretase\")",
      "function": "Complex",
      "id": "1d63a5e54ef46d1f4aab2af3cf55f47eae490d0e0c9b2552a92547343bba2c0f609ef995ead266d208e28a0ecce88eeecd67ff2cece721fe507c2e893cd6f82d",
      "name": "Gamma_secretase",
      "namespace": "FPLX"
    },
    {
      "bel": "complex(a(CHEBI:acetylcholine), p(FPLX:\"G_protein\"), p(HGNCGENEFAMILY:\"Cholinergic receptors muscarinic\"))",
      "function": "Complex",
      "id": "54e647b777ce0863fcb4ae0024dea862aeaa3d92be6470dac77d6927476b8338e42ed1c83f7980595ae6faa7f0968e3c36c83b7e4e202a166b782cf181237f95",
      "members": [
        {
          "bel": "a(CHEBI:acetylcholine)",
          "function": "Abundance",
          "id": "bae5841bb74f1e9eb73cd433cda657927031217c24e17f21bb2975128d1d9be4dc899448ede71d9aa18224145a1681b90b33287454eabf938f405bc1b8894b62",
          "name": "acetylcholine",
          "namespace": "CHEBI"
        },
        {
          "bel": "p(FPLX:\"G_protein\")",
          "function": "Protein",
          "id": "a9e0ddc6aecbfb75f850b86f363f0e60dbc525c49092429fd0c85d60a92b31be4b3409fd70559a21b127cb65544060ebdd457d0e33d786e4fd446ee62416f90a",
          "name": "G_protein",
          "namespace": "FPLX"
        },
        {
          "bel": "p(HGNCGENEFAMILY:\"Cholinergic receptors muscarinic\")",
          "function": "Protein",
          "id": "bc4355d51c8dab82808ce004ae55c19edf51d387a57828854966a6340f3b344bfdc99f1e6c56624b645fd7994f14bb952a8d8607088690e787c1d934048706cc",
          "name": "Cholinergic receptors muscarinic",
          "namespace": "HGNCGENEFAMILY"
        }
      ]
    },
    {
      "bel": "complex(a(CHEBI:acetylcholine), p(HGNC:CHRM1))",
      "function": "Complex",
      "id": "c79df49028478fb2d33bb3d1db7eda42a8f0e5cbbd7c25d389ab8836283fe02b533927ef8adc56cc385314916533b760085335dee8dcabd6475a04d25fd301af",
      "members": [
        {
          "bel": "a(CHEBI:acetylcholine)",
          "function": "Abundance",
          "id": "bae5841bb74f1e9eb73cd433cda657927031217c24e17f21bb2975128d1d9be4dc899448ede71d9aa18224145a1681b90b33287454eabf938f405bc1b8894b62",
          "name": "acetylcholine",
          "namespace": "CHEBI"
        },
        {
          "bel": "p(HGNC:CHRM1)",
          "function": "Protein",
          "id": "962b8a84d274a6e78416261efc2137bcf03c8035a7be3138736624f9c08fe9ae92738ac20d9edd54a6ace6ff161f28793df367f2e084e2837fd799e530fddbbd",
          "name": "CHRM1",
          "namespace": "HGNC"
        }
      ]
    },
    {
      "bel": "complex(p(FPLX:\"G_protein\"), p(HGNC:CHRM1))",
      "function": "Complex",
      "id": "0e215a2647b43f6005fc07b40bdc7c64217c085fddff6b5feb71fbd1901d14cec3697fcc4a92deaf77c87238367769e0218052023b8f4ee33a1a8758fc00c991",
      "members": [
        {
          "bel": "p(FPLX:\"G_protein\")",
          "function": "Protein",
          "id": "a9e0ddc6aecbfb75f850b86f363f0e60dbc525c49092429fd0c85d60a92b31be4b3409fd70559a21b127cb65544060ebdd457d0e33d786e4fd446ee62416f90a",
          "name": "G_protein",
          "namespace": "FPLX"
        },
        {
          "bel": "p(HGNC:CHRM1)",
          "function": "Protein",
          "id": "962b8a84d274a6e78416261efc2137bcf03c8035a7be3138736624f9c08fe9ae92738ac20d9edd54a6ace6ff161f28793df367f2e084e2837fd799e530fddbbd",
          "name": "CHRM1",
          "namespace": "HGNC"
        }
      ]
    },
    {
      "bel": "complex(p(HGNC:BACE1), p(HGNC:CHRM1))",
      "function": "Complex",
      "id": "aab2bbee47508e6ba3a7e499e3a44e5a882248bb015712d5a17b282578d636c83aa41f8e9d337b0e3b4a5b5d959711a5c9a1503beeac3e93d7dd6127ba4412e9",
      "members": [
        {
          "bel": "p(HGNC:BACE1)",
          "function": "Protein",
          "id": "88f17e7dffb6947c01414f79e5a3bb9cdd3e932c355af7f0c8907d2b5d07742883eaf63866fe7fc938401ce0c366856fd5e306f324e6c1f474c1a984c8e46a51",
          "name": "BACE1",
          "namespace": "HGNC"
        },
        {
          "bel": "p(HGNC:CHRM1)",
          "function": "Protein",
          "id": "962b8a84d274a6e78416261efc2137bcf03c8035a7be3138736624f9c08fe9ae92738ac20d9edd54a6ace6ff161f28793df367f2e084e2837fd799e530fddbbd",
          "name": "CHRM1",
          "namespace": "HGNC"
        }
      ]
    },
    {
      "bel": "complex(p(HGNC:CHRM1), p(HGNC:GNA11))",
      "function": "Complex",
      "id": "7798a63f929440d501ef990d7fa62cace8d73780de0108d9ac2b924785ecfae1c600f81ccb8f213cedcf32b0ab915bee0eb07042354a5637b9199c1698848635",
      "members": [
        {
          "bel": "p(HGNC:CHRM1)",
          "function": "Protein",
          "id": "962b8a84d274a6e78416261efc2137bcf03c8035a7be3138736624f9c08fe9ae92738ac20d9edd54a6ace6ff161f28793df367f2e084e2837fd799e530fddbbd",
          "name": "CHRM1",
          "namespace": "HGNC"
        },
        {
          "bel": "p(HGNC:GNA11)",
          "function": "Protein",
          "id": "645d4edfc0f66057326c271a349b70d3c06d0a7111067dca10a3adbf4d99acbbb61ac9addbad9f143617fa1f1f6ec545f527def0fa0efaa5984fe343b3438941",
          "name": "GNA11",
          "namespace": "HGNC"
        }
      ]
    },
    {
      "bel": "complex(p(HGNC:CHRM2), p(HGNC:GNAO1))",
      "function": "Complex",
      "id": "d672a8aa50cd1bed1940aa14dcc91bb5e0dca6341332b007f8e310b1bf4953027a12b52502d9ee30a1915fb6c64ce964bab456a5192ce1aa379332ecf955a9c9",
      "members": [
        {
          "bel": "p(HGNC:CHRM2)",
          "function": "Protein",
          "id": "3f3bd4efac7c25609453f906264cb2c3b1de4eb8eee23d557332d4dec2c604a062717a3aaa3a273ae625f7290f3815251c76cd5b9300f8f684085d5526c1cbb5",
          "name": "CHRM2",
          "namespace": "HGNC"
        },
        {
          "bel": "p(HGNC:GNAO1)",
          "function": "Protein",
          "id": "10f65cafc54ad93453aa850f9e999f8906eaa0b997dc2f1b7704b212b5fc7a97b92ba60597152ba2118f4b96a012cb722694c818ca20d69315182e2ed54f6dda",
          "name": "GNAO1",
          "namespace": "HGNC"
        }
      ]
    },
    {
      "bel": "complex(p(HGNC:CHRM3), p(HGNC:GNA11))",
      "function": "Complex",
      "id": "161cccacb4e603021b4c547d64dc437df398cf02c463990f09ad5095c14995e83fc1201a563e274cb69168d29ff19a429cf42b1cf72f76acc8e0a1bb27fae7b2",
      "members": [
        {
          "bel": "p(HGNC:CHRM3)",
          "function": "Protein",
          "id": "321acd12eb1b51bc2a14b21c01d30c83c6a4ce5c3255ef3cf2690b65596f9594c541dc6fe9a23210d952a2fdac2f2d05aa91e4299d1942926ea0932119e338ff",
          "name": "CHRM3",
          "namespace": "HGNC"
        },
        {
          "bel": "p(HGNC:GNA11)",
          "function": "Protein",
          "id": "645d4edfc0f66057326c271a349b70d3c06d0a7111067dca10a3adbf4d99acbbb61ac9addbad9f143617fa1f1f6ec545f527def0fa0efaa5984fe343b3438941",
          "name": "GNA11",
          "namespace": "HGNC"
        }
      ]
    },
    {
      "bel": "complex(p(HGNC:CHRM4), p(HGNC:GNAO1))",
      "function": "Complex",
      "id": "cfb3cf91be4612725f934855e2edb363c3af5c67778b68ff760af7a544664a337b60855c970080d949146f01df668db79aec182d22e27bcc1610606f78fbe877",
      "members": [
        {
          "bel": "p(HGNC:CHRM4)",
          "function": "Protein",
          "id": "92e568f0e1bc4f13da9c8c905c0894d766ba624982320637733a3097dc72ffc572e6c948301c16f49c9bcbd674b9c3586f48c8643e70247024048401ae1dd969",
          "name": "CHRM4",
          "namespace": "HGNC"
        },
        {
          "bel": "p(HGNC:GNAO1)",
          "function": "Protein",
          "id": "10f65cafc54ad93453aa850f9e999f8906eaa0b997dc2f1b7704b212b5fc7a97b92ba60597152ba2118f4b96a012cb722694c818ca20d69315182e2ed54f6dda",
          "name": "GNAO1",
          "namespace": "HGNC"
        }
      ]
    },
    {
      "bel": "complex(p(HGNC:CHRM5), p(HGNC:GNA11))",
      "function": "Complex",
      "id": "68d3ed290fdf8f5b0477ab4e6e3cca059fc6ec1b31421635a1d3a01ca97b40fc6defa8f4c9e8f16e9195890b5742c1ba2c7eed17b65e9df2d25d045604d1751d",
      "members": [
        {
          "bel": "p(HGNC:CHRM5)",
          "function": "Protein",
          "id": "7127c478eb6b98b42d944576f420df9017725b724e77febd046f52a2dcc8662133f1e33f6981df086ad9fb9aafb0854d39dffa37131f122cd1e0fd6d4cbc981b",
          "name": "CHRM5",
          "namespace": "HGNC"
        },
        {
          "bel": "p(HGNC:GNA11)",
          "function": "Protein",
          "id": "645d4edfc0f66057326c271a349b70d3c06d0a7111067dca10a3adbf4d99acbbb61ac9addbad9f143617fa1f1f6ec545f527def0fa0efaa5984fe343b3438941",
          "name": "GNA11",
          "namespace": "HGNC"
        }
      ]
    },
    {
      "bel": "p(CONSO:\"sAPP-alpha\")",
      "function": "Protein",
      "id": "ed93b0dc34eaef3af160558aee0b3a7ddac2727804ae9edba36ae15828b0209345d1f55a65b19b68604395ec17d3900de157f1a39fd6519540b3d4f3d48d475e",
      "name": "sAPP-alpha",
      "namespace": "CONSO"
    },
    {
      "bel": "p(CONSO:\"sAPP-beta\")",
      "function": "Protein",
      "id": "5398d4984129759e9b240bafa6b1c68a4fa29a53cd3b11c8c3e9a0cf7ed4ad658837071ea10d874d9f67aa0a38eda520f01d74ce3462dcdcad62c2669f34828d",
      "name": "sAPP-beta",
      "namespace": "CONSO"
    },
    {
      "bel": "p(CONSO:AICD)",
      "function": "Protein",
      "id": "a8b7fa031a45deb8ff3768da62e0280a59a10ac971e0e2a349c3675a5b72e6c34e680202e488488e642a5932b7ce70db3c23eb1ad802f6c1a8cfddddb643c636",
      "name": "AICD",
      "namespace": "CONSO"
    },
    {
      "bel": "p(CONSO:C99)",
      "function": "Protein",
      "id": "8a740562b73802ce217eda0e22b5441f129eaebe7ac833dff643b1f916b8450215de64262678986d70816be3a117c471e5931327b7bac802ad4cbd5eb2b4dccc",
      "name": "C99",
      "namespace": "CONSO"
    },
    {
      "bel": "p(FPLX:\"G_protein\")",
      "function": "Protein",
      "id": "a9e0ddc6aecbfb75f850b86f363f0e60dbc525c49092429fd0c85d60a92b31be4b3409fd70559a21b127cb65544060ebdd457d0e33d786e4fd446ee62416f90a",
      "name": "G_protein",
      "namespace": "FPLX"
    },
    {
      "bel": "p(FPLX:PKC)",
      "function": "Protein",
      "id": "12137fadfdc5eb838cd33edabcf36ac0b775609d7303971d52755e1335928a559973fe26211ce3ac9a8599ee75c77a978b44d1d7114437a922a8911d9016aceb",
      "name": "PKC",
      "namespace": "FPLX"
    },
    {
      "bel": "p(FPLX:PLC)",
      "function": "Protein",
      "id": "a954cf31d48b6ddffaacdf9ac551464d6edda5fead07120c8d6453a89aab5a325ac1795b97e6993441005e73dd31fed063aa1c7c5b0b2ac77d1783fc8006e68c",
      "name": "PLC",
      "namespace": "FPLX"
    },
    {
      "bel": "p(HGNC:ADAM10)",
      "function": "Protein",
      "id": "bd47ad5cb480f1f5352dc919edee75d506c0cbfe44ed1a4c53dd9e9c7f7ab383ca2111205a1c12d47100e58c5a5d80d33a56372524bad144da469c574748e8c1",
      "name": "ADAM10",
      "namespace": "HGNC"
    },
    {
      "bel": "p(HGNC:APP)",
      "function": "Protein",
      "id": "ed1d45f3255226e4210017e6c179950e0e04a300727326d7fea6a9659868e8818ff64fd5e8a2a92a703fb1566b3f48323750ac6c28e7adb40843053d276710bc",
      "name": "APP",
      "namespace": "HGNC"
    },
    {
      "bel": "p(HGNC:BACE1)",
      "function": "Protein",
      "id": "88f17e7dffb6947c01414f79e5a3bb9cdd3e932c355af7f0c8907d2b5d07742883eaf63866fe7fc938401ce0c366856fd5e306f324e6c1f474c1a984c8e46a51",
      "name": "BACE1",
      "namespace": "HGNC"
    },
    {
      "bel": "p(HGNC:CHAT)",
      "function": "Protein",
      "id": "83616fc651645c99c1241b56d867a50ae4c018175bde3ba565013689e69f634139b6a62407ad56c90279b66bb2ed0f021686ef2123872c34ad71eb747efce213",
      "name": "CHAT",
      "namespace": "HGNC"
    },
    {
      "bel": "p(HGNC:CHRM1)",
      "function": "Protein",
      "id": "962b8a84d274a6e78416261efc2137bcf03c8035a7be3138736624f9c08fe9ae92738ac20d9edd54a6ace6ff161f28793df367f2e084e2837fd799e530fddbbd",
      "name": "CHRM1",
      "namespace": "HGNC"
    },
    {
      "bel": "p(HGNC:CHRM2)",
      "function": "Protein",
      "id": "3f3bd4efac7c25609453f906264cb2c3b1de4eb8eee23d557332d4dec2c604a062717a3aaa3a273ae625f7290f3815251c76cd5b9300f8f684085d5526c1cbb5",
      "name": "CHRM2",
      "namespace": "HGNC"
    },
    {
      "bel": "p(HGNC:CHRM3)",
      "function": "Protein",
      "id": "321acd12eb1b51bc2a14b21c01d30c83c6a4ce5c3255ef3cf2690b65596f9594c541dc6fe9a23210d952a2fdac2f2d05aa91e4299d1942926ea0932119e338ff",
      "name": "CHRM3",
      "namespace": "HGNC"
    },
    {
      "bel": "p(HGNC:CHRM4)",
      "function": "Protein",
      "id": "92e568f0e1bc4f13da9c8c905c0894d766ba624982320637733a3097dc72ffc572e6c948301c16f49c9bcbd674b9c3586f48c8643e70247024048401ae1dd969",
      "name": "CHRM4",
      "namespace": "HGNC"
    },
    {
      "bel": "p(HGNC:CHRM5)",
      "function": "Protein",
      "id": "7127c478eb6b98b42d944576f420df9017725b724e77febd046f52a2dcc8662133f1e33f6981df086ad9fb9aafb0854d39dffa37131f122cd1e0fd6d4cbc981b",
      "name": "CHRM5",
      "namespace": "HGNC"
    },
    {
      "bel": "p(HGNC:DRD1)",
      "function": "Protein",
      "id": "374faa30d8ea2b30a3ea00e1683e06bda20f60c501024b372171cd645b166df7aa94a8b1fbb6f1e1a8af61f9648bc25e6eff49a565bfbf37c764e0b8977d3a28",
      "name": "DRD1",
      "namespace": "HGNC"
    },
    {
      "bel": "p(HGNC:GNA11)",
      "function": "Protein",
      "id": "645d4edfc0f66057326c271a349b70d3c06d0a7111067dca10a3adbf4d99acbbb61ac9addbad9f143617fa1f1f6ec545f527def0fa0efaa5984fe343b3438941",
      "name": "GNA11",
      "namespace": "HGNC"
    },
    {
      "bel": "p(HGNC:GNAO1)",
      "function": "Protein",
      "id": "10f65cafc54ad93453aa850f9e999f8906eaa0b997dc2f1b7704b212b5fc7a97b92ba60597152ba2118f4b96a012cb722694c818ca20d69315182e2ed54f6dda",
      "name": "GNAO1",
      "namespace": "HGNC"
    },
    {
      "bel": "p(HGNC:GSK3B)",
      "function": "Protein",
      "id": "ac819ecac7786e3ea9b6906b318167c6a94fbbf428aff46f85083b83c50b9604342d39c1c36ff49c2cb3a04e491913164c3e4e7889dedd513b6196d9b0560c7c",
      "name": "GSK3B",
      "namespace": "HGNC"
    },
    {
      "bel": "p(HGNC:MAPT)",
      "function": "Protein",
      "id": "ad82d360f02888e890bb2d1f91d1dc020c21cebed2b4eed0193a58e6b396b5f0797d607568dea382c05ffe2a003537d10190b020739af8d51c8d7dbc19bf5ab1",
      "name": "MAPT",
      "namespace": "HGNC"
    },
    {
      "bel": "p(HGNC:MAPT, pmod(Ph))",
      "function": "Protein",
      "id": "526bae251987f8c4f55f6e2451662fa55e087c57585beae7c389b020d73487c739834e9b8ec841783de6a5b5fb9df8b138e9eff4406a9ec5e606766575dcac0e",
      "name": "MAPT",
      "namespace": "HGNC",
      "variants": [
        {
          "identifier": {
            "name": "Ph",
            "namespace": "bel"
          },
          "kind": "pmod"
        }
      ]
    },
    {
      "bel": "p(HGNCGENEFAMILY:\"Adenylate cyclases\")",
      "function": "Protein",
      "id": "c911801a259e4f223abd3c935a3e2cda5ca1a92fed8ea9781e218676cb0bbf57410c5130994d735388665060e6caebd730fb32f03c17bfb515265b3cfbb05789",
      "name": "Adenylate cyclases",
      "namespace": "HGNCGENEFAMILY"
    },
    {
      "bel": "p(HGNCGENEFAMILY:\"Cholinergic receptors muscarinic\")",
      "function": "Protein",
      "id": "bc4355d51c8dab82808ce004ae55c19edf51d387a57828854966a6340f3b344bfdc99f1e6c56624b645fd7994f14bb952a8d8607088690e787c1d934048706cc",
      "name": "Cholinergic receptors muscarinic",
      "namespace": "HGNCGENEFAMILY"
    },
    {
      "bel": "p(HGNCGENEFAMILY:\"Cholinergic receptors nicotinic subunits\")",
      "function": "Protein",
      "id": "d55bebfe65f49c8e66d1ed0b491af0f01aba4b030a649599e59150e53ed4d3e4cd2199be8863b95c7033ab2185d8d7ea9203e5418faea9d7dcc86757b9bcf4dd",
      "name": "Cholinergic receptors nicotinic subunits",
      "namespace": "HGNCGENEFAMILY"
    },
    {
      "bel": "p(HGNCGENEFAMILY:Caspases)",
      "function": "Protein",
      "id": "365113b4284e715e4190939461b59f5c11a9331f328e7b78e451623d2640e74dd006f26b320e9c933bf259b188e4ac0c456a2a3a7b656df6a42a390cafe2caf7",
      "name": "Caspases",
      "namespace": "HGNCGENEFAMILY"
    },
    {
      "bel": "p(MGI:Bace1)",
      "function": "Protein",
      "id": "0ed08903c69f611a662ac9b5d440fe052d2fa731e4ca12d3b56f81efcf760a1333e4ad10a5c3ede57dedebb2462cdb32f458ea86d531a9a2113aa8b026505c94",
      "name": "Bace1",
      "namespace": "MGI"
    },
    {
      "bel": "p(MGI:Chrm1)",
      "function": "Protein",
      "id": "45b464adf68bffe5d23f53634e7064e00306d71fed21b4cb0954c6336acf4bc5dae8b45abaf6ee19656e8ca4815e390c82062a5f79cd7dae6da61103e87f5e29",
      "name": "Chrm1",
      "namespace": "MGI"
    },
    {
      "bel": "p(MGI:Chrm2)",
      "function": "Protein",
      "id": "0898b52bdeeba797a5b3085b1f87b94f9a0a5debfbf997ff754a3f5cdc149440fb710ca458c62761eedcb2dff76a4fdd6914dfb8180eac23d71406077d91e4de",
      "name": "Chrm2",
      "namespace": "MGI"
    },
    {
      "bel": "p(MGI:Chrm3)",
      "function": "Protein",
      "id": "33bf713136742f84a68fab549fb015cecafd1cf270d27a2aa9d92ccaa359a3d8e35275d481e8b09a1d195072b74d00bc3eb8f54c818a9282de0724952f799a2e",
      "name": "Chrm3",
      "namespace": "MGI"
    },
    {
      "bel": "p(MGI:Chrm4)",
      "function": "Protein",
      "id": "c5078486b54ee1c2b9f11e99715457719771e8c62d17d9b9357b7b0bb3928f9f14c5c1c4267f7a2c20cf42c7b2eca175d6b082a34a3a2b614fdb25a7c8506301",
      "name": "Chrm4",
      "namespace": "MGI"
    },
    {
      "bel": "p(MGI:Drd1)",
      "function": "Protein",
      "id": "12b641ec94aa053d87f0766466ab17a3f89c2bef18da1e9be644c3815f19d0f29e0dd73350d460518b804c8172d1c1f3cfd0f4de3297c44c6e2285e526422218",
      "name": "Drd1",
      "namespace": "MGI"
    },
    {
      "bel": "p(MGI:Gh)",
      "function": "Protein",
      "id": "d7f92edc77b4c161e5d84b91489d81d4b55c77a3d6105d45f2cc3a11000ed0455afb38a827cb0e97d68b3a5a83072a59387f08cd43d6a0cf4d19bcd89dafbc39",
      "name": "Gh",
      "namespace": "MGI"
    },
    {
      "bel": "p(MGI:Prl)",
      "function": "Protein",
      "id": "7874495d5315ca9e963f25c66429bfcae1effc1d5fb138f3264ba10d2c89796a778abf7094e89463ed81462e65d014a4a66149161650f8d99567af71e69c5648",
      "name": "Prl",
      "namespace": "MGI"
    },
    {
      "bel": "path(CONSO:neurotoxicity)",
      "function": "Pathology",
      "id": "402444c8075c3bd4b2a209c0756b87c8625726c4cfc69dd572f0a15c0a7067840791a25f05826f03ec0ea0dcf00ab468b9eb7f98f7b0637f76ef544893ce6952",
      "name": "neurotoxicity",
      "namespace": "CONSO"
    },
    {
      "bel": "path(MESH:\"Alzheimer Disease\")",
      "function": "Pathology",
      "id": "00f72839b5d655cb4cb088b0eb8874bd406284d98a2afd0bdd73de0a34adb78af374b0eb26990387f41d3b41cda0e32c1b5ff5f86ed63d0fdc841bac17865541",
      "name": "Alzheimer Disease",
      "namespace": "MESH"
    },
    {
      "bel": "path(MESH:\"Cognitive Dysfunction\")",
      "function": "Pathology",
      "id": "bd78fa3131dd9ef6067a5fe3ee8689c946c79d0da1bedb054d1f4400b9ad0d3ae041837faa0fbacee0af5a57a4cd343d11e73fd53fd05269e3558803a56df69c",
      "name": "Cognitive Dysfunction",
      "namespace": "MESH"
    },
    {
      "bel": "path(MESH:\"DNA Damage\")",
      "function": "Pathology",
      "id": "f96ef7d814ee1b694c9cc016eeb7a05555370289c4f2eb593a8cab6ebf7d3a6c1279096723b4b25c886ae2c5af5fc8b09b92ba4485f092baea51ce5eab42a747",
      "name": "DNA Damage",
      "namespace": "MESH"
    },
    {
      "bel": "path(MESH:\"Executive Function\")",
      "function": "Pathology",
      "id": "49eccc7c6474d853d3f7d9f266a96b278d78b96c15d0f1691b4c116f7c58d193008d088b30c310c4af65bda65369134dc12957dfb47cb73fc2eecaeeead3efe2",
      "name": "Executive Function",
      "namespace": "MESH"
    },
    {
      "bel": "path(MESH:\"Gastrointestinal Diseases\")",
      "function": "Pathology",
      "id": "07870689a78137a0f6af838a11875b70f1be8fca9474ffbbfe76db7b0b225226aaa18250a6171334e075791ff8d4a6f80757a60910f25d272c642225713c1702",
      "name": "Gastrointestinal Diseases",
      "namespace": "MESH"
    },
    {
      "bel": "path(MESH:\"Neurodegenerative Diseases\")",
      "function": "Pathology",
      "id": "95863a6d11beb3bd993523e1c8c7e210d281b0c092553f6a4cf27dd3ecf2fa51b49c5056b8aed6f7ac7c82f99101c34bc9fc0afc3dce117fe011d159ba9e4c89",
      "name": "Neurodegenerative Diseases",
      "namespace": "MESH"
    },
    {
      "bel": "path(MESH:\"Neurofibrillary Tangles\")",
      "function": "Pathology",
      "id": "c475029455d40226db06d868a00a3a41d06cefa8e543a1d8f39d53e4799c7ffe095363d7c845684b8e8caaabc2215365a2b4e2f78261e428bc64159b2edf5825",
      "name": "Neurofibrillary Tangles",
      "namespace": "MESH"
    },
    {
      "bel": "path(MESH:\"Nociceptive Pain\")",
      "function": "Pathology",
      "id": "b4fd285eeaacd7ed5ce516b8a78ecf328fe02ba34fa3dac7680dd19940596ceb7208e18ba72cc64d24e068e23452eb1da00db26ae15ab305ad023c5224074530",
      "name": "Nociceptive Pain",
      "namespace": "MESH"
    },
    {
      "bel": "path(MESH:\"Oxidative Stress\")",
      "function": "Pathology",
      "id": "b6f3383d4577b7ffb283f413a60e49c2f8226fe39c6edaf2b736361a5b4736b32b9a04bf41293e96599630d35eb5d897dbfda02cf25fd3c75122f5f0f37243ed",
      "name": "Oxidative Stress",
      "namespace": "MESH"
    },
    {
      "bel": "path(MESH:\"Parkinson Disease\")",
      "function": "Pathology",
      "id": "d7f039170f83b3fcc27595412f3b0352cd1fe95f8481a2b1144ce311ac81bb5f0087a0a7e682f498d193e00b8e8fb29908a6e0b8e23da5ef349aeeb4723b9be0",
      "name": "Parkinson Disease",
      "namespace": "MESH"
    },
    {
      "bel": "path(MESH:\"Plaque, Amyloid\")",
      "function": "Pathology",
      "id": "888c33ecabc995942e605aace0106831b95c6e6d4eb99ee4ac4c1de25ff7c58c0cb67b5e941c2d3f3a399aada51a34de03850a43011389d2ab7dae07536cea30",
      "name": "Plaque, Amyloid",
      "namespace": "MESH"
    },
    {
      "bel": "path(MESH:\"Psychotic Disorders\")",
      "function": "Pathology",
      "id": "70e20ca93acc2bc96dda4f1d7f9d91f213e4188846a55f6ba562f6d3c489ee095289bd631135cbb96349aad7f3154820384e0188a9bfacfd4c50994fb3d0c308",
      "name": "Psychotic Disorders",
      "namespace": "MESH"
    },
    {
      "bel": "path(MESH:\"Sjogren's Syndrome\")",
      "function": "Pathology",
      "id": "0ae7f7b80b1aba7b796174f37f7e9abc42c66a3fcc48ef85ae4ec0600b4327633de4fc2e73daa7143936cb40126e973119a2857e9aaa046bf01b911155690d71",
      "name": "Sjogren's Syndrome",
      "namespace": "MESH"
    },
    {
      "bel": "path(MESH:Asthenia)",
      "function": "Pathology",
      "id": "62e230ff26db1d25989647dc7050d4e82df4871971f116f03df36707648609380dcafde4de8ce67e5bba86c90e498e711ca9ad65f847e074ffc3e807917cde57",
      "name": "Asthenia",
      "namespace": "MESH"
    },
    {
      "bel": "path(MESH:Attention)",
      "function": "Pathology",
      "id": "67735e2aaf2e17459a41794138aa7720fd27fb15a51cb7f34b74132b92accef7585efb2a338de3ca85bd2a5ae6bc4f7aac672d1a06b2e19c5e45400ba7b94036",
      "name": "Attention",
      "namespace": "MESH"
    },
    {
      "bel": "path(MESH:Confusion)",
      "function": "Pathology",
      "id": "6123db3d8a89419fa5464a3a3d01981e76bec8de0e5311d7df944e38edd7bdf970ca9b2807b7a608d0bbeb00b051f6bfb83fc43af97ce161fd8f1bb570695948",
      "name": "Confusion",
      "namespace": "MESH"
    },
    {
      "bel": "path(MESH:Diarrhea)",
      "function": "Pathology",
      "id": "9bf6d33475a509074370f207fc10381d0ea271858e394f0ae3e5238930adbc79cd7669af668eedd5bcda39dd5f0e78c06198d91af427be35dd31f26297f0c602",
      "name": "Diarrhea",
      "namespace": "MESH"
    },
    {
      "bel": "path(MESH:Hypothermia)",
      "function": "Pathology",
      "id": "3b6306e7ce97afcbc01b6f27284dbf8266438e35a65ee0ec69666c72228bd5d930ea8c49b65bb2156c1a7559964945e76980d3993ab18a8b6f4f34e5596d7612",
      "name": "Hypothermia",
      "namespace": "MESH"
    },
    {
      "bel": "path(MESH:Nociception)",
      "function": "Pathology",
      "id": "711b886347e9a54d49cc1677229e898421dc351164134ea87beb8578c53f21555c68d7c79fa6a481da2da1b8204d0c1f04ea7d039aeb920a1f8645447f21c0f4",
      "name": "Nociception",
      "namespace": "MESH"
    },
    {
      "bel": "path(MESH:Salivation)",
      "function": "Pathology",
      "id": "bea69435545a2067d2bdb48c299d3498e0f4615fb3cee13a39380cb7bd38b75be73bb645300809a22c71a07c791835c70dc11109d3d91cb78ef1e5ae567144ad",
      "name": "Salivation",
      "namespace": "MESH"
    },
    {
      "bel": "path(MESH:Sweating)",
      "function": "Pathology",
      "id": "3ba19da0f330354542b49d0f09c2a63a98be1704ee1fcdea572a314d259429a42fd6baebd1584189a6fe36b70c1b9c697c806d462b7011bc2fba3b850c0675be",
      "name": "Sweating",
      "namespace": "MESH"
    },
    {
      "bel": "path(MESH:Tauopathies)",
      "function": "Pathology",
      "id": "d2087b32a76c528191af8305652f4664cbeb31b3f4e3f9627aaf61259e271f83a7d1be65f83e9178ccf3811482ece65b940fe4ce9a714b2281f705c0d499502b",
      "name": "Tauopathies",
      "namespace": "MESH"
    }
  ]
}